Eigene Vorlage

Dossier zur Nutzenbewertung gemäß § 35a SGB V

Ponatinib (Iclusig®)

Incyte Biosciences Germany GmbH

Statistische Analyse

Erwachsene Patienten mit chronischer myeloischer Leukämie (CML) in der chronischen Phase, akzelerierten Phase oder Blastenkrise, die behandlungsresistent gegenüber Dasatinib bzw. Nilotinib sind, die Dasatinib oder Nilotinib nicht vertragen und bei denen eine anschließende Behandlung mit Imatinib klinisch nicht geeignet ist, oder bei denen eine T315I-Mutation vorliegt

Stand: 26.05.2020

STATISTISCHE ANALYSE

zum

Dossier zur Nutzenbewertung

gemäß § 35a SGB V

zu

Ponatinib (Iclusig®)

Incyte Biosciences Germany GmbH

Erwachsene Patienten mit chronischer myeloischer Leukämie (CML) in der chronischen Phase, akzelerierten Phase oder Blastenkrise, die behandlungsresistent gegenüber Dasatinib bzw. Nilotinib sind, die Dasatinib oder Nilotinib nicht vertragen und bei denen eine anschließende Behandlung mit Imatinib klinisch nicht geeignet ist, oder bei denen eine T315I-Mutation vorliegt, sowie erwachsene Patienten mit Philadelphia-Chromosom-positiver akuter Lymphoblastenleukämie (Ph+ ALL), die behandlungsresistent gegenüber Dasatinib sind, die Dasatinib nicht vertragen und bei denen eine anschließende Behandlung mit Imatinib klinisch nicht geeignet ist, oder bei denen eine T315I-Mutation vorliegt.

Autor(en): **Prof. Dr. Eva Susanne Dietrich**

Statistische Programmierung: **Cogitars GmbH**

Version: **2.0**

Datum: **26. Mai 2020**

Table of Contents

1 Document 1: CML

1.1 Demographic and other baseline characteristics

1.1.1 Patients in CP, AP, or BP

Table 1.1.1.1 (Study 101)
Demographic and Baseline Characteristics
Safety Population - CML Patients

Variable	*Category*	*Statistic*	*CP-CML (N=43)*	*AP-CML (N=9)*	*BP-CML (N=8)*
T315I mutation	Yes	n (%)	12 (27.9%)	1 (11.1%)	2 (25.0%)
	No	n (%)	31 (72.1%)	8 (88.9%)	6 (75.0%)
Gender	Male	n (%)	21 (48.8%)	6 (66.7%)	5 (62.5%)
	Female	n (%)	22 (51.2%)	3 (33.3%)	3 (37.5%)
Age	(Years)	Mean (SD)	56.5 (14.38)	61.4 (12.14)	50.6 (16.67)
		Median	55.0	61.0	50.5
		Min, Max	(27, 85)	(42, 77)	(26, 73)
ECOG	Grade 0	n (%)	19 (44.2%)	2 (22.2%)	4 (50.0%)
	Grade 1	n (%)	22 (51.2%)	7 (77.8%)	1 (12.5%)
	Grade 2	n (%)	2 (4.7%)	0 (0.0%)	3 (37.5%)
Number of prior TKI(s)	1	n (%)	1 (2.3%)	0 (0.0%)	0 (0.0%)
	2	n (%)	16 (37.2%)	1 (11.1%)	2 (25.0%)

Safety Population: All treated patients
Percentages are based on the safety population.
[1] Percentages are based on the patients previously treated with dasatinib or nilotinib.

Run Date/Time: 26MAY2020 11:07

Table 1.1.1.1 (Study 101)
Demographic and Baseline Characteristics
Safety Population - CML Patients

Variable	*Category*	*Statistic*	*CP-CML (N=43)*	*AP-CML (N=9)*	*BP-CML (N=8)*
	>=3	n (%)	26 (60.5%)	8 (88.9%)	6 (75.0%)
Prior Approved TKI	Imatinib	n (%)	43 (100.0%)	9 (100.0%)	8 (100.0%)
	Dasatinib	n (%)	35 (81.4%)	9 (100.0%)	8 (100.0%)
	Nilotinib	n (%)	24 (55.8%)	7 (77.8%)	5 (62.5%)
Time since diagnosis	(Years)	Mean (SD)	7.6 (5.16)	8.8 (4.69)	7.0 (5.69)
		Median	6.6	6.7	6.5
		Min, Max	(0.8, 23.5)	(2.7, 16.2)	(1.6, 19.8)
Prior dasatinib or nilotinib [1]	All	n	40	9	8
	Intolerant	n (%)	12 (30.0%)	3 (33.3%)	3 (37.5%)

Safety Population: All treated patients
Percentages are based on the safety population.
[1] Percentages are based on the patients previously treated with dasatinib or nilotinib.

Table 1.1.1.1 (Study 201)
Demographic and Baseline Characteristics
Safety Population - CML Patients

Variable	*Category*	*Statistic*	*CP-CML (N=270)*	*AP-CML (N=85)*	*BP-CML (N=62)*
T315I mutation [1]	Yes	n (%)	64 (23.7%)	18 (21.2%)	24 (38.7%)
	No	n (%)	206 (76.3%)	67 (78.8%)	38 (61.3%)
Gender	Male	n (%)	144 (53.3%)	37 (43.5%)	37 (59.7%)
	Female	n (%)	126 (46.7%)	48 (56.5%)	25 (40.3%)
Age	(Years)	Mean (SD)	57.6 (15.08)	55.4 (14.80)	50.2 (16.53)
		Median	60.0	60.0	53.0
		Min, Max	(18, 94)	(23, 82)	(18, 74)
ECOG	Grade 0	n (%)	189 (70.0%)	47 (55.3%)	20 (32.3%)
	Grade 1	n (%)	77 (28.5%)	31 (36.5%)	22 (35.5%)
	Grade 2	n (%)	4 (1.5%)	7 (8.2%)	19 (30.6%)
	Grade 3	n (%)	0 (0.0%)	0 (0.0%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.
[1] T315I Yes: Patients in Cohorts B and D.
T315I No: Three patients in the CP-CML group and two patients in the AP-CML group were excluded from the Treated Population.

Table 1.1.1.1 (Study 201)
Demographic and Baseline Characteristics
Safety Population - CML Patients

Variable	*Category*	*Statistic*	*CP-CML (N=270)*	*AP-CML (N=85)*	*BP-CML (N=62)*
Number of prior TKI(s)	1	n (%)	18 (6.7%)	5 (5.9%)	2 (3.2%)
	2	n (%)	90 (33.3%)	29 (34.1%)	23 (37.1%)
	>=3	n (%)	162 (60.0%)	51 (60.0%)	37 (59.7%)
Prior approved TKI(s)	No Prior Approved TKI	n (%)	1 (0.4%)	0 (0.0%)	0 (0.0%)
	1 Prior Approved TKI	n (%)	19 (7.0%)	6 (7.1%)	2 (3.2%)
	- Imatinib	n (%)	13 (4.8%)	5 (5.9%)	1 (1.6%)
	- Dasatinib	n (%)	5 (1.9%)	0 (0.0%)	1 (1.6%)
	- Nilotinib	n (%)	1 (0.4%)	1 (1.2%)	0 (0.0%)
	2 Prior Approved TKIs	n (%)	106 (39.3%)	33 (38.8%)	24 (38.7%)
	- Imatinib + 2nd Generation TKI	n (%)	104 (38.5%)	33 (38.8%)	22 (35.5%)
	- Imatinib + Dasatinib	n (%)	66 (24.4%)	24 (28.2%)	19 (30.6%)
	- Imatinib + Nilotinib	n (%)	38 (14.1%)	9 (10.6%)	3 (4.8%)
	- Dasatinib + Nilotinib	n (%)	2 (0.7%)	0 (0.0%)	2 (3.2%)
	3 Prior Approved TKIs	n (%)	144 (53.3%)	46 (54.1%)	36 (58.1%)
	- Imatinib + Dassatinib + Nilotinib	n (%)	144 (53.3%)	46 (54.1%)	36 (58.1%)
Time since diagnosis	(Years)	Mean (SD)	8.0 (5.50)	9.0 (6.34)	5.5 (5.26)

Safety Population: All treated patients
Percentages are based on the safety population.
[1] T315I Yes: Patients in Cohorts B and D.
T315I No: Three patients in the CP-CML group and two patients in the AP-CML group were excluded from the Treated Population.

Table 1.1.1.1 (Study 201)
Demographic and Baseline Characteristics
Safety Population - CML Patients

Variable	*Category*	*Statistic*	*CP-CML (N=270)*	*AP-CML (N=85)*	*BP-CML (N=62)*
		Median	7.0	7.0	4.0
		Min, Max	(0.5, 27.4)	(0.3, 28.5)	(0.5, 27.2)
Prior dasatinib or nilotinib	Resistant	n (%)	215 (79.6%)	74 (87.1%)	59 (95.2%)
	Intolerant but not resistant	n (%)	39 (14.4%)	6 (7.1%)	2 (3.2%)
	Not Resistant or intolerant	n (%)	16 (5.9%)	5 (5.9%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.
[1] T315I Yes: Patients in Cohorts B and D.
T315I No: Three patients in the CP-CML group and two patients in the AP-CML group were excluded from the Treated Population.

Table 1.1.1.2 (Study 101)
Follow-up and treatment duration
Safety Population - CML Patients

Variable	*Category*	*Statistic*	*CP-CML (N=43)*	*AP-CML (N=9)*	*BP-CML (N=8)*
Follow-up duration	(Weeks)	N	43	9	8
		Mean (SD)	225 (125.6)	76.2 (75.60)	16.9 (11.30)
		Median	241.0	58.1	15.4
		Min, Max	(7.3, 397.1)	(2.1, 213.7)	(4.6, 39.6)
Follow-up duration	(Months)	N	43	9	8
		Mean (SD)	51.7 (28.92)	17.5 (17.41)	3.9 (2.60)
		Median	55.49	13.39	3.55
		Min, Max	(1.68, 91.45)	(0.49, 49.21)	(1.05, 9.11)
Treatment duration	(Weeks)	N	43	9	8
		Mean (SD)	219 (126.1)	67.1 (78.05)	7.9 (6.99)
		Median	231.9	32.0	5.6
		Min, Max	(2.7, 394.1)	(0.4, 213.4)	(1.4, 21.0)
Treatment duration	(Months)	N	43	9	8
		Mean (SD)	50.5 (29.04)	15.5 (17.97)	1.8 (1.61)

Safety Population: All treated patients

Table 1.1.1.2 (Study 101)
Follow-up and treatment duration
Safety Population - CML Patients

Variable	*Category*	*Statistic*	*CP-CML (N=43)*	*AP-CML (N=9)*	*BP-CML (N=8)*
		Median	53.39	7.37	1.30
		Min, Max	(0.63, 90.76)	(0.10, 49.14)	(0.33, 4.84)

Table 1.1.1.2 (Study 201)
Follow-up and treatment duration
Safety Population - CML Patients

Variable	*Category*	*Statistic*	*CP-CML (N=270)*	*AP-CML (N=85)*	*BP-CML (N=62)*
Follow-up duration	(Weeks)	N	270	85	62
		Mean (SD)	190 (95.80)	157 (91.37)	54.5 (72.15)
		Median	246.9	140.2	26.9
		Min, Max	(0.6, 317.8)	(15.7, 312.2)	(0.3, 288.3)
Follow-up duration	(Months)	N	270	85	62
		Mean (SD)	43.8 (22.05)	36.1 (21.03)	12.5 (16.61)
		Median	56.83	32.27	6.19
		Min, Max	(0.13, 73.13)	(3.62, 71.84)	(0.07, 66.35)
Treatment duration	(Weeks)	N	270	85	62
		Mean (SD)	144 (104.4)	114 (95.53)	32.9 (59.01)
		Median	139.8	84.3	12.7
		Min, Max	(0.4, 317.6)	(2.3, 309.9)	(0.1, 256.9)
Treatment duration	(Months)	N	270	85	62
		Mean (SD)	33.1 (24.04)	26.2 (22.00)	7.6 (13.59)

Safety Population: All treated patients

Table 1.1.1.2 (Study 201)
Follow-up and treatment duration
Safety Population - CML Patients

Variable	*Category*	*Statistic*	*CP-CML (N=270)*	*AP-CML (N=85)*	*BP-CML (N=62)*
		Median	32.19	19.41	2.93
		Min, Max	(0.10, 73.13)	(0.53, 71.35)	(0.03, 59.14)

Safety Population: All treated patients

1.1.2 Patients in CP, AP, or BP by T315I status

Table 1.1.2.1 (Study 101)
Demographic and Baseline Characteristics by T315I Status
Safety Population - CP-CML Patients

T315I	*Variable*	*Category*	*Statistic*	*CP-CML (N=43)*
Yes	T315I	Yes	n (%)	12 (100%)
No	T315I	No	n (%)	31 (100%)
Yes	Gender	Female	n (%)	4 (33.3%)
		Male	n (%)	8 (66.7%)
No	Gender	Female	n (%)	18 (58.1%)
		Male	n (%)	13 (41.9%)
Yes	Age	(Years)	Mean (SD)	48.1 (9.28)
			Median	45.5
			Min, Max	(33, 64)
No	Age	(Years)	Mean (SD)	59.8 (14.78)
			Median	62.0

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
[1] Percentages are based on the patients previously treated with dasatinib or nilotinib.

Table 1.1.2.1 (Study 101)
Demographic and Baseline Characteristics by T315I Status
Safety Population - CP-CML Patients

T315I	*Variable*	*Category*	*Statistic*	*CP-CML (N=43)*
			Min, Max	(27, 85)
Yes	ECOG	Grade 0	n (%)	5 (41.7%)
		Grade 1	n (%)	6 (50.0%)
		Grade 2	n (%)	1 (8.3%)
No	ECOG	Grade 0	n (%)	14 (45.2%)
		Grade 1	n (%)	16 (51.6%)
		Grade 2	n (%)	1 (3.2%)
Yes	Number of prior TKI(s)	2	n (%)	8 (66.7%)
		>=3	n (%)	4 (33.3%)
No	Number of prior TKI(s)	1	n (%)	1 (3.2%)
		2	n (%)	8 (25.8%)
		>=3	n (%)	22 (71.0%)
Yes	Prior Approved TKI	Imatinib	n (%)	12 (100.0%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
[1] Percentages are based on the patients previously treated with dasatinib or nilotinib.

Table 1.1.2.1 (Study 101)
Demographic and Baseline Characteristics by T315I Status
Safety Population - CP-CML Patients

T315I	*Variable*	*Category*	*Statistic*	*CP-CML (N=43)*
		Dasatinib	n (%)	11 (91.7%)
		Nilotinib	n (%)	3 (25.0%)
No	Prior Approved TKI	Imatinib	n (%)	31 (100.0%)
		Dasatinib	n (%)	24 (77.4%)
		Nilotinib	n (%)	21 (67.7%)
Yes	Time since diagnosis	(Years)	Mean (SD)	5.3 (4.82)
			Median	3.9
			Min, Max	(0.8, 16.6)
No	Time since diagnosis	(Years)	Mean (SD)	8.4 (5.11)
			Median	6.8
			Min, Max	(0.9, 23.5)
Yes	Prior dasatinib or nilotinib [1]	All	n	12
		Intolerant	n (%)	3 (25.0%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
[1] Percentages are based on the patients previously treated with dasatinib or nilotinib.

Table 1.1.2.1 (Study 101)
Demographic and Baseline Characteristics by T315I Status
Safety Population - CP-CML Patients

T315I	*Variable*	*Category*	*Statistic*	*CP-CML (N=43)*
No	Prior dasatinib or nilotinib [1]	All	n	28
		Intolerant	n (%)	9 (32.1%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
[1] Percentages are based on the patients previously treated with dasatinib or nilotinib.

Table 1.1.2.1 (Study 201)
Demographic and Baseline Characteristics by T315I Status
Treated Population - CML Patients

T315I [1]	*Variable*	*Category*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
Yes	T315I		n (%)	64 (100%)	18 (100%)	24 (100%)
No	T315I		n (%)	203 (100%)	65 (100%)	38 (100%)
Yes	Gender	Male	n (%)	48 (75.0%)	11 (61.1%)	12 (50.0%)
		Female	n (%)	16 (25.0%)	7 (38.9%)	12 (50.0%)
No	Gender	Male	n (%)	95 (46.8%)	25 (38.5%)	25 (65.8%)
		Female	n (%)	108 (53.2%)	40 (61.5%)	13 (34.2%)
Yes	Age	(Years)	Mean (SD)	52.7 (16.74)	54.1 (16.40)	45.9 (17.46)
			Median	52.0	54.0	45.0
			Min, Max	(18, 87)	(24, 78)	(18, 74)
No	Age	(Years)	Mean (SD)	59.2 (14.29)	55.4 (14.56)	52.9 (15.54)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
[1] T315I Yes: Patients in Cohorts B and D.
T315I No: Three patients in the CP-CML group and two patients in the AP-CML group were excluded from the Treated Population.

Table 1.1.2.1 (Study 201)
Demographic and Baseline Characteristics by T315I Status
Treated Population - CML Patients

T315I [1]	*Variable*	*Category*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
			Median	61.0	60.0	54.5
			Min, Max	(22, 94)	(23, 82)	(18, 74)
Yes	ECOG	Grade 0	n (%)	47 (73.4%)	12 (66.7%)	8 (33.3%)
		Grade 1	n (%)	17 (26.6%)	6 (33.3%)	8 (33.3%)
		Grade 2	n (%)	0 (0.0%)	0 (0.0%)	8 (33.3%)
No	ECOG	Grade 0	n (%)	139 (68.5%)	33 (50.8%)	12 (31.6%)
		Grade 1	n (%)	60 (29.6%)	25 (38.5%)	14 (36.8%)
		Grade 2	n (%)	4 (2.0%)	7 (10.8%)	11 (28.9%)
		Grade 3	n (%)	0 (0.0%)	0 (0.0%)	1 (2.6%)
Yes	Number of prior TKI(s)	1	n (%)	11 (17.2%)	3 (16.7%)	1 (4.2%)
		2	n (%)	27 (42.2%)	6 (33.3%)	13 (54.2%)
		>=3	n (%)	26 (40.6%)	9 (50.0%)	10 (41.7%)
No	Number of prior TKI(s)	1	n (%)	4 (2.0%)	1 (1.5%)	1 (2.6%)
		2	n (%)	63 (31.0%)	22 (33.8%)	10 (26.3%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
[1] T315I Yes: Patients in Cohorts B and D.
T315I No: Three patients in the CP-CML group and two patients in the AP-CML group were excluded from the Treated Population.

Table 1.1.2.1 (Study 201)
Demographic and Baseline Characteristics by T315I Status
Treated Population - CML Patients

T315I [1]	*Variable*	*Category*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
		>=3	n (%)	136 (67.0%)	42 (64.6%)	27 (71.1%)
Yes	Prior approved TKI(s)	No Prior Approved TKI	n (%)	1 (1.6%)	0 (0.0%)	0 (0.0%)
		1 Prior Approved TKI	n (%)	11 (17.2%)	3 (16.7%)	1 (4.2%)
		- Imatinib	n (%)	10 (15.6%)	3 (16.7%)	1 (4.2%)
		- Dasatinib	n (%)	1 (1.6%)	0 (0.0%)	0 (0.0%)
		2 Prior Approved TKIs	n (%)	31 (48.4%)	6 (33.3%)	14 (58.3%)
		- Imatinib + 2nd Generation TKI	n (%)	31 (48.4%)	6 (33.3%)	12 (50.0%)
		- Imatinib + Dasatinib	n (%)	19 (29.7%)	6 (33.3%)	12 (50.0%)
		- Imatinib + Nilotinib	n (%)	12 (18.8%)	0 (0.0%)	0 (0.0%)
		- Dasatinib + Nilotinib	n (%)	0 (0.0%)	0 (0.0%)	2 (8.3%)
		3 Prior Approved TKIs	n (%)	21 (32.8%)	9 (50.0%)	9 (37.5%)
		- Imatinib + Dassatinib + Nilotinib	n (%)	21 (32.8%)	9 (50.0%)	9 (37.5%)
No	Prior approved TKI(s)	1 Prior Approved TKI	n (%)	5 (2.5%)	1 (1.5%)	1 (2.6%)
		- Dasatinib	n (%)	4 (2.0%)	0 (0.0%)	1 (2.6%)
		- Nilotinib	n (%)	1 (0.5%)	1 (1.5%)	0 (0.0%)
		2 Prior Approved TKIs	n (%)	75 (36.9%)	27 (41.5%)	10 (26.3%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
[1] T315I Yes: Patients in Cohorts B and D.
T315I No: Three patients in the CP-CML group and two patients in the AP-CML group were excluded from the Treated Population.

Table 1.1.2.1 (Study 201)
Demographic and Baseline Characteristics by T315I Status
Treated Population - CML Patients

T315I [1]	*Variable*	*Category*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
		- Imatinib + 2nd Generation TKI	n (%)	73 (36.0%)	27 (41.5%)	10 (26.3%)
		- Imatinib + Dasatinib	n (%)	47 (23.2%)	18 (27.7%)	7 (18.4%)
		- Imatinib + Nilotinib	n (%)	26 (12.8%)	9 (13.8%)	3 (7.9%)
		- Dasatinib + Nilotinib	n (%)	2 (1.0%)	0 (0.0%)	0 (0.0%)
		3 Prior Approved TKIs	n (%)	123 (60.6%)	37 (56.9%)	27 (71.1%)
		- Imatinib + Dassatinib + Nilotinib	n (%)	123 (60.6%)	37 (56.9%)	27 (71.1%)
Yes	Time since diagnosis	(Years)	Mean (SD)	5.7 (4.14)	7.5 (4.66)	4.1 (4.15)
			Median	4.8	6.6	2.1
			Min, Max	(1.2, 19.5)	(1.2, 15.9)	(0.5, 14.1)
No	Time since diagnosis	(Years)	Mean (SD)	8.7 (5.70)	9.3 (6.67)	6.4 (5.72)
			Median	7.9	7.1	5.1
			Min, Max	(0.5, 27.4)	(0.3, 28.5)	(0.6, 27.2)
Yes	Prior dasatinib or nilotinib	Resistant	n (%)	50 (78.1%)	14 (77.8%)	23 (95.8%)
		Intolerant but not resistant	n (%)	1 (1.6%)	1 (5.6%)	0 (0.0%)
		Not Resistant or intolerant	n (%)	13 (20.3%)	3 (16.7%)	1 (4.2%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
[1] T315I Yes: Patients in Cohorts B and D.
T315I No: Three patients in the CP-CML group and two patients in the AP-CML group were excluded from the Treated Population.

Table 1.1.2.1 (Study 201)
Demographic and Baseline Characteristics by T315I Status
Treated Population - CML Patients

T315I [1]	*Variable*	*Category*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
No	Prior dasatinib or nilotinib	Resistant	n (%)	165 (81.3%)	60 (92.3%)	36 (94.7%)
		Intolerant but not resistant	n (%)	38 (18.7%)	5 (7.7%)	2 (5.3%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
[1] T315I Yes: Patients in Cohorts B and D.
T315I No: Three patients in the CP-CML group and two patients in the AP-CML group were excluded from the Treated Population.

1.1.2.2 (Study 101)
Follow-up and treatment duration by T315I status
Safety Population - CP-CML Patients

Variable	*Category*	*T315I*	*Statistic*	*CP-CML (N=43)*
Follow-up duration	(Weeks)	Yes	N	12
			Mean (SD)	304 (84.17)
			Median	322.1
			Min, Max	(76.4, 397.1)
Follow-up duration	(Months)	Yes	N	12
			Mean (SD)	70.1 (19.38)
			Median	74.16
			Min, Max	(17.60, 91.45)
Treatment duration	(Weeks)	Yes	N	12
			Mean (SD)	301 (85.05)
			Median	320.1
			Min, Max	(71.1, 394.1)
Treatment duration	(Months)	Yes	N	12
			Mean (SD)	69.2 (19.58)

Safety Population: All treated patients

1.1.2.2 (Study 101)
Follow-up and treatment duration by T315I status
Safety Population - CP-CML Patients

Variable	*Category*	*T315I*	*Statistic*	*CP-CML (N=43)*
			Median	73.70
			Min, Max	(16.38, 90.76)

Safety Population: All treated patients

Table 1.1.2.2 (Study 201)
Follow-up and treatment duration by T315I status
Treated Population - CML Patients

Variable	*Category*	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
Follow-up duration	(Weeks)	Yes	N	64	18	24
			Mean (SD)	189 (96.05)	136 (102.3)	39.6 (38.76)
			Median	236.2	129.8	27.7
			Min, Max	(6.4, 314.7)	(18.4, 312.2)	(1.9, 158.9)
		No	N	203	65	38
			Mean (SD)	190 (96.35)	161 (88.92)	63.9 (86.10)
			Median	249.2	140.2	24.4
			Min, Max	(0.6, 317.8)	(15.7, 310.0)	(0.3, 288.3)
Follow-up duration	(Months)	Yes	N	64	18	24
			Mean (SD)	43.4 (22.10)	31.4 (23.54)	9.1 (8.92)
			Median	54.36	29.87	6.37
			Min, Max	(1.48, 72.43)	(4.24, 71.84)	(0.43, 36.58)
		No	N	203	65	38
			Mean (SD)	43.7 (22.17)	37.0 (20.46)	14.7 (19.82)
			Median	57.34	32.27	5.61

Treated Population: All treated patients who were also assigned to a cohort.

Run Date/Time: 26MAY2020 11:08

Table 1.1.2.2 (Study 201)
Follow-up and treatment duration by T315I status
Treated Population - CML Patients

Variable	*Category*	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
			Min, Max	(0.13, 73.13)	(3.62, 71.35)	(0.07, 66.35)
Treatment duration	(Weeks)	Yes	N	64	18	24
			Mean (SD)	143 (103.6)	113 (93.93)	14.5 (10.59)
			Median	140.5	105.7	10.4
			Min, Max	(3.9, 314.6)	(9.4, 286.9)	(1.6, 33.1)
		No	N	203	65	38
			Mean (SD)	143 (105.1)	111 (96.46)	44.5 (72.88)
			Median	138.6	72.9	13.6
			Min, Max	(0.4, 317.6)	(2.3, 309.9)	(0.1, 256.9)
Treatment duration	(Months)	Yes	N	64	18	24
			Mean (SD)	32.9 (23.87)	25.9 (21.63)	3.3 (2.44)
			Median	32.35	24.34	2.38
			Min, Max	(0.89, 72.43)	(2.17, 66.05)	(0.36, 7.63)
		No	N	203	65	38
			Mean (SD)	32.8 (24.19)	25.7 (22.21)	10.3 (16.78)

Treated Population: All treated patients who were also assigned to a cohort.

Run Date/Time: 26MAY2020 11:08

Table 1.1.2.2 (Study 201)
Follow-up and treatment duration by T315I status
Treated Population - CML Patients

Variable	*Category*	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
			Median	31.91	16.78	3.13
			Min, Max	(0.10, 73.13)	(0.53, 71.35)	(0.03, 59.14)

Treated Population: All treated patients who were also assigned to a cohort.

1.2. Results

1.2.1 Efficacy

1.2.1.1 Mortality

1.2.1.1.1 Patients in CP, AP, or BP

1.2.1.1.1.1 Deaths

Table 1.2.1.1.1.1 (Study 101)
Deaths
Safety Population - CML Patients

Variable	*Category*	*Statistic*	*CP-CML (N=43)*	*AP-CML (N=9)*	*BP-CML (N=8)*
Patient status	Deaths at 24 months	N (%)	1 (2.3%)	1 (11.1%)	5 (62.5%)
		95% CI (Clopper-Pearson)	(0.1%, 12.3%)	(0.3%, 48.2%)	(24.5%, 91.5%)
Patient status	Deaths at 48 months	N (%)	2 (4.7%)	2 (22.2%)	5 (62.5%)
		95% CI (Clopper-Pearson)	(0.6%, 15.8%)	(2.8%, 60.0%)	(24.5%, 91.5%)
Patient status	Deaths at end of trial	N (%)	3 (7.0%)	3 (33.3%)	5 (62.5%)
		95% CI (Clopper-Pearson)	(1.5%, 19.1%)	(7.5%, 70.1%)	(24.5%, 91.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.1.1.1.1 (Study 201)
Deaths
Treated Population - CML Patients

Variable	*Category*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
Patient status	Deaths at 24 months	N (%)	34 (12.7%)	22 (26.5%)	49 (79.0%)
		95% CI (Clopper-Pearson)	(9.0%, 17.3%)	(17.4%, 37.3%)	(66.8%, 88.3%)
Patient status	Deaths at 48 months	N (%)	54 (20.2%)	36 (43.4%)	54 (87.1%)
		95% CI (Clopper-Pearson)	(15.6%, 25.5%)	(32.5%, 54.7%)	(76.1%, 94.3%)
Patient status	Deaths at end of trial	N (%)	59 (22.1%)	39 (47.0%)	54 (87.1%)
		95% CI (Clopper-Pearson)	(17.3%, 27.6%)	(35.9%, 58.3%)	(76.1%, 94.3%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the treated population.

1.2.1.1.1.2 Overall Survival, OS

Figure 1.2.1.1.1.2 (Study 101)
Overall Survival (OS)
Safety Population - CML Patients



	Subjects	Event	Censored	Median Survival	95% CL	
AP-CML	9	3	6	165	30.86	213.6
BP-CML	8	5	3	12	4.429	22
CP-CML	43	3	40	.	.	.

Run Date/Time: 26MAY2020 11:07

Figure 1.2.1.1.1.2 (Study 201)
Overall Survival (OS)
Treated Population - CML Patients



	Subjects	Event	Censored	Median Survival	95% CL	
AP-CML	83	39	44	241.3	140	.
BP-CML	62	54	8	29.86	17	40.57
CP-CML	267	59	208	.	.	.

Run Date/Time: 26MAY2020 11:08

Table 1.2.1.1.1.3 (Study 101)
Overall Survival (OS) at 24 and 48 Months
Safety Population - CML Patients

Diagnosis	*Month*	*Week*	*Number at risk*	*OS (%)*	*95% CI*
CP-CML (N=43)	24	104	31	97.1%	(80.9%, 99.6%)
	48	208	25	93.7%	(77.0%, 98.4%)
AP-CML (N=9)	24	104	3	83.3%	(27.3%, 97.5%)
	48	208	1	41.7%	(1.1%, 84.3%)
BP-CML (N=8)	24	104	0	0.0%	(0.0%, 0.0%)
	48	208	0	0.0%	(0.0%, 0.0%)

Safety Population: All treated patients
Estimates were derived using the Kaplan-Meier method.

Table 1.2.1.1.1.3 (Study 201)
Overall Survival (OS) at 24 and 48 Months
Treated Population - CML Patients

Diagnosis	*Month*	*Week*	*Number at risk*	*OS (%)*	*95% CI*
CP-CML (N=267)	24	104	199	86.0%	(81.0%, 89.8%)
	48	208	161	76.9%	(70.9%, 81.8%)
AP-CML (N=83)	24	104	53	72.2%	(60.9%, 80.8%)
	48	208	31	51.1%	(38.9%, 62.1%)
BP-CML (N=62)	24	104	10	17.5%	(9.0%, 28.3%)
	48	208	5	8.8%	(3.2%, 17.8%)

Treated Population: All treated patients who were also assigned to a cohort.
Estimates were derived using the Kaplan-Meier method.

1.2.1.1.2 Patients in CP, AP, or BP by T315I status

1.2.1.1.2.1 Deaths

Table 1.2.1.1.2.1 (Study 101)
Deaths by T315I status
Safety Population - CP-CML Patients

Variable	*Category*	*T315I*	*Statistic*	*CP-CML (N=43)*
Patient status	Deaths at 24 months	Yes	N total	12
			N (%)	0 (0.0%)
			95% CI (Clopper-Pearson)	(0.0%, 26.5%)
		No	N total	31
			N (%)	1 (3.2%)
			95% CI (Clopper-Pearson)	(0.1%, 16.7%)
			p-value Fisher's exact test	1.0000
	Deaths at 48 months	Yes	N total	12
			N (%)	0 (0.0%)
			95% CI (Clopper-Pearson)	(0.0%, 26.5%)
		No	N total	31
			N (%)	2 (6.5%)
			95% CI (Clopper-Pearson)	(0.8%, 21.4%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.

Table 1.2.1.1.2.1 (Study 101)
Deaths by T315I status
Safety Population - CP-CML Patients

Variable	*Category*	*T315I*	*Statistic*	*CP-CML (N=43)*
			p-value Fisher's exact test	1.0000
Patient status	Deaths at end of trial	Yes	N total	12
			N (%)	0 (0.0%)
			95% CI (Clopper-Pearson)	(0.0%, 26.5%)
		No	N total	31
			N (%)	3 (9.7%)
			95% CI (Clopper-Pearson)	(2.0%, 25.8%)
			p-value Fisher's exact test	0.5478

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.

Table 1.2.1.1.2.1 (Study 201)
Deaths by T315I status
Treated Population - CML Patients

Variable	*Category*	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
Patient status	Deaths at 24 months	Yes	N total	64	18	24
			N (%)	11 (17.2%)	5 (27.8%)	19 (79.2%)
			95% CI (Clopper-Pearson)	(8.9%, 28.7%)	(9.7%, 53.5%)	(57.8%, 92.9%)
		No	N total	203	65	38
			N (%)	23 (11.3%)	17 (26.2%)	30 (78.9%)
			95% CI (Clopper-Pearson)	(7.3%, 16.5%)	(16.0%, 38.5%)	(62.7%, 90.4%)
			p-value Fisher's exact test	0.2809	1.0000	1.0000
	Deaths at 48 months	Yes	N total	64	18	24
			N (%)	16 (25.0%)	7 (38.9%)	22 (91.7%)
			95% CI (Clopper-Pearson)	(15.0%, 37.4%)	(17.3%, 64.3%)	(73.0%, 99.0%)
		No	N total	203	65	38
			N (%)	38 (18.7%)	29 (44.6%)	32 (84.2%)
			95% CI (Clopper-Pearson)	(13.6%, 24.8%)	(32.3%, 57.5%)	(68.7%, 94.0%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.

Table 1.2.1.1.2.1 (Study 201)
Deaths by T315I status
Treated Population - CML Patients

Variable	*Category*	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
			p-value Fisher's exact test	0.2873	0.7903	0.4675
Patient status	Deaths at end of trial	Yes	N total	64	18	24
			N (%)	18 (28.1%)	9 (50.0%)	22 (91.7%)
			95% CI (Clopper-Pearson)	(17.6%, 40.8%)	(26.0%, 74.0%)	(73.0%, 99.0%)
		No	N total	203	65	38
			N (%)	41 (20.2%)	30 (46.2%)	32 (84.2%)
			95% CI (Clopper-Pearson)	(14.9%, 26.4%)	(33.7%, 59.0%)	(68.7%, 94.0%)
			p-value Fisher's exact test	0.2259	0.7957	0.4675

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.

1.2.1.1.2.2 Overall Survival, OS

Figure 1.2.1.1.2.2 (Study 101)
Overall Survival (OS) by T315I status
Safety Population - CP-CML Patients



Run Date/Time: 26MAY2020 11:07

Figure 1.2.1.1.2.2 (Study 201)
Overall Survival by T315I status
Treated Population - CP-CML Patients



Run Date/Time: 26MAY2020 11:08

Figure 1.2.1.1.2.2 (Study 201)
Overall Survival by T315I status
Treated Population - AP-CML Patients



Run Date/Time: 26MAY2020 11:08

Figure 1.2.1.1.2.2 (Study 201)
Overall Survival by T315I status
Treated Population - BP-CML Patients



Table 1.2.1.1.2.3 (Study 101)
Overall Survival (OS) at 24 and 48 Months by T315I Status
Safety Population - CP-CML Patients

Diagnosis	*T315I*	*Month*	*Week*	*Number at risk*	*OS*	*95% CI*
CP-CML (T315I Yes: N=12, No: N=31)	Yes	24	104	11	100.0%	(100.0%, 100.0%)
		48	208	11	100.0%	(100.0%, 100.0%)
	No	24	104	20	95.7%	(72.9%, 99.4%)
		48	208	14	90.3%	(66.3%, 97.5%)

Safety Population: All treated patients
Estimates were derived using the Kaplan-Meier method.

Table 1.2.1.1.2.3 (Study 201)
Overall Survival (OS) at 24 and 48 Months by T315I Status
Treated Population - CML Patients

Diagnosis	*T315I*	*Month*	*Week*	*Number at risk*	*OS (%)*	*95% CI*
CP-CML (T315I Yes: N=64, No: N=203)	Yes	24	104	46	81.5%	(69.1%, 89.3%)
		48	208	37	72.0%	(58.3%, 81.9%)
	No	24	104	153	87.5%	(81.8%, 91.5%)
		48	208	124	78.5%	(71.6%, 83.9%)
AP-CML (T315I Yes: N=18, No: N=65)	Yes	24	104	11	68.8%	(40.5%, 85.6%)
		48	208	5	52.1%	(23.4%, 74.6%)
	No	24	104	42	72.9%	(60.1%, 82.2%)
		48	208	26	50.7%	(37.1%, 62.8%)
BP-CML (T315I Yes: N=24, No: N=38)	Yes	24	104	3	14.4%	(3.6%, 32.2%)
		48	208	0	0.0%	(0.0%, 0.0%)
	No	24	104	7	19.1%	(8.4%, 33.1%)
		48	208	5	13.7%	(5.0%, 26.6%)

Treated Population: All treated patients who were also assigned to a cohort.
Estimates were derived using the Kaplan-Meier method.

1.2.1.2 Major Molecular Response, MMR

1.2.1.2.1 Patients in CP, AP, or BP

Table 1.2.1.2.1.1 (Study 101)
MMR
Safety Population - CML Patients

Variable	*Category*	*Statistic*	*CP-CML (N=43)*	*AP-CML (N=9)*	*BP-CML (N=8)*
MMR	MMR reached before 12 months	N (%)	15 (34.9%)	1 (11.1%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(21.0%, 50.9%)	(0.3%, 48.2%)	(0.0%, 36.9%)
MMR	MMR reached before 24 months	N (%)	19 (44.2%)	1 (11.1%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(29.1%, 60.1%)	(0.3%, 48.2%)	(0.0%, 36.9%)
MMR	MMR reached at any time during trial	N (%)	24 (55.8%)	1 (11.1%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(39.9%, 70.9%)	(0.3%, 48.2%)	(0.0%, 36.9%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.1.2.1.1 (Study 201)
MMR
Treated Population - CML Patients

Variable	*Category*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
MMR	MMR reached before 12 months	N (%)	81 (30.3%)	11 (13.3%)	8 (12.9%)
		95% CI (Clopper-Pearson)	(24.9%, 36.2%)	(6.8%, 22.5%)	(5.7%, 23.9%)
MMR	MMR reached before 24 months	N (%)	96 (36.0%)	16 (19.3%)	8 (12.9%)
		95% CI (Clopper-Pearson)	(30.2%, 42.0%)	(11.4%, 29.4%)	(5.7%, 23.9%)
MMR	MMR reached at any time during trial	N (%)	108 (40.4%)	18 (21.7%)	8 (12.9%)
		95% CI (Clopper-Pearson)	(34.5%, 46.6%)	(13.4%, 32.1%)	(5.7%, 23.9%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the treated population.

Figure 1.2.1.2.1.2 (Study 101)
Time to MMR
Safety Population - CML Patients



Run Date/Time: 26MAY2020 11:07

Figure 1.2.1.2.1.2 (Study 201)
Time to MMR
Treated Population - CML Patients



	Subjects	Event	Censored	Median Survival	95% CL	
AP-CML	83	18	65	.	132.1	.
BP-CML	62	8	54	.	.	.
CP-CML	267	108	159	107.7	72	229.7

Run Date/Time: 26MAY2020 11:08

Table 1.2.1.2.1.3 (Study 101)
Time to MMR in responders
Safety Population - CML Patients

Variable	*Statistic*	*CP-CML (N=43)*	*AP-CML (N=9)*	*BP-CML (N=8)*
Time to MMR (weeks), responders only	N	24	1	0
	Median	32.1	8.1	
	Min, Max	7.7, 264.1	8.1, 8.1	

Safety Population: All treated patients

Table 1.2.1.2.1.3 (Study 201)
Time to MMR in responders
Treated Population - CML Patients

Variable	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
Time to MMR (weeks), responders only	N	108	18	8
	Median	24.0	48.1	8.1
	Min, Max	7.9, 240.9	7.9, 194.9	7.7, 16.1

Treated Population: All treated patients who were also assigned to a cohort.

Table 1.2.1.2.1.4 (Study 101)
Probability of no MMR yet at 12 and 24 months
Safety Population - CML Patients

Diagnosis	*Month*	*Week*	*Number at risk*	*No MMR yet (%)*	*95% CI*
CP-CML (N=43)	12	52	21	61.4%	(44.2%, 74.7%)
	24	104	13	47.6%	(30.2%, 63.1%)
AP-CML (N=9)	12	52	3	83.3%	(27.3%, 97.5%)
	24	104	3	83.3%	(27.3%, 97.5%)
BP-CML (N=8)	12	52	.	.%	(.%, .%)
	24	104	.	.%	(.%, .%)

Safety Population: All treated patients
Total numbers refer to the patients with an MMR.
Estimates were derived using the Kaplan-Meier method.

Table 1.2.1.2.1.4 (Study 201)
Probability of no MMR yet at 12 and 24 months
Treated Population - CML Patients

Diagnosis	*Month*	*Week*	*Number at risk*	*No MMR yet (%)*	*95% CI*
CP-CML (N=267)	12	52	99	62.5%	(55.6%, 68.8%)
	24	104	65	52.4%	(44.9%, 59.4%)
AP-CML (N=83)	12	52	37	80.9%	(67.6%, 89.1%)
	24	104	17	67.7%	(51.7%, 79.4%)
BP-CML (N=62)	12	52	2	72.7%	(50.2%, 86.3%)
	24	104	1	72.7%	(50.2%, 86.3%)

Treated Population: All treated patients who were also assigned to a cohort.
Estimates were derived using the Kaplan-Meier method.

1.2.1.2.2 Patients in CP, AP, or BP by T315I status

Table 1.2.1.2.2.1 (Study 101)
MMR by T315I status
Safety Population - CP-CML Patients

Variable	*Category*	*T315I*	*Statistic*	*CP-CML (N=43)*
MMR	MMR reached before 12 months	Yes	N total	12
			N (%)	5 (41.7%)
			95% CI (Clopper-Pearson)	(15.2%, 72.3%)
		No	N total	31
			N (%)	10 (32.3%)
			95% CI (Clopper-Pearson)	(16.7%, 51.4%)
			p-value Fisher's exact test	0.7234
MMR	MMR reached before 24 months	Yes	N total	12
			N (%)	8 (66.7%)
			95% CI (Clopper-Pearson)	(34.9%, 90.1%)
		No	N total	31
			N (%)	11 (35.5%)
			95% CI (Clopper-Pearson)	(19.2%, 54.6%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.

Table 1.2.1.2.2.1 (Study 101)
MMR by T315I status
Safety Population - CP-CML Patients

Variable	*Category*	*T315I*	*Statistic*	*CP-CML (N=43)*
			p-value Fisher's exact test	0.0915
MMR	MMR reached at any time during trial	Yes	N total	12
			N (%)	9 (75.0%)
			95% CI (Clopper-Pearson)	(42.8%, 94.5%)
		No	N total	31
			N (%)	15 (48.4%)
			95% CI (Clopper-Pearson)	(30.2%, 66.9%)
			p-value Fisher's exact test	0.1741

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.

Table 1.2.1.2.2.1 (Study 201)
MMR by T315I status
Treated Population - CML Patients

Variable	*Category*	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
MMR	MMR reached before 12 months	Yes	N total	64	18	24
			N (%)	9 (14.1%)	4 (22.2%)	1 (4.2%)
			95% CI (Clopper-Pearson)	(6.6%, 25.0%)	(6.4%, 47.6%)	(0.1%, 21.1%)
		No	N total	203	65	38
			N (%)	27 (13.3%)	6 (9.2%)	4 (10.5%)
			95% CI (Clopper-Pearson)	(9.0%, 18.8%)	(3.5%, 19.0%)	(2.9%, 24.8%)
			p-value Fisher's exact test	0.8365	0.2124	0.6402
MMR	MMR reached before 24 months	Yes	N total	64	18	24
			N (%)	18 (28.1%)	5 (27.8%)	1 (4.2%)
			95% CI (Clopper-Pearson)	(17.6%, 40.8%)	(9.7%, 53.5%)	(0.1%, 21.1%)
		No	N total	203	65	38
			N (%)	31 (15.3%)	7 (10.8%)	4 (10.5%)
			95% CI (Clopper-Pearson)	(10.6%, 21.0%)	(4.4%, 20.9%)	(2.9%, 24.8%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.

Run Date/Time: 26MAY2020 11:09

Table 1.2.1.2.2.1 (Study 201)
MMR by T315I status
Treated Population - CML Patients

Variable	*Category*	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
			p-value Fisher's exact test	0.0263	0.1221	0.6402
MMR	MMR reached at any time during trial	Yes	N total	64	18	24
			N (%)	37 (57.8%)	6 (33.3%)	1 (4.2%)
			95% CI (Clopper-Pearson)	(44.8%, 70.1%)	(13.3%, 59.0%)	(0.1%, 21.1%)
		No	N total	203	65	38
			N (%)	71 (35.0%)	12 (18.5%)	7 (18.4%)
			95% CI (Clopper-Pearson)	(28.4%, 42.0%)	(9.9%, 30.0%)	(7.7%, 34.3%)
			p-value Fisher's exact test	0.0020	0.2027	0.1361

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.

Figure 1.2.1.2.2.2 (Study 101)
Time to MMR by T315I status
Safety Population - CP-CML Patients



Run Date/Time: 26MAY2020 11:07

Figure 1.2.1.2.2.2 (Study 201)
Time to MMR by T315I status
Treated Population - CP-CML Patients



Figure 1.2.1.2.2.2 (Study 201)
Time to MMR by T315I status
Treated Population - AP-CML Patients



Run Date/Time: 26MAY2020 11:08

Figure 1.2.1.2.2.2 (Study 201)
Time to MMR by T315I status
Treated Population - BP-CML Patients



Table 1.2.1.2.2.3 (Study 101)
Time to MMR in responders by T315I status
Safety Population - CP-CML Patients

Variable	*T315I*	*Statistic*	*CP-CML (N=43)*
Time to MMR (weeks), responders only	Yes	N	9
		Median	32.1
		Min, Max	8.3, 168.3
	No	N	15
		Median	32.1
		Min, Max	7.7, 264.1

Safety Population: All treated patients

Table 1.2.1.2.2.3 (Study 201)
Time to MMR in responders by T315I status
Treated Population - CML Patients

Variable	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
Time to MMR (weeks), responders only	Yes	N	37	6	1
		Median	23.9	47.9	9.6
		Min, Max	11.6, 108.0	15.3, 132.1	9.6, 9.6
	No	N	71	12	7
		Median	24.7	48.6	8.0
		Min, Max	7.9, 240.9	7.9, 194.9	7.7, 16.1

Treated Population: All treated patients who were also assigned to a cohort.

Table 1.2.1.2.2.4 (Study 101)
Probability of no MMR yet at 12 and 24 months by T315I Status
Safety Population - CP-CML Patients

Diagnosis	*T315I*	*Month*	*Week*	*Number at risk*	*No MMR yet (%)*	*95% CI*
CP-CML (T315I Yes: N=12, No: N=31)	Yes	12	52	7	58.3%	(27.0%, 80.1%)
		24	104	3	31.3%	(8.4%, 57.8%)
	No	12	52	14	62.6%	(41.4%, 78.0%)
		24	104	10	56.9%	(35.0%, 73.9%)

Safety Population: All treated patients
Estimates were derived using the Kaplan-Meier method.

Table 1.2.1.2.2.4 (Study 201)
Probability of no MMR yet at 12 and 24 months by T315I Status
Treated Population - CML Patients

Diagnosis	*T315I*	*Month*	*Week*	*Number at risk*	*No MMR yet (%)*	*95% CI*
CP-CML (T315I Yes: N=64, No: N=203)	Yes	12	52	13	34.2%	(21.0%, 47.8%)
		24	104	5	28.0%	(15.4%, 42.0%)
	No	12	52	86	71.5%	(63.7%, 77.8%)
		24	104	60	60.1%	(51.5%, 67.8%)
AP-CML (T315I Yes: N=18, No: N=65)	Yes	12	52	4	54.2%	(17.5%, 80.6%)
		24	104	2	40.6%	(9.8%, 70.5%)
	No	12	52	33	85.8%	(71.9%, 93.1%)
		24	104	15	73.0%	(55.4%, 84.6%)
BP-CML (T315I Yes: N=24, No: N=38)	Yes	12	52	.	.%	(.%, .%)
		24	104	.	.%	(.%, .%)
	No	12	52	2	66.4%	(39.2%, 83.6%)
		24	104	1	66.4%	(39.2%, 83.6%)

Treated Population: All treated patients who were also assigned to a cohort.
Estimates were derived using the Kaplan-Meier method.

1.2.1.3 Duration of MMR

1.2.1.3.1 Patients in CP, AP, or BP

Table 1.2.1.3.1.1 (Study 101)
Duration of MMR
Safety Population - CML Patients

Diagnosis	*Month*	*Week*	*Number at risk*	*Remaining in response (%)*	*95% CI*
CP-CML (N=24)	6	26	18	75.0%	(52.6%, 87.9%)
	12	52	15	62.5%	(40.3%, 78.4%)
	36	156	11	45.8%	(25.6%, 64.0%)
	48	208	10	45.8%	(25.6%, 64.0%)
	60	260	8	45.8%	(25.6%, 64.0%)
AP-CML (N=1)	6	26	0	0.0%	(0.0%, 0.0%)
	12	52	0	0.0%	(0.0%, 0.0%)
	36	156	0	0.0%	(0.0%, 0.0%)
	48	208	0	0.0%	(0.0%, 0.0%)
	60	260	0	0.0%	(0.0%, 0.0%)

Safety Population: All treated patients
Total numbers refer to the patients with an MMR.
Estimates were derived using the Kaplan-Meier method.

Table 1.2.1.3.1.1 (Study 201)
Duration of MMR
Treated Population - CML Patients

Diagnosis	*Month*	*Week*	*Number at risk*	*Remaining in response (%)*	*95% CI*
CP-CML (N=108)	6	26	81	79.9%	(70.9%, 86.4%)
	12	52	72	73.9%	(64.3%, 81.3%)
	36	156	47	61.0%	(50.6%, 69.8%)
	48	208	40	61.0%	(50.6%, 69.8%)
	60	260	5	59.2%	(48.5%, 68.4%)
AP-CML (N=18)	6	26	12	75.0%	(46.3%, 89.8%)
	12	52	8	50.0%	(24.5%, 71.0%)
	36	156	5	37.5%	(15.4%, 59.8%)
	48	208	2	37.5%	(15.4%, 59.8%)
	60	260	.	.%	(.%, .%)
BP-CML (N=8)	6	26	4	50.0%	(15.2%, 77.5%)
	12	52	3	50.0%	(15.2%, 77.5%)
	36	156	2	50.0%	(15.2%, 77.5%)
	48	208	2	50.0%	(15.2%, 77.5%)
	60	260	.	.%	(.%, .%)

Treated Population: All treated patients who were also assigned to a cohort.
Total numbers refer to the patients with an MMR.
Estimates were derived using the Kaplan-Meier method.

Figure 1.2.1.3.1.2 (Study 101)
Duration of MMR
Safety Population - CML Patients



Run Date/Time: 26MAY2020 11:07

Figure 1.2.1.3.1.2 (Study 201)
Duration of MMR
Treated Population - CML Patients



AP-CML	18	8	6	5	4	0
BP-CML	8	3	3	2	2	0
CP-CML	108	72	59	48	40	9

	Subjects	Event	Censored	Median Survival	95% CL	
AP-CML	18	10	8	58.07	20.29	.
BP-CML	8	4	4	.	5.857	.
CP-CML	108	40	68	.	223	.

1.2.1.3.2 Patients in CP, AP, or BP by T315I status

Table 1.2.1.3.2.1 (Study 101)
Duration of MMR by T315I status
Safety Population - CP-CML Patients

Diagnosis	*T315I*	*Month*	*Week*	*Number at risk*	*Remaining in response (%)*	*95% CI*
CP-CML (T315I Yes: N=9, No: N=15)	Yes	6	26	8	88.9%	(43.3%, 98.4%)
		12	52	7	77.8%	(36.5%, 93.9%)
		36	156	5	55.6%	(20.4%, 80.5%)
		48	208	5	55.6%	(20.4%, 80.5%)
		60	260	4	55.6%	(20.4%, 80.5%)
	No	6	26	10	66.7%	(37.5%, 84.6%)
		12	52	8	53.3%	(26.3%, 74.4%)
		36	156	6	40.0%	(16.5%, 62.8%)
		48	208	5	40.0%	(16.5%, 62.8%)
		60	260	4	40.0%	(16.5%, 62.8%)

Safety Population: All treated patients
Total numbers refer to the patients with an MMR.
Estimates were derived using the Kaplan-Meier method.

Table 1.2.1.3.2.1 (Study 201)
Duration of MMR by T315I status
Treated Population - CML Patients

Diagnosis	*T315I*	*Month*	*Week*	*Number at risk*	*Remaining in response (%)*	*95% CI*
CP-CML (T315I Yes: N=37, No: N=71)	Yes	6	26	29	88.6%	(72.4%, 95.5%)
		12	52	28	85.5%	(68.6%, 93.7%)
		36	156	17	65.3%	(45.8%, 79.2%)
		48	208	16	65.3%	(45.8%, 79.2%)
		60	260	2	60.3%	(39.9%, 75.6%)
	No	6	26	52	75.7%	(63.8%, 84.1%)
		12	52	44	68.3%	(55.9%, 77.8%)
		36	156	30	58.8%	(46.1%, 69.5%)
		48	208	24	58.8%	(46.1%, 69.5%)
		60	260	3	58.8%	(46.1%, 69.5%)
AP-CML (T315I Yes: N=6, No: N=12)	Yes	6	26	3	60.0%	(12.6%, 88.2%)
		12	52	2	40.0%	(5.2%, 75.3%)
		36	156	.	.%	(.%, .%)
		48	208	.	.%	(.%, .%)

Treated Population: All treated patients who were also assigned to a cohort.
Total numbers refer to the patients with an MMR.
Estimates were derived using the Kaplan-Meier method.

Run Date/Time: 26MAY2020 11:09

Table 1.2.1.3.2.1 (Study 201)
Duration of MMR by T315I status
Treated Population - CML Patients

Diagnosis	*T315I*	*Month*	*Week*	*Number at risk*	*Remaining in response (%)*	*95% CI*
		60	260	.	.%	(.%, .%)
	No	6	26	9	81.8%	(44.7%, 95.1%)
		12	52	6	54.5%	(22.9%, 78.0%)
		36	156	5	45.5%	(16.7%, 70.7%)
		48	208	2	45.5%	(16.7%, 70.7%)
		60	260	.	.%	(.%, .%)
BP-CML (T315I Yes: N=1, No: N=7)	Yes	6	26	0	0.0%	(0.0%, 0.0%)
		12	52	0	0.0%	(0.0%, 0.0%)
		36	156	0	0.0%	(0.0%, 0.0%)
		48	208	0	0.0%	(0.0%, 0.0%)
		60	260	0	0.0%	(0.0%, 0.0%)
	No	6	26	4	57.1%	(17.2%, 83.7%)
		12	52	3	57.1%	(17.2%, 83.7%)
		36	156	2	57.1%	(17.2%, 83.7%)

Treated Population: All treated patients who were also assigned to a cohort.
Total numbers refer to the patients with an MMR.
Estimates were derived using the Kaplan-Meier method.

Table 1.2.1.3.2.1 (Study 201)
Duration of MMR by T315I status
Treated Population - CML Patients

Diagnosis	*T315I*	*Month*	*Week*	*Number at risk*	*Remaining in response (%)*	*95% CI*
		48	208	2	57.1%	(17.2%, 83.7%)
		60	260	.	.%	(.%, .%)

Treated Population: All treated patients who were also assigned to a cohort.
Total numbers refer to the patients with an MMR.
Estimates were derived using the Kaplan-Meier method.

Figure 1.2.1.3.2.2 (Study 101)
Duration of MMR by T315I status
Safety Population - CP-CML Patients



Run Date/Time: 26MAY2020 11:07

Figure 1.2.1.3.2.2 (Study 201)
Duration of MMR by T315I status
Treated Population - CP-CML Patients



Run Date/Time: 26MAY2020 11:09

Figure 1.2.1.3.2.2 (Study 201)
Duration of MMR by T315I status
Treated Population - AP-CML Patients



Figure 1.2.1.3.2.2 (Study 201)
Duration of MMR by T315I status
Treated Population - BP-CML Patients



1.2.1.4 Disease progression in blast crisis

1.2.1.4.1 Patients in CP, AP, or BP

Table 1.2.1.4.1 (Study 101)
Blast crisis
Safety Population - CML Patients

Variable	*Statistic*	*CP-CML (N=43)*	*AP-CML (N=9)*	*BP-CML (N=8)*
Blast crisis [1]	N (%)	1 (2.3%)	0 (0.0%)	1 (12.5%)
	95% CI (Clopper-Pearson)	(0.1%, 12.3%)	(0.0%, 33.6%)	(0.3%, 52.7%)

Safety Population: All treated patients
Percentages are based on the safety population.
[1] Patients with any TEAE of BLAST CRISIS IN MYELOGENOUS LEUKAEMIA.

Table 1.2.1.4.1 (Study 201)
Blast crisis
Safety Population - CML Patients

Variable	*Statistic*	*CP-CML (N=270)*	*AP-CML (N=85)*	*BP-CML (N=62)*
Blast crisis [1]	N (%)	0 (0.0%)	2 (2.4%)	2 (3.2%)
	95% CI (Clopper-Pearson)	(0.0%, 1.4%)	(0.3%, 8.2%)	(0.4%, 11.2%)

Safety Population: All treated patients
Percentages are based on the Safety Population.
[1] Patients with any TEAE of BLAST CRISIS IN MYELOGENOUS LEUKAEMIA.

1.2.1.4.2 Patients in CP, AP, or BP by T315I status

Table 1.2.1.4.2 (Study 101)
Blast crisis by T315I status
Safety Population - CP-CML Patients

Variable	*Category*	*T315I*	*Statistic*	*CP-CML (N=43)*
Patient status	Blast crisis [1]	Yes	N total	12
			N (%)	0 (0.0%)
			95% CI (Clopper-Pearson)	(0.0%, 26.5%)
		No	N total	31
			N (%)	1 (3.2%)
			95% CI (Clopper-Pearson)	(0.1%, 16.7%)
			p-value Fisher's exact test	1.0000

Safety Population: All treated patients
Percentages are based on the safety population.
[1] Patients with any TEAE of BLAST CRISIS IN MYELOGENOUS LEUKAEMIA.

Table 1.2.1.4.2 (Study 201)
Blast crisis by T315I Status
Treated Population - CML Patients

Variable	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
Blast crisis [1]	Yes	N total	64	18	24
		N (%)	0 (0.0%)	1 (5.6%)	1 (4.2%)
		95% CI (Clopper-Pearson)	(0.0%, 5.6%)	(0.1%, 27.3%)	(0.1%, 21.1%)
	No	N total	203	65	38
		N (%)	0 (0.0%)	1 (1.5%)	1 (2.6%)
		95% CI (Clopper-Pearson)	(0.0%, 1.8%)	(0.0%, 8.3%)	(0.1%, 13.8%)
		p-value Fisher's exact test		0.3888	1.0000

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
[1] Patients with any TEAE of BLAST CRISIS IN MYELOGENOUS LEUKAEMIA.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.1.4.3 (Study 201)
Blast crisis by T315I Status
Safety Population - CML Patients Excluded From Treated Population

Variable	*T315I*	*Statistic*	*CP-CML (N=3)*	*AP-CML (N=2)*
Blast crisis [1]	No	N total	3	2
		N (%)	0 (0.0%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(0.0%, 84.2%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
[1] Patients with any TEAE of BLAST CRISIS IN MYELOGENOUS LEUKAEMIA.

1.2.2 Safety and Tolerability

1.2.2.1 Overview TEAE

1.2.2.1.1 Patients in CP, AP, or BP

Table 1.2.2.1.1 (Study 101)
Overview of Adverse Events
Safety Population - CML Patients

Patients with any		*CP-CML (N=43)*	*AP-CML (N=9)*	*BP-CML (N=8)*
Treatment-emergent AE (TEAE)		43 (100.0%)	9 (100.0%)	8 (100.0%)
Serious TEAE (SAE)		33 (76.7%)	8 (88.9%)	8 (100.0%)
TEAE leading to permanent discontinuation		11 (25.6%)	4 (44.4%)	0 (0.0%)
TEAE of Grade 3 & 4		34 (79.1%)	4 (44.4%)	3 (37.5%)
TEAE of Grade 5		3 (7.0%)	3 (33.3%)	5 (62.5%)
TEAE of Grade >=3		37 (86.0%)	7 (77.8%)	8 (100.0%)
TEAE of special interest (AESI)	Arterial Occlusive Events	19 (44.2%)	2 (22.2%)	4 (50.0%)
	Cardiovascular Arterial Occlusive Events	14 (32.6%)	0 (0.0%)	3 (37.5%)
	Cerebrovascular Arterial Occlusive Events	5 (11.6%)	1 (11.1%)	1 (12.5%)
	Peripheral Vascular Arterial Occlusive Events	8 (18.6%)	1 (11.1%)	0 (0.0%)
	Venous Thrombotic/Embolic Events	3 (7.0%)	0 (0.0%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.1.1 (Study 101)
Overview of Adverse Events
Safety Population - CML Patients

Patients with any		*CP-CML (N=43)*	*AP-CML (N=9)*	*BP-CML (N=8)*
	Vascular Occlusive Events	20 (46.5%)	2 (22.2%)	5 (62.5%)
	Hepatoxicity	14 (32.6%)	3 (33.3%)	4 (50.0%)
	Cardiac Failure	5 (11.6%)	1 (11.1%)	0 (0.0%)
	Skin and subcutaneous tissue disorders	36 (83.7%)	5 (55.6%)	5 (62.5%)
	Infections and infestations	35 (81.4%)	6 (66.7%)	6 (75.0%)
	Myelosuppression	25 (58.1%)	6 (66.7%)	5 (62.5%)
	Edema and Fluid Retention	22 (51.2%)	5 (55.6%)	4 (50.0%)
	Hypertension	21 (48.8%)	4 (44.4%)	2 (25.0%)
	Eye disorder	19 (44.2%)	4 (44.4%)	3 (37.5%)
	Bleeding Events	17 (39.5%)	2 (22.2%)	4 (50.0%)
	Pancreatitis	19 (44.2%)	3 (33.3%)	0 (0.0%)
	Clinical Pancreatitis	8 (18.6%)	3 (33.3%)	0 (0.0%)
	Chemical Pancreatitis	16 (37.2%)	2 (22.2%)	0 (0.0%)
	Cardiac Arrhythmias	15 (34.9%)	2 (22.2%)	6 (75.0%)
	Hypothyroidism	4 (9.3%)	0 (0.0%)	1 (12.5%)
SAE of special interest (Serious AESI)	Arterial Occlusive Events	16 (37.2%)	2 (22.2%)	2 (25.0%)
	Cardiovascular Arterial Occlusive Events	10 (23.3%)	0 (0.0%)	2 (25.0%)
	Cerebrovascular Arterial Occlusive Events	4 (9.3%)	1 (11.1%)	0 (0.0%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.1.1 (Study 101)
Overview of Adverse Events
Safety Population - CML Patients

Patients with any		*CP-CML (N=43)*	*AP-CML (N=9)*	*BP-CML (N=8)*
	Peripheral Vascular Arterial Occlusive Events	6 (14.0%)	1 (11.1%)	0 (0.0%)
	Venous Thrombotic/Embolic Events	1 (2.3%)	0 (0.0%)	1 (12.5%)
	Vascular Occlusive Events	16 (37.2%)	2 (22.2%)	3 (37.5%)
	Hepatoxicity	1 (2.3%)	0 (0.0%)	0 (0.0%)
	Cardiac Failure	2 (4.7%)	0 (0.0%)	0 (0.0%)
	Skin and subcutaneous tissue disorders	2 (4.7%)	0 (0.0%)	0 (0.0%)
	Infections and infestations	12 (27.9%)	5 (55.6%)	5 (62.5%)
	Myelosuppression	3 (7.0%)	1 (11.1%)	3 (37.5%)
	Edema and Fluid Retention	1 (2.3%)	1 (11.1%)	0 (0.0%)
	Hypertension	1 (2.3%)	0 (0.0%)	0 (0.0%)
	Eye disorder	1 (2.3%)	1 (11.1%)	0 (0.0%)
	Bleeding Events	3 (7.0%)	0 (0.0%)	1 (12.5%)
	Pancreatitis	4 (9.3%)	3 (33.3%)	0 (0.0%)
	Clinical Pancreatitis	4 (9.3%)	3 (33.3%)	0 (0.0%)
	Cardiac Arrhythmias	5 (11.6%)	1 (11.1%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.1.1 (Study 201)
Overview of Adverse Events
Safety Population - CML Patients

Patients with any		*CP-CML (N=270)*	*AP-CML (N=85)*	*BP-CML (N=62)*
Treatment-emergent AE (TEAE)		270 (100.0%)	85 (100.0%)	62 (100.0%)
Serious TEAE (SAE)		171 (63.3%)	59 (69.4%)	53 (85.5%)
TEAE leading to permanent discontinuation		57 (21.1%)	10 (11.8%)	9 (14.5%)
TEAE of Grade 3 & 4		221 (81.9%)	60 (70.6%)	26 (41.9%)
TEAE of Grade 5		18 (6.7%)	18 (21.2%)	32 (51.6%)
TEAE of Grade >=3		239 (88.5%)	78 (91.8%)	58 (93.5%)
TEAE of special interest (AESI)	Arterial Occlusive Events	84 (31.1%)	17 (20.0%)	7 (11.3%)
	Cardiovascular Arterial Occlusive Events	42 (15.6%)	12 (14.1%)	4 (6.5%)
	Cerebrovascular Arterial Occlusive Events	35 (13.0%)	5 (5.9%)	0 (0.0%)
	Peripheral Vascular Arterial Occlusive Events	38 (14.1%)	5 (5.9%)	2 (3.2%)
	Venous Thrombotic/Embolic Events	15 (5.6%)	3 (3.5%)	6 (9.7%)

Safety Population: All treated patients
Percentages are based on the Safety Population.

Table 1.2.2.1.1 (Study 201)
Overview of Adverse Events
Safety Population - CML Patients

Patients with any		*CP-CML (N=270)*	*AP-CML (N=85)*	*BP-CML (N=62)*
	Vascular Occlusive Events	92 (34.1%)	19 (22.4%)	11 (17.7%)
	Hepatoxicity	78 (28.9%)	31 (36.5%)	20 (32.3%)
	Cardiac Failure	22 (8.1%)	6 (7.1%)	9 (14.5%)
	Skin and subcutaneous tissue disorders	223 (82.6%)	68 (80.0%)	43 (69.4%)
	Infections and infestations	171 (63.3%)	65 (76.5%)	35 (56.5%)
	Myelosuppression	148 (54.8%)	60 (70.6%)	42 (67.7%)
	Edema and Fluid Retention	79 (29.3%)	30 (35.3%)	20 (32.3%)
	Hypertension	100 (37.0%)	22 (25.9%)	14 (22.6%)
	Eye disorder	87 (32.2%)	28 (32.9%)	12 (19.4%)
	Bleeding Events	61 (22.6%)	32 (37.6%)	23 (37.1%)
	Pancreatitis	86 (31.9%)	19 (22.4%)	12 (19.4%)
	Clinical Pancreatitis	21 (7.8%)	7 (8.2%)	3 (4.8%)
	Chemical Pancreatitis	77 (28.5%)	16 (18.8%)	9 (14.5%)
	Cardiac Arrhythmias	52 (19.3%)	14 (16.5%)	15 (24.2%)
	QT Prolongation	17 (6.3%)	5 (5.9%)	2 (3.2%)
	Hypothyroidism	9 (3.3%)	4 (4.7%)	1 (1.6%)
	Tumour lysis syndrome	0 (0.0%)	2 (2.4%)	1 (1.6%)
SAE of special interest (Serious AESI)	Arterial Occlusive Events	69 (25.6%)	13 (15.3%)	5 (8.1%)

Safety Population: All treated patients
Percentages are based on the Safety Population.

Table 1.2.2.1.1 (Study 201)
Overview of Adverse Events
Safety Population - CML Patients

Patients with any		*CP-CML (N=270)*	*AP-CML (N=85)*	*BP-CML (N=62)*
	Cardiovascular Arterial Occlusive Events	33 (12.2%)	8 (9.4%)	3 (4.8%)
	Cerebrovascular Arterial Occlusive Events	28 (10.4%)	4 (4.7%)	0 (0.0%)
	Peripheral Vascular Arterial Occlusive Events	31 (11.5%)	3 (3.5%)	1 (1.6%)
	Venous Thrombotic/Embolic Events	13 (4.8%)	2 (2.4%)	6 (9.7%)
	Vascular Occlusive Events	78 (28.9%)	14 (16.5%)	10 (16.1%)
	Hepatoxicity	7 (2.6%)	4 (4.7%)	1 (1.6%)
	Cardiac Failure	13 (4.8%)	5 (5.9%)	8 (12.9%)
	Skin and subcutaneous tissue disorders	8 (3.0%)	4 (4.7%)	2 (3.2%)
	Infections and infestations	42 (15.6%)	29 (34.1%)	19 (30.6%)
	Myelosuppression	17 (6.3%)	13 (15.3%)	12 (19.4%)
	Edema and Fluid Retention	9 (3.3%)	4 (4.7%)	4 (6.5%)
	Hypertension	11 (4.1%)	3 (3.5%)	0 (0.0%)
	Eye disorder	8 (3.0%)	2 (2.4%)	0 (0.0%)
	Bleeding Events	9 (3.3%)	11 (12.9%)	5 (8.1%)
	Pancreatitis	23 (8.5%)	6 (7.1%)	3 (4.8%)
	Clinical Pancreatitis	19 (7.0%)	5 (5.9%)	2 (3.2%)
	Chemical Pancreatitis	7 (2.6%)	1 (1.2%)	1 (1.6%)
	Cardiac Arrhythmias	23 (8.5%)	3 (3.5%)	6 (9.7%)

Safety Population: All treated patients
Percentages are based on the Safety Population.

Table 1.2.2.1.1 (Study 201)
Overview of Adverse Events
Safety Population - CML Patients

Patients with any		*CP-CML (N=270)*	*AP-CML (N=85)*	*BP-CML (N=62)*
	QT Prolongation	8 (3.0%)	2 (2.4%)	1 (1.6%)
	Tumour lysis syndrome	0 (0.0%)	1 (1.2%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the Safety Population.

1.2.2.1.2 Patients in CP, AP, or BP by T315I status

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=43)*
Treatment-emergent AE (TEAE)	Yes	N total	12
		N (%)	12 (100.0%)
		95% CI (Clopper-Pearson)	(73.5%, 100.0%)
	No	N total	31
		N (%)	31 (100.0%)
		95% CI (Clopper-Pearson)	(88.8%, 100.0%)
Serious TEAE (SAE)	Yes	N total	12
		N (%)	10 (83.3%)
		95% CI (Clopper-Pearson)	(51.6%, 97.9%)
	No	N total	31
		N (%)	23 (74.2%)
		95% CI (Clopper-Pearson)	(55.4%, 88.1%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=43)*
		p-value Fisher's exact test	0.6983
TEAE leading to permanent discontinuation	Yes	N total	12
		N (%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 26.5%)
	No	N total	31
		N (%)	11 (35.5%)
		95% CI (Clopper-Pearson)	(19.2%, 54.6%)
		p-value Fisher's exact test	0.0195
TEAE of Grade 3 & 4	Yes	N total	12
		N (%)	10 (83.3%)
		95% CI (Clopper-Pearson)	(51.6%, 97.9%)
	No	N total	31
		N (%)	24 (77.4%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Run Date/Time: 26MAY2020 11:08

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=43)*
		95% CI (Clopper-Pearson)	(58.9%, 90.4%)
		p-value Fisher's exact test	1.0000
TEAE of Grade 5	Yes	N total	12
		N (%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 26.5%)
	No	N total	31
		N (%)	3 (9.7%)
		95% CI (Clopper-Pearson)	(2.0%, 25.8%)
		p-value Fisher's exact test	0.5478
TEAE of Grade >=3	Yes	N total	12
		N (%)	10 (83.3%)
		95% CI (Clopper-Pearson)	(51.6%, 97.9%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any		*T315I*	*Statistic*	*CP-CML (N=43)*
		No	N total	31
			N (%)	27 (87.1%)
			95% CI (Clopper-Pearson)	(70.2%, 96.4%)
			p-value Fisher's exact test	1.0000
TEAE of special interest (AESI)	Arterial Occlusive Events	Yes	N total	12
			N (%)	1 (8.3%)
			95% CI (Clopper-Pearson)	(0.2%, 38.5%)
		No	N total	31
			N (%)	18 (58.1%)
			95% CI (Clopper-Pearson)	(39.1%, 75.5%)
			p-value Fisher's exact test	0.0051
	Cardiovascular Arterial Occlusive Events	Yes	N total	12
			N (%)	1 (8.3%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=43)*
		95% CI (Clopper-Pearson)	(0.2%, 38.5%)
	No	N total	31
		N (%)	13 (41.9%)
		95% CI (Clopper-Pearson)	(24.5%, 60.9%)
		p-value Fisher's exact test	0.0667
Cerebrovascular Arterial Occlusive Events	Yes	N total	12
		N (%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 26.5%)
	No	N total	31
		N (%)	5 (16.1%)
		95% CI (Clopper-Pearson)	(5.5%, 33.7%)
		p-value Fisher's exact test	0.2996

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any		*T315I*	*Statistic*	*CP-CML (N=43)*
	Peripheral Vascular Arterial Occlusive Events	Yes	N total	12
			N (%)	1 (8.3%)
			95% CI (Clopper-Pearson)	(0.2%, 38.5%)
		No	N total	31
			N (%)	7 (22.6%)
			95% CI (Clopper-Pearson)	(9.6%, 41.1%)
			p-value Fisher's exact test	0.4071
	Venous Thrombotic/Embolic Events	Yes	N total	12
			N (%)	1 (8.3%)
			95% CI (Clopper-Pearson)	(0.2%, 38.5%)
		No	N total	31
			N (%)	2 (6.5%)
			95% CI (Clopper-Pearson)	(0.8%, 21.4%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=43)*
		p-value Fisher's exact test	1.0000
Vascular Occlusive Events	Yes	N total	12
		N (%)	2 (16.7%)
		95% CI (Clopper-Pearson)	(2.1%, 48.4%)
	No	N total	31
		N (%)	18 (58.1%)
		95% CI (Clopper-Pearson)	(39.1%, 75.5%)
		p-value Fisher's exact test	0.0193
Hepatoxicity	Yes	N total	12
		N (%)	5 (41.7%)
		95% CI (Clopper-Pearson)	(15.2%, 72.3%)
	No	N total	31
		N (%)	9 (29.0%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any		*T315I*	*Statistic*	*CP-CML (N=43)*
			95% CI (Clopper-Pearson)	(14.2%, 48.0%)
			p-value Fisher's exact test	0.4822
	Cardiac Failure	Yes	N total	12
			N (%)	2 (16.7%)
			95% CI (Clopper-Pearson)	(2.1%, 48.4%)
		No	N total	31
			N (%)	3 (9.7%)
			95% CI (Clopper-Pearson)	(2.0%, 25.8%)
			p-value Fisher's exact test	0.6077
	Skin and subcutaneous tissue disorders	Yes	N total	12
			N (%)	12 (100.0%)
			95% CI (Clopper-Pearson)	(73.5%, 100.0%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=43)*
	No	N total	31
		N (%)	24 (77.4%)
		95% CI (Clopper-Pearson)	(58.9%, 90.4%)
		p-value Fisher's exact test	0.1630
Infections and infestations	Yes	N total	12
		N (%)	11 (91.7%)
		95% CI (Clopper-Pearson)	(61.5%, 99.8%)
	No	N total	31
		N (%)	24 (77.4%)
		95% CI (Clopper-Pearson)	(58.9%, 90.4%)
		p-value Fisher's exact test	0.4071
Myelosuppression	Yes	N total	12
		N (%)	8 (66.7%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=43)*
		95% CI (Clopper-Pearson)	(34.9%, 90.1%)
	No	N total	31
		N (%)	17 (54.8%)
		95% CI (Clopper-Pearson)	(36.0%, 72.7%)
		p-value Fisher's exact test	0.7315
Edema and Fluid Retention	Yes	N total	12
		N (%)	10 (83.3%)
		95% CI (Clopper-Pearson)	(51.6%, 97.9%)
	No	N total	31
		N (%)	12 (38.7%)
		95% CI (Clopper-Pearson)	(21.8%, 57.8%)
		p-value Fisher's exact test	0.0157

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any		*T315I*	*Statistic*	*CP-CML (N=43)*
	Hypertension	Yes	N total	12
			N (%)	8 (66.7%)
			95% CI (Clopper-Pearson)	(34.9%, 90.1%)
		No	N total	31
			N (%)	13 (41.9%)
			95% CI (Clopper-Pearson)	(24.5%, 60.9%)
			p-value Fisher's exact test	0.1854
	Eye disorder	Yes	N total	12
			N (%)	6 (50.0%)
			95% CI (Clopper-Pearson)	(21.1%, 78.9%)
		No	N total	31
			N (%)	13 (41.9%)
			95% CI (Clopper-Pearson)	(24.5%, 60.9%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=43)*
		p-value Fisher's exact test	0.7376
Bleeding Events	Yes	N total	12
		N (%)	8 (66.7%)
		95% CI (Clopper-Pearson)	(34.9%, 90.1%)
	No	N total	31
		N (%)	9 (29.0%)
		95% CI (Clopper-Pearson)	(14.2%, 48.0%)
		p-value Fisher's exact test	0.0374
Pancreatitis	Yes	N total	12
		N (%)	7 (58.3%)
		95% CI (Clopper-Pearson)	(27.7%, 84.8%)
	No	N total	31
		N (%)	12 (38.7%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any		*T315I*	*Statistic*	*CP-CML (N=43)*
			95% CI (Clopper-Pearson)	(21.8%, 57.8%)
			p-value Fisher's exact test	0.3137
	Clinical Pancreatitis	Yes	N total	12
			N (%)	3 (25.0%)
			95% CI (Clopper-Pearson)	(5.5%, 57.2%)
		No	N total	31
			N (%)	5 (16.1%)
			95% CI (Clopper-Pearson)	(5.5%, 33.7%)
			p-value Fisher's exact test	0.6649
	Chemical Pancreatitis	Yes	N total	12
			N (%)	5 (41.7%)
			95% CI (Clopper-Pearson)	(15.2%, 72.3%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=43)*
	No	N total	31
		N (%)	11 (35.5%)
		95% CI (Clopper-Pearson)	(19.2%, 54.6%)
		p-value Fisher's exact test	0.7366
Cardiac Arrhythmias	Yes	N total	12
		N (%)	3 (25.0%)
		95% CI (Clopper-Pearson)	(5.5%, 57.2%)
	No	N total	31
		N (%)	12 (38.7%)
		95% CI (Clopper-Pearson)	(21.8%, 57.8%)
		p-value Fisher's exact test	0.4916
QT Prolongation	Yes	N total	12
		N (%)	0 (0.0%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=43)*
		95% CI (Clopper-Pearson)	(0.0%, 26.5%)
	No	N total	31
		N (%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 11.2%)
Hypothyroidism	Yes	N total	12
		N (%)	1 (8.3%)
		95% CI (Clopper-Pearson)	(0.2%, 38.5%)
	No	N total	31
		N (%)	3 (9.7%)
		95% CI (Clopper-Pearson)	(2.0%, 25.8%)
		p-value Fisher's exact test	1.0000
Tumour lysis syndrome	Yes	N total	12
		N (%)	0 (0.0%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any		*T315I*	*Statistic*	*CP-CML (N=43)*
			95% CI (Clopper-Pearson)	(0.0%, 26.5%)
		No	N total	31
			N (%)	0 (0.0%)
			95% CI (Clopper-Pearson)	(0.0%, 11.2%)
SAE of special interest (Serious AESI)	Arterial Occlusive Events	Yes	N total	12
			N (%)	1 (8.3%)
			95% CI (Clopper-Pearson)	(0.2%, 38.5%)
		No	N total	31
			N (%)	15 (48.4%)
			95% CI (Clopper-Pearson)	(30.2%, 66.9%)
			p-value Fisher's exact test	0.0171
	Cardiovascular Arterial Occlusive Events	Yes	N total	12
			N (%)	1 (8.3%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Run Date/Time: 26MAY2020 11:08

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=43)*
		95% CI (Clopper-Pearson)	(0.2%, 38.5%)
	No	N total	31
		N (%)	9 (29.0%)
		95% CI (Clopper-Pearson)	(14.2%, 48.0%)
		p-value Fisher's exact test	0.2366
Cerebrovascular Arterial Occlusive Events	Yes	N total	12
		N (%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 26.5%)
	No	N total	31
		N (%)	4 (12.9%)
		95% CI (Clopper-Pearson)	(3.6%, 29.8%)
		p-value Fisher's exact test	0.5629

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any		*T315I*	*Statistic*	*CP-CML (N=43)*
	Peripheral Vascular Arterial Occlusive Events	Yes	N total	12
			N (%)	1 (8.3%)
			95% CI (Clopper-Pearson)	(0.2%, 38.5%)
		No	N total	31
			N (%)	5 (16.1%)
			95% CI (Clopper-Pearson)	(5.5%, 33.7%)
			p-value Fisher's exact test	0.6594
	Venous Thrombotic/Embolic Events	Yes	N total	12
			N (%)	0 (0.0%)
			95% CI (Clopper-Pearson)	(0.0%, 26.5%)
		No	N total	31
			N (%)	1 (3.2%)
			95% CI (Clopper-Pearson)	(0.1%, 16.7%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=43)*
		p-value Fisher's exact test	1.0000
Vascular Occlusive Events	Yes	N total	12
		N (%)	1 (8.3%)
		95% CI (Clopper-Pearson)	(0.2%, 38.5%)
	No	N total	31
		N (%)	15 (48.4%)
		95% CI (Clopper-Pearson)	(30.2%, 66.9%)
		p-value Fisher's exact test	0.0171
Hepatoxicity	Yes	N total	12
		N (%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 26.5%)
	No	N total	31
		N (%)	1 (3.2%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any		*T315I*	*Statistic*	*CP-CML (N=43)*
			95% CI (Clopper-Pearson)	(0.1%, 16.7%)
			p-value Fisher's exact test	1.0000
	Cardiac Failure	Yes	N total	12
			N (%)	1 (8.3%)
			95% CI (Clopper-Pearson)	(0.2%, 38.5%)
		No	N total	31
			N (%)	1 (3.2%)
			95% CI (Clopper-Pearson)	(0.1%, 16.7%)
			p-value Fisher's exact test	0.4850
	Skin and subcutaneous tissue disorders	Yes	N total	12
			N (%)	1 (8.3%)
			95% CI (Clopper-Pearson)	(0.2%, 38.5%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=43)*
	No	N total	31
		N (%)	1 (3.2%)
		95% CI (Clopper-Pearson)	(0.1%, 16.7%)
		p-value Fisher's exact test	0.4850
Infections and infestations	Yes	N total	12
		N (%)	2 (16.7%)
		95% CI (Clopper-Pearson)	(2.1%, 48.4%)
	No	N total	31
		N (%)	10 (32.3%)
		95% CI (Clopper-Pearson)	(16.7%, 51.4%)
		p-value Fisher's exact test	0.4563
Myelosuppression	Yes	N total	12
		N (%)	1 (8.3%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=43)*
		95% CI (Clopper-Pearson)	(0.2%, 38.5%)
	No	N total	31
		N (%)	2 (6.5%)
		95% CI (Clopper-Pearson)	(0.8%, 21.4%)
		p-value Fisher's exact test	1.0000
Edema and Fluid Retention	Yes	N total	12
		N (%)	1 (8.3%)
		95% CI (Clopper-Pearson)	(0.2%, 38.5%)
	No	N total	31
		N (%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 11.2%)
		p-value Fisher's exact test	0.2791

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any		*T315I*	*Statistic*	*CP-CML (N=43)*
	Hypertension	Yes	N total	12
			N (%)	1 (8.3%)
			95% CI (Clopper-Pearson)	(0.2%, 38.5%)
		No	N total	31
			N (%)	0 (0.0%)
			95% CI (Clopper-Pearson)	(0.0%, 11.2%)
			p-value Fisher's exact test	0.2791
	Eye disorder	Yes	N total	12
			N (%)	0 (0.0%)
			95% CI (Clopper-Pearson)	(0.0%, 26.5%)
		No	N total	31
			N (%)	1 (3.2%)
			95% CI (Clopper-Pearson)	(0.1%, 16.7%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=43)*
		p-value Fisher's exact test	1.0000
Bleeding Events	Yes	N total	12
		N (%)	1 (8.3%)
		95% CI (Clopper-Pearson)	(0.2%, 38.5%)
	No	N total	31
		N (%)	2 (6.5%)
		95% CI (Clopper-Pearson)	(0.8%, 21.4%)
		p-value Fisher's exact test	1.0000
Pancreatitis	Yes	N total	12
		N (%)	2 (16.7%)
		95% CI (Clopper-Pearson)	(2.1%, 48.4%)
	No	N total	31
		N (%)	2 (6.5%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Run Date/Time: 26MAY2020 11:08

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any		*T315I*	*Statistic*	*CP-CML (N=43)*
			95% CI (Clopper-Pearson)	(0.8%, 21.4%)
			p-value Fisher's exact test	0.3080
	Clinical Pancreatitis	Yes	N total	12
			N (%)	2 (16.7%)
			95% CI (Clopper-Pearson)	(2.1%, 48.4%)
		No	N total	31
			N (%)	2 (6.5%)
			95% CI (Clopper-Pearson)	(0.8%, 21.4%)
			p-value Fisher's exact test	0.3080
	Chemical Pancreatitis	Yes	N total	12
			N (%)	0 (0.0%)
			95% CI (Clopper-Pearson)	(0.0%, 26.5%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=43)*
	No	N total	31
		N (%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 11.2%)
Cardiac Arrhythmias	Yes	N total	12
		N (%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 26.5%)
	No	N total	31
		N (%)	5 (16.1%)
		95% CI (Clopper-Pearson)	(5.5%, 33.7%)
		p-value Fisher's exact test	0.2996
QT Prolongation	Yes	N total	12
		N (%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 26.5%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=43)*
	No	N total	31
		N (%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 11.2%)
Hypothyroidism	Yes	N total	12
		N (%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 26.5%)
	No	N total	31
		N (%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 11.2%)
Tumour lysis syndrome	Yes	N total	12
		N (%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 26.5%)
	No	N total	31

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 101)
Overview of Adverse Events by T315I Status
Safety Population - CP-CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=43)*
		N (%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 11.2%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
Treatment-emergent AE (TEAE)	Yes	N total	64	18	24
		N (%)	64 (100.0%)	18 (100.0%)	24 (100.0%)
		95% CI (Clopper-Pearson)	(94.4%, 100.0%)	(81.5%, 100.0%)	(85.8%, 100.0%)
	No	N total	203	65	38
		N (%)	203 (100.0%)	65 (100.0%)	38 (100.0%)
		95% CI (Clopper-Pearson)	(98.2%, 100.0%)	(94.5%, 100.0%)	(90.7%, 100.0%)
Serious TEAE (SAE)	Yes	N total	64	18	24
		N (%)	39 (60.9%)	13 (72.2%)	20 (83.3%)
		95% CI (Clopper-Pearson)	(47.9%, 72.9%)	(46.5%, 90.3%)	(62.6%, 95.3%)
	No	N total	203	65	38
		N (%)	131 (64.5%)	44 (67.7%)	33 (86.8%)
		95% CI (Clopper-Pearson)	(57.5%, 71.1%)	(54.9%, 78.8%)	(71.9%, 95.6%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Run Date/Time: 26MAY2020 11:09

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
		p-value Fisher's exact test	0.6555	0.7821	0.7246
TEAE leading to permanent discontinuation	Yes	N total	64	18	24
		N (%)	11 (17.2%)	2 (11.1%)	4 (16.7%)
		95% CI (Clopper-Pearson)	(8.9%, 28.7%)	(1.4%, 34.7%)	(4.7%, 37.4%)
	No	N total	203	65	38
		N (%)	45 (22.2%)	7 (10.8%)	5 (13.2%)
		95% CI (Clopper-Pearson)	(16.7%, 28.5%)	(4.4%, 20.9%)	(4.4%, 28.1%)
		p-value Fisher's exact test	0.4823	1.0000	0.7246
TEAE of Grade 3 & 4	Yes	N total	64	18	24
		N (%)	44 (68.8%)	11 (61.1%)	11 (45.8%)
		95% CI (Clopper-Pearson)	(55.9%, 79.8%)	(35.7%, 82.7%)	(25.6%, 67.2%)
	No	N total	203	65	38
		N (%)	176 (86.7%)	48 (73.8%)	15 (39.5%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Run Date/Time: 26MAY2020 11:09

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
		95% CI (Clopper-Pearson)	(81.2%, 91.0%)	(61.5%, 84.0%)	(24.0%, 56.6%)
		p-value Fisher's exact test	0.0022	0.3790	0.7921
TEAE of Grade 5	Yes	N total	64	18	24
		N (%)	6 (9.4%)	5 (27.8%)	10 (41.7%)
		95% CI (Clopper-Pearson)	(3.5%, 19.3%)	(9.7%, 53.5%)	(22.1%, 63.4%)
	No	N total	203	65	38
		N (%)	12 (5.9%)	12 (18.5%)	22 (57.9%)
		95% CI (Clopper-Pearson)	(3.1%, 10.1%)	(9.9%, 30.0%)	(40.8%, 73.7%)
		p-value Fisher's exact test	0.3903	0.5092	0.2975
TEAE of Grade >=3	Yes	N total	64	18	24
		N (%)	50 (78.1%)	16 (88.9%)	21 (87.5%)
		95% CI (Clopper-Pearson)	(66.0%, 87.5%)	(65.3%, 98.6%)	(67.6%, 97.3%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any		*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
		No	N total	203	65	38
			N (%)	188 (92.6%)	60 (92.3%)	37 (97.4%)
			95% CI (Clopper-Pearson)	(88.1%, 95.8%)	(83.0%, 97.5%)	(86.2%, 99.9%)
			p-value Fisher's exact test	0.0024	0.6419	0.2892
TEAE of special interest (AESI)	Arterial Occlusive Events	Yes	N total	64	18	24
			N (%)	26 (40.6%)	5 (27.8%)	0 (0.0%)
			95% CI (Clopper-Pearson)	(28.5%, 53.6%)	(9.7%, 53.5%)	(0.0%, 14.2%)
		No	N total	203	65	38
			N (%)	57 (28.1%)	11 (16.9%)	7 (18.4%)
			95% CI (Clopper-Pearson)	(22.0%, 34.8%)	(8.8%, 28.3%)	(7.7%, 34.3%)
			p-value Fisher's exact test	0.0645	0.3220	0.0368
	Cardiovascular Arterial Occlusive Events	Yes	N total	64	18	24
			N (%)	15 (23.4%)	3 (16.7%)	0 (0.0%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
		95% CI (Clopper-Pearson)	(13.8%, 35.7%)	(3.6%, 41.4%)	(0.0%, 14.2%)
	No	N total	203	65	38
		N (%)	27 (13.3%)	8 (12.3%)	4 (10.5%)
		95% CI (Clopper-Pearson)	(9.0%, 18.8%)	(5.5%, 22.8%)	(2.9%, 24.8%)
		p-value Fisher's exact test	0.0746	0.6970	0.1514
Cerebrovascular Arterial Occlusive Events	Yes	N total	64	18	24
		N (%)	12 (18.8%)	2 (11.1%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(10.1%, 30.5%)	(1.4%, 34.7%)	(0.0%, 14.2%)
	No	N total	203	65	38
		N (%)	23 (11.3%)	3 (4.6%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(7.3%, 16.5%)	(1.0%, 12.9%)	(0.0%, 9.3%)
		p-value Fisher's exact test	0.1388	0.2958	

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Run Date/Time: 26MAY2020 11:09

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any		*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
	Peripheral Vascular Arterial Occlusive Events	Yes	N total	64	18	24
			N (%)	11 (17.2%)	2 (11.1%)	0 (0.0%)
			95% CI (Clopper-Pearson)	(8.9%, 28.7%)	(1.4%, 34.7%)	(0.0%, 14.2%)
		No	N total	203	65	38
			N (%)	26 (12.8%)	3 (4.6%)	2 (5.3%)
			95% CI (Clopper-Pearson)	(8.5%, 18.2%)	(1.0%, 12.9%)	(0.6%, 17.7%)
			p-value Fisher's exact test	0.4079	0.2958	0.5177
	Venous Thrombotic/Embolic Events	Yes	N total	64	18	24
			N (%)	4 (6.3%)	1 (5.6%)	2 (8.3%)
			95% CI (Clopper-Pearson)	(1.7%, 15.2%)	(0.1%, 27.3%)	(1.0%, 27.0%)
		No	N total	203	65	38
			N (%)	11 (5.4%)	2 (3.1%)	4 (10.5%)
			95% CI (Clopper-Pearson)	(2.7%, 9.5%)	(0.4%, 10.7%)	(2.9%, 24.8%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
		p-value Fisher's exact test	0.7611	0.5246	1.0000
Vascular Occlusive Events	Yes	N total	64	18	24
		N (%)	28 (43.8%)	5 (27.8%)	2 (8.3%)
		95% CI (Clopper-Pearson)	(31.4%, 56.7%)	(9.7%, 53.5%)	(1.0%, 27.0%)
	No	N total	203	65	38
		N (%)	63 (31.0%)	13 (20.0%)	9 (23.7%)
		95% CI (Clopper-Pearson)	(24.7%, 37.9%)	(11.1%, 31.8%)	(11.4%, 40.2%)
		p-value Fisher's exact test	0.0702	0.5237	0.1776
Hepatoxicity	Yes	N total	64	18	24
		N (%)	20 (31.3%)	6 (33.3%)	7 (29.2%)
		95% CI (Clopper-Pearson)	(20.2%, 44.1%)	(13.3%, 59.0%)	(12.6%, 51.1%)
	No	N total	203	65	38
		N (%)	58 (28.6%)	25 (38.5%)	13 (34.2%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
		95% CI (Clopper-Pearson)	(22.5%, 35.3%)	(26.7%, 51.4%)	(19.6%, 51.4%)
		p-value Fisher's exact test	0.7528	0.7874	0.7837
Cardiac Failure	Yes	N total	64	18	24
		N (%)	6 (9.4%)	2 (11.1%)	2 (8.3%)
		95% CI (Clopper-Pearson)	(3.5%, 19.3%)	(1.4%, 34.7%)	(1.0%, 27.0%)
	No	N total	203	65	38
		N (%)	16 (7.9%)	3 (4.6%)	7 (18.4%)
		95% CI (Clopper-Pearson)	(4.6%, 12.5%)	(1.0%, 12.9%)	(7.7%, 34.3%)
		p-value Fisher's exact test	0.7943	0.2958	0.4617
Skin and subcutaneous tissue disorders	Yes	N total	64	18	24
		N (%)	55 (85.9%)	14 (77.8%)	18 (75.0%)
		95% CI (Clopper-Pearson)	(75.0%, 93.4%)	(52.4%, 93.6%)	(53.3%, 90.2%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
	No	N total	203	65	38
		N (%)	165 (81.3%)	52 (80.0%)	25 (65.8%)
		95% CI (Clopper-Pearson)	(75.2%, 86.4%)	(68.2%, 88.9%)	(48.6%, 80.4%)
		p-value Fisher's exact test	0.4557	1.0000	0.5745
Infections and infestations	Yes	N total	64	18	24
		N (%)	39 (60.9%)	15 (83.3%)	12 (50.0%)
		95% CI (Clopper-Pearson)	(47.9%, 72.9%)	(58.6%, 96.4%)	(29.1%, 70.9%)
	No	N total	203	65	38
		N (%)	129 (63.5%)	49 (75.4%)	23 (60.5%)
		95% CI (Clopper-Pearson)	(56.5%, 70.2%)	(63.1%, 85.2%)	(43.4%, 76.0%)
		p-value Fisher's exact test	0.7670	0.7518	0.4427
Myelosuppression	Yes	N total	64	18	24
		N (%)	26 (40.6%)	10 (55.6%)	16 (66.7%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Run Date/Time: 26MAY2020 11:09

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
		95% CI (Clopper-Pearson)	(28.5%, 53.6%)	(30.8%, 78.5%)	(44.7%, 84.4%)
	No	N total	203	65	38
		N (%)	122 (60.1%)	48 (73.8%)	26 (68.4%)
		95% CI (Clopper-Pearson)	(53.0%, 66.9%)	(61.5%, 84.0%)	(51.3%, 82.5%)
		p-value Fisher's exact test	0.0091	0.1545	1.0000
Edema and Fluid Retention	Yes	N total	64	18	24
		N (%)	16 (25.0%)	7 (38.9%)	4 (16.7%)
		95% CI (Clopper-Pearson)	(15.0%, 37.4%)	(17.3%, 64.3%)	(4.7%, 37.4%)
	No	N total	203	65	38
		N (%)	63 (31.0%)	22 (33.8%)	16 (42.1%)
		95% CI (Clopper-Pearson)	(24.7%, 37.9%)	(22.6%, 46.6%)	(26.3%, 59.2%)
		p-value Fisher's exact test	0.4329	0.7819	0.0516

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any		*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
	Hypertension	Yes	N total	64	18	24
			N (%)	21 (32.8%)	8 (44.4%)	3 (12.5%)
			95% CI (Clopper-Pearson)	(21.6%, 45.7%)	(21.5%, 69.2%)	(2.7%, 32.4%)
		No	N total	203	65	38
			N (%)	77 (37.9%)	14 (21.5%)	11 (28.9%)
			95% CI (Clopper-Pearson)	(31.2%, 45.0%)	(12.3%, 33.5%)	(15.4%, 45.9%)
			p-value Fisher's exact test	0.5522	0.0707	0.2124
	Eye disorder	Yes	N total	64	18	24
			N (%)	21 (32.8%)	6 (33.3%)	4 (16.7%)
			95% CI (Clopper-Pearson)	(21.6%, 45.7%)	(13.3%, 59.0%)	(4.7%, 37.4%)
		No	N total	203	65	38
			N (%)	66 (32.5%)	21 (32.3%)	8 (21.1%)
			95% CI (Clopper-Pearson)	(26.1%, 39.4%)	(21.2%, 45.1%)	(9.6%, 37.3%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
		p-value Fisher's exact test	1.0000	1.0000	0.7517
Bleeding Events	Yes	N total	64	18	24
		N (%)	11 (17.2%)	3 (16.7%)	10 (41.7%)
		95% CI (Clopper-Pearson)	(8.9%, 28.7%)	(3.6%, 41.4%)	(22.1%, 63.4%)
	No	N total	203	65	38
		N (%)	49 (24.1%)	28 (43.1%)	13 (34.2%)
		95% CI (Clopper-Pearson)	(18.4%, 30.6%)	(30.8%, 56.0%)	(19.6%, 51.4%)
		p-value Fisher's exact test	0.3037	0.0542	0.5975
Pancreatitis	Yes	N total	64	18	24
		N (%)	17 (26.6%)	3 (16.7%)	3 (12.5%)
		95% CI (Clopper-Pearson)	(16.3%, 39.1%)	(3.6%, 41.4%)	(2.7%, 32.4%)
	No	N total	203	65	38
		N (%)	69 (34.0%)	16 (24.6%)	9 (23.7%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Run Date/Time: 26MAY2020 11:09

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
		95% CI (Clopper-Pearson)	(27.5%, 41.0%)	(14.8%, 36.9%)	(11.4%, 40.2%)
		p-value Fisher's exact test	0.2872	0.7518	0.3391
Clinical Pancreatitis	Yes	N total	64	18	24
		N (%)	5 (7.8%)	0 (0.0%)	1 (4.2%)
		95% CI (Clopper-Pearson)	(2.6%, 17.3%)	(0.0%, 18.5%)	(0.1%, 21.1%)
	No	N total	203	65	38
		N (%)	16 (7.9%)	7 (10.8%)	2 (5.3%)
		95% CI (Clopper-Pearson)	(4.6%, 12.5%)	(4.4%, 20.9%)	(0.6%, 17.7%)
		p-value Fisher's exact test	1.0000	0.3375	1.0000
Chemical Pancreatitis	Yes	N total	64	18	24
		N (%)	16 (25.0%)	3 (16.7%)	2 (8.3%)
		95% CI (Clopper-Pearson)	(15.0%, 37.4%)	(3.6%, 41.4%)	(1.0%, 27.0%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
	No	N total	203	65	38
		N (%)	61 (30.0%)	13 (20.0%)	7 (18.4%)
		95% CI (Clopper-Pearson)	(23.8%, 36.9%)	(11.1%, 31.8%)	(7.7%, 34.3%)
		p-value Fisher's exact test	0.5273	1.0000	0.4617
Cardiac Arrhythmias	Yes	N total	64	18	24
		N (%)	9 (14.1%)	1 (5.6%)	7 (29.2%)
		95% CI (Clopper-Pearson)	(6.6%, 25.0%)	(0.1%, 27.3%)	(12.6%, 51.1%)
	No	N total	203	65	38
		N (%)	43 (21.2%)	12 (18.5%)	8 (21.1%)
		95% CI (Clopper-Pearson)	(15.8%, 27.5%)	(9.9%, 30.0%)	(9.6%, 37.3%)
		p-value Fisher's exact test	0.2773	0.2800	0.5483
QT Prolongation	Yes	N total	64	18	24
		N (%)	4 (6.3%)	0 (0.0%)	1 (4.2%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Run Date/Time: 26MAY2020 11:09

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
		95% CI (Clopper-Pearson)	(1.7%, 15.2%)	(0.0%, 18.5%)	(0.1%, 21.1%)
	No	N total	203	65	38
		N (%)	13 (6.4%)	5 (7.7%)	1 (2.6%)
		95% CI (Clopper-Pearson)	(3.5%, 10.7%)	(2.5%, 17.0%)	(0.1%, 13.8%)
		p-value Fisher's exact test	1.0000	0.5803	1.0000
Hypothyroidism	Yes	N total	64	18	24
		N (%)	2 (3.1%)	0 (0.0%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.4%, 10.8%)	(0.0%, 18.5%)	(0.0%, 14.2%)
	No	N total	203	65	38
		N (%)	7 (3.4%)	4 (6.2%)	1 (2.6%)
		95% CI (Clopper-Pearson)	(1.4%, 7.0%)	(1.7%, 15.0%)	(0.1%, 13.8%)
		p-value Fisher's exact test	1.0000	0.5721	1.0000

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Run Date/Time: 26MAY2020 11:09

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any		*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
	Tumour lysis syndrome	Yes	N total	64	18	24
			N (%)	0 (0.0%)	1 (5.6%)	0 (0.0%)
			95% CI (Clopper-Pearson)	(0.0%, 5.6%)	(0.1%, 27.3%)	(0.0%, 14.2%)
		No	N total	203	65	38
			N (%)	0 (0.0%)	1 (1.5%)	1 (2.6%)
			95% CI (Clopper-Pearson)	(0.0%, 1.8%)	(0.0%, 8.3%)	(0.1%, 13.8%)
			p-value Fisher's exact test		0.3888	1.0000
SAE of special interest (Serious AESI)	Arterial Occlusive Events	Yes	N total	64	18	24
			N (%)	23 (35.9%)	4 (22.2%)	0 (0.0%)
			95% CI (Clopper-Pearson)	(24.3%, 48.9%)	(6.4%, 47.6%)	(0.0%, 14.2%)
		No	N total	203	65	38
			N (%)	45 (22.2%)	8 (12.3%)	5 (13.2%)
			95% CI (Clopper-Pearson)	(16.7%, 28.5%)	(5.5%, 22.8%)	(4.4%, 28.1%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Run Date/Time: 26MAY2020 11:09

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
		p-value Fisher's exact test	0.0328	0.2815	0.1465
Cardiovascular Arterial Occlusive Events	Yes	N total	64	18	24
		N (%)	14 (21.9%)	3 (16.7%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(12.5%, 34.0%)	(3.6%, 41.4%)	(0.0%, 14.2%)
	No	N total	203	65	38
		N (%)	19 (9.4%)	4 (6.2%)	3 (7.9%)
		95% CI (Clopper-Pearson)	(5.7%, 14.2%)	(1.7%, 15.0%)	(1.7%, 21.4%)
		p-value Fisher's exact test	0.0148	0.1698	0.2766
Cerebrovascular Arterial Occlusive Events	Yes	N total	64	18	24
		N (%)	10 (15.6%)	1 (5.6%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(7.8%, 26.9%)	(0.1%, 27.3%)	(0.0%, 14.2%)
	No	N total	203	65	38
		N (%)	18 (8.9%)	3 (4.6%)	0 (0.0%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
		95% CI (Clopper-Pearson)	(5.3%, 13.7%)	(1.0%, 12.9%)	(0.0%, 9.3%)
		p-value Fisher's exact test	0.1584	1.0000	
Peripheral Vascular Arterial Occlusive Events	Yes	N total	64	18	24
		N (%)	8 (12.5%)	1 (5.6%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(5.6%, 23.2%)	(0.1%, 27.3%)	(0.0%, 14.2%)
	No	N total	203	65	38
		N (%)	22 (10.8%)	2 (3.1%)	1 (2.6%)
		95% CI (Clopper-Pearson)	(6.9%, 15.9%)	(0.4%, 10.7%)	(0.1%, 13.8%)
		p-value Fisher's exact test	0.8204	0.5246	1.0000
Venous Thrombotic/Embolic Events	Yes	N total	64	18	24
		N (%)	3 (4.7%)	1 (5.6%)	2 (8.3%)
		95% CI (Clopper-Pearson)	(1.0%, 13.1%)	(0.1%, 27.3%)	(1.0%, 27.0%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
	No	N total	203	65	38
		N (%)	10 (4.9%)	1 (1.5%)	4 (10.5%)
		95% CI (Clopper-Pearson)	(2.4%, 8.9%)	(0.0%, 8.3%)	(2.9%, 24.8%)
		p-value Fisher's exact test	1.0000	0.3888	1.0000
Vascular Occlusive Events	Yes	N total	64	18	24
		N (%)	25 (39.1%)	4 (22.2%)	2 (8.3%)
		95% CI (Clopper-Pearson)	(27.1%, 52.1%)	(6.4%, 47.6%)	(1.0%, 27.0%)
	No	N total	203	65	38
		N (%)	52 (25.6%)	9 (13.8%)	8 (21.1%)
		95% CI (Clopper-Pearson)	(19.8%, 32.2%)	(6.5%, 24.7%)	(9.6%, 37.3%)
		p-value Fisher's exact test	0.0568	0.4649	0.2912
Hepatoxicity	Yes	N total	64	18	24
		N (%)	2 (3.1%)	0 (0.0%)	0 (0.0%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Run Date/Time: 26MAY2020 11:09

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
		95% CI (Clopper-Pearson)	(0.4%, 10.8%)	(0.0%, 18.5%)	(0.0%, 14.2%)
	No	N total	203	65	38
		N (%)	5 (2.5%)	4 (6.2%)	1 (2.6%)
		95% CI (Clopper-Pearson)	(0.8%, 5.7%)	(1.7%, 15.0%)	(0.1%, 13.8%)
		p-value Fisher's exact test	0.6744	0.5721	1.0000
Cardiac Failure	Yes	N total	64	18	24
		N (%)	5 (7.8%)	2 (11.1%)	2 (8.3%)
		95% CI (Clopper-Pearson)	(2.6%, 17.3%)	(1.4%, 34.7%)	(1.0%, 27.0%)
	No	N total	203	65	38
		N (%)	8 (3.9%)	2 (3.1%)	6 (15.8%)
		95% CI (Clopper-Pearson)	(1.7%, 7.6%)	(0.4%, 10.7%)	(6.0%, 31.3%)
		p-value Fisher's exact test	0.3138	0.2037	0.4675

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any		*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
	Skin and subcutaneous tissue disorders	Yes	N total	64	18	24
			N (%)	1 (1.6%)	1 (5.6%)	1 (4.2%)
			95% CI (Clopper-Pearson)	(0.0%, 8.4%)	(0.1%, 27.3%)	(0.1%, 21.1%)
		No	N total	203	65	38
			N (%)	7 (3.4%)	3 (4.6%)	1 (2.6%)
			95% CI (Clopper-Pearson)	(1.4%, 7.0%)	(1.0%, 12.9%)	(0.1%, 13.8%)
			p-value Fisher's exact test	0.6844	1.0000	1.0000
	Infections and infestations	Yes	N total	64	18	24
			N (%)	10 (15.6%)	8 (44.4%)	7 (29.2%)
			95% CI (Clopper-Pearson)	(7.8%, 26.9%)	(21.5%, 69.2%)	(12.6%, 51.1%)
		No	N total	203	65	38
			N (%)	32 (15.8%)	20 (30.8%)	12 (31.6%)
			95% CI (Clopper-Pearson)	(11.0%, 21.5%)	(19.9%, 43.4%)	(17.5%, 48.7%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
		p-value Fisher's exact test	1.0000	0.3983	1.0000
Myelosuppression	Yes	N total	64	18	24
		N (%)	2 (3.1%)	2 (11.1%)	7 (29.2%)
		95% CI (Clopper-Pearson)	(0.4%, 10.8%)	(1.4%, 34.7%)	(12.6%, 51.1%)
	No	N total	203	65	38
		N (%)	15 (7.4%)	11 (16.9%)	5 (13.2%)
		95% CI (Clopper-Pearson)	(4.2%, 11.9%)	(8.8%, 28.3%)	(4.4%, 28.1%)
		p-value Fisher's exact test	0.3769	0.7238	0.1864
Edema and Fluid Retention	Yes	N total	64	18	24
		N (%)	2 (3.1%)	0 (0.0%)	2 (8.3%)
		95% CI (Clopper-Pearson)	(0.4%, 10.8%)	(0.0%, 18.5%)	(1.0%, 27.0%)
	No	N total	203	65	38
		N (%)	7 (3.4%)	3 (4.6%)	2 (5.3%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Run Date/Time: 26MAY2020 11:09

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
		95% CI (Clopper-Pearson)	(1.4%, 7.0%)	(1.0%, 12.9%)	(0.6%, 17.7%)
		p-value Fisher's exact test	1.0000	1.0000	0.6371
Hypertension	Yes	N total	64	18	24
		N (%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 5.6%)	(0.0%, 18.5%)	(0.0%, 14.2%)
	No	N total	203	65	38
		N (%)	11 (5.4%)	3 (4.6%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(2.7%, 9.5%)	(1.0%, 12.9%)	(0.0%, 9.3%)
		p-value Fisher's exact test	0.0713	1.0000	
Eye disorder	Yes	N total	64	18	24
		N (%)	2 (3.1%)	1 (5.6%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.4%, 10.8%)	(0.1%, 27.3%)	(0.0%, 14.2%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Run Date/Time: 26MAY2020 11:09

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
	No	N total	203	65	38
		N (%)	6 (3.0%)	1 (1.5%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(1.1%, 6.3%)	(0.0%, 8.3%)	(0.0%, 9.3%)
		p-value Fisher's exact test	1.0000	0.3888	
Bleeding Events	Yes	N total	64	18	24
		N (%)	4 (6.3%)	1 (5.6%)	3 (12.5%)
		95% CI (Clopper-Pearson)	(1.7%, 15.2%)	(0.1%, 27.3%)	(2.7%, 32.4%)
	No	N total	203	65	38
		N (%)	5 (2.5%)	9 (13.8%)	2 (5.3%)
		95% CI (Clopper-Pearson)	(0.8%, 5.7%)	(6.5%, 24.7%)	(0.6%, 17.7%)
		p-value Fisher's exact test	0.2246	0.6825	0.3664
Pancreatitis	Yes	N total	64	18	24
		N (%)	5 (7.8%)	0 (0.0%)	0 (0.0%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Run Date/Time: 26MAY2020 11:09

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
		95% CI (Clopper-Pearson)	(2.6%, 17.3%)	(0.0%, 18.5%)	(0.0%, 14.2%)
	No	N total	203	65	38
		N (%)	18 (8.9%)	6 (9.2%)	3 (7.9%)
		95% CI (Clopper-Pearson)	(5.3%, 13.7%)	(3.5%, 19.0%)	(1.7%, 21.4%)
		p-value Fisher's exact test	1.0000	0.3317	0.2766
Clinical Pancreatitis	Yes	N total	64	18	24
		N (%)	5 (7.8%)	0 (0.0%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(2.6%, 17.3%)	(0.0%, 18.5%)	(0.0%, 14.2%)
	No	N total	203	65	38
		N (%)	14 (6.9%)	5 (7.7%)	2 (5.3%)
		95% CI (Clopper-Pearson)	(3.8%, 11.3%)	(2.5%, 17.0%)	(0.6%, 17.7%)
		p-value Fisher's exact test	0.7837	0.5803	0.5177

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any		*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
	Chemical Pancreatitis	Yes	N total	64	18	24
			N (%)	3 (4.7%)	0 (0.0%)	0 (0.0%)
			95% CI (Clopper-Pearson)	(1.0%, 13.1%)	(0.0%, 18.5%)	(0.0%, 14.2%)
		No	N total	203	65	38
			N (%)	4 (2.0%)	1 (1.5%)	1 (2.6%)
			95% CI (Clopper-Pearson)	(0.5%, 5.0%)	(0.0%, 8.3%)	(0.1%, 13.8%)
			p-value Fisher's exact test	0.3635	1.0000	1.0000
	Cardiac Arrhythmias	Yes	N total	64	18	24
			N (%)	6 (9.4%)	0 (0.0%)	3 (12.5%)
			95% CI (Clopper-Pearson)	(3.5%, 19.3%)	(0.0%, 18.5%)	(2.7%, 32.4%)
		No	N total	203	65	38
			N (%)	17 (8.4%)	3 (4.6%)	3 (7.9%)
			95% CI (Clopper-Pearson)	(5.0%, 13.1%)	(1.0%, 12.9%)	(1.7%, 21.4%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
		p-value Fisher's exact test	0.8005	1.0000	0.6686
QT Prolongation	Yes	N total	64	18	24
		N (%)	2 (3.1%)	0 (0.0%)	1 (4.2%)
		95% CI (Clopper-Pearson)	(0.4%, 10.8%)	(0.0%, 18.5%)	(0.1%, 21.1%)
	No	N total	203	65	38
		N (%)	6 (3.0%)	2 (3.1%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(1.1%, 6.3%)	(0.4%, 10.7%)	(0.0%, 9.3%)
		p-value Fisher's exact test	1.0000	1.0000	0.3871
Hypothyroidism	Yes	N total	64	18	24
		N (%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 5.6%)	(0.0%, 18.5%)	(0.0%, 14.2%)
	No	N total	203	65	38
		N (%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.2 (Study 201)
Overview of Adverse Events by T315I Status
Treated Population - CML Patients

Patients with any	*T315I*	*Statistic*	*CP-CML (N=267)*	*AP-CML (N=83)*	*BP-CML (N=62)*
		95% CI (Clopper-Pearson)	(0.0%, 1.8%)	(0.0%, 5.5%)	(0.0%, 9.3%)
Tumour lysis syndrome	Yes	N total	64	18	24
		N (%)	0 (0.0%)	1 (5.6%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 5.6%)	(0.1%, 27.3%)	(0.0%, 14.2%)
	No	N total	203	65	38
		N (%)	0 (0.0%)	0 (0.0%)	1 (2.6%)
		95% CI (Clopper-Pearson)	(0.0%, 1.8%)	(0.0%, 5.5%)	(0.1%, 13.8%)
		p-value Fisher's exact test		0.2169	1.0000

Treated Population: All treated patients who were also assigned to a cohort.
Percentages are based on the patients with the respective T315I status.
Note: Fisher's exact test is not performed if AE frequencies are 0% or 100% in both groups.

Table 1.2.2.1.3 (Study 201)
Overview of Adverse Events by T315I Status
Safety Population - CML Patients Excluded From Treated Population

Patients with any	*T315I*	*Statistic*	*CP-CML (N=3)*	*AP-CML (N=2)*
Treatment-emergent AE (TEAE)	No	N (%)	3 (100.0%)	2 (100.0%)
		95% CI (Clopper-Pearson)	(29.2%, 100.0%)	(15.8%, 100.0%)
Serious TEAE (SAE)	No	N (%)	1 (33.3%)	2 (100.0%)
		95% CI (Clopper-Pearson)	(0.8%, 90.6%)	(15.8%, 100.0%)
TEAE leading to permanent discontinuation	No	N (%)	1 (33.3%)	1 (50.0%)
		95% CI (Clopper-Pearson)	(0.8%, 90.6%)	(1.3%, 98.7%)
TEAE of Grade 3 & 4	No	N (%)	1 (33.3%)	1 (50.0%)
		95% CI (Clopper-Pearson)	(0.8%, 90.6%)	(1.3%, 98.7%)
TEAE of Grade 5	No	N (%)	0 (0.0%)	1 (50.0%)
		95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(1.3%, 98.7%)
TEAE of Grade >=3	No	N (%)	1 (33.3%)	2 (100.0%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.

Table 1.2.2.1.3 (Study 201)
Overview of Adverse Events by T315I Status
Safety Population - CML Patients Excluded From Treated Population

Patients with any		*T315I*	*Statistic*	*CP-CML (N=3)*	*AP-CML (N=2)*
			95% CI (Clopper-Pearson)	(0.8%, 90.6%)	(15.8%, 100.0%)
TEAE of special interest (AESI)	Arterial Occlusive Events	No	N (%)	1 (33.3%)	1 (50.0%)
			95% CI (Clopper-Pearson)	(0.8%, 90.6%)	(1.3%, 98.7%)
	Cardiovascular Arterial Occlusive Events	No	N (%)	0 (0.0%)	1 (50.0%)
			95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(1.3%, 98.7%)
	Cerebrovascular Arterial Occlusive Events	No	N (%)	0 (0.0%)	0 (0.0%)
			95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(0.0%, 84.2%)
	Peripheral Vascular Arterial Occlusive Events	No	N (%)	1 (33.3%)	0 (0.0%)
			95% CI (Clopper-Pearson)	(0.8%, 90.6%)	(0.0%, 84.2%)
	Venous Thrombotic/Embolic Events	No	N (%)	0 (0.0%)	0 (0.0%)
			95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(0.0%, 84.2%)
	Vascular Occlusive Events	No	N (%)	1 (33.3%)	1 (50.0%)
			95% CI (Clopper-Pearson)	(0.8%, 90.6%)	(1.3%, 98.7%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.

Table 1.2.2.1.3 (Study 201)
Overview of Adverse Events by T315I Status
Safety Population - CML Patients Excluded From Treated Population

Patients with any	*T315I*	*Statistic*	*CP-CML (N=3)*	*AP-CML (N=2)*
Hepatoxicity	No	N (%)	0 (0.0%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(0.0%, 84.2%)
Cardiac Failure	No	N (%)	0 (0.0%)	1 (50.0%)
		95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(1.3%, 98.7%)
Skin and subcutaneous tissue disorders	No	N (%)	3 (100.0%)	2 (100.0%)
		95% CI (Clopper-Pearson)	(29.2%, 100.0%)	(15.8%, 100.0%)
Infections and infestations	No	N (%)	3 (100.0%)	1 (50.0%)
		95% CI (Clopper-Pearson)	(29.2%, 100.0%)	(1.3%, 98.7%)
Myelosuppression	No	N (%)	0 (0.0%)	2 (100.0%)
		95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(15.8%, 100.0%)
Edema and Fluid Retention	No	N (%)	0 (0.0%)	1 (50.0%)
		95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(1.3%, 98.7%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.

Table 1.2.2.1.3 (Study 201)
Overview of Adverse Events by T315I Status
Safety Population - CML Patients Excluded From Treated Population

Patients with any		*T315I*	*Statistic*	*CP-CML (N=3)*	*AP-CML (N=2)*
	Hypertension	No	N (%)	2 (66.7%)	0 (0.0%)
			95% CI (Clopper-Pearson)	(9.4%, 99.2%)	(0.0%, 84.2%)
	Eye disorder	No	N (%)	0 (0.0%)	1 (50.0%)
			95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(1.3%, 98.7%)
	Bleeding Events	No	N (%)	1 (33.3%)	1 (50.0%)
			95% CI (Clopper-Pearson)	(0.8%, 90.6%)	(1.3%, 98.7%)
	Pancreatitis	No	N (%)	0 (0.0%)	0 (0.0%)
			95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(0.0%, 84.2%)
	Clinical Pancreatitis	No	N (%)	0 (0.0%)	0 (0.0%)
			95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(0.0%, 84.2%)
	Chemical Pancreatitis	No	N (%)	0 (0.0%)	0 (0.0%)
			95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(0.0%, 84.2%)
	Cardiac Arrhythmias	No	N (%)	0 (0.0%)	1 (50.0%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.

Table 1.2.2.1.3 (Study 201)
Overview of Adverse Events by T315I Status
Safety Population - CML Patients Excluded From Treated Population

Patients with any		*T315I*	*Statistic*	*CP-CML (N=3)*	*AP-CML (N=2)*
			95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(1.3%, 98.7%)
	QT Prolongation	No	N (%)	0 (0.0%)	0 (0.0%)
			95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(0.0%, 84.2%)
	Hypothyroidism	No	N (%)	0 (0.0%)	0 (0.0%)
			95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(0.0%, 84.2%)
	Tumour lysis syndrome	No	N (%)	0 (0.0%)	0 (0.0%)
			95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(0.0%, 84.2%)
SAE of special interest (Serious AESI)	Arterial Occlusive Events	No	N (%)	1 (33.3%)	1 (50.0%)
			95% CI (Clopper-Pearson)	(0.8%, 90.6%)	(1.3%, 98.7%)
	Cardiovascular Arterial Occlusive Events	No	N (%)	0 (0.0%)	1 (50.0%)
			95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(1.3%, 98.7%)
	Cerebrovascular Arterial Occlusive Events	No	N (%)	0 (0.0%)	0 (0.0%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.

Table 1.2.2.1.3 (Study 201)
Overview of Adverse Events by T315I Status
Safety Population - CML Patients Excluded From Treated Population

Patients with any	*T315I*	*Statistic*	*CP-CML (N=3)*	*AP-CML (N=2)*
		95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(0.0%, 84.2%)
Peripheral Vascular Arterial Occlusive Events	No	N (%)	1 (33.3%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.8%, 90.6%)	(0.0%, 84.2%)
Venous Thrombotic/Embolic Events	No	N (%)	0 (0.0%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(0.0%, 84.2%)
Vascular Occlusive Events	No	N (%)	1 (33.3%)	1 (50.0%)
		95% CI (Clopper-Pearson)	(0.8%, 90.6%)	(1.3%, 98.7%)
Hepatoxicity	No	N (%)	0 (0.0%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(0.0%, 84.2%)
Cardiac Failure	No	N (%)	0 (0.0%)	1 (50.0%)
		95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(1.3%, 98.7%)
Skin and subcutaneous tissue disorders	No	N (%)	0 (0.0%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(0.0%, 84.2%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.

Table 1.2.2.1.3 (Study 201)
Overview of Adverse Events by T315I Status
Safety Population - CML Patients Excluded From Treated Population

Patients with any	*T315I*	*Statistic*	*CP-CML (N=3)*	*AP-CML (N=2)*
Infections and infestations	No	N (%)	0 (0.0%)	1 (50.0%)
		95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(1.3%, 98.7%)
Myelosuppression	No	N (%)	0 (0.0%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(0.0%, 84.2%)
Edema and Fluid Retention	No	N (%)	0 (0.0%)	1 (50.0%)
		95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(1.3%, 98.7%)
Hypertension	No	N (%)	0 (0.0%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(0.0%, 84.2%)
Eye disorder	No	N (%)	0 (0.0%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(0.0%, 84.2%)
Bleeding Events	No	N (%)	0 (0.0%)	1 (50.0%)
		95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(1.3%, 98.7%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.

Table 1.2.2.1.3 (Study 201)
Overview of Adverse Events by T315I Status
Safety Population - CML Patients Excluded From Treated Population

Patients with any	*T315I*	*Statistic*	*CP-CML (N=3)*	*AP-CML (N=2)*
Pancreatitis	No	N (%)	0 (0.0%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(0.0%, 84.2%)
Clinical Pancreatitis	No	N (%)	0 (0.0%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(0.0%, 84.2%)
Chemical Pancreatitis	No	N (%)	0 (0.0%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(0.0%, 84.2%)
Cardiac Arrhythmias	No	N (%)	0 (0.0%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(0.0%, 84.2%)
QT Prolongation	No	N (%)	0 (0.0%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(0.0%, 84.2%)
Hypothyroidism	No	N (%)	0 (0.0%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(0.0%, 84.2%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.

Table 1.2.2.1.3 (Study 201)
Overview of Adverse Events by T315I Status
Safety Population - CML Patients Excluded From Treated Population

Patients with any	*T315I*	*Statistic*	*CP-CML (N=3)*	*AP-CML (N=2)*
Tumour lysis syndrome	No	N (%)	0 (0.0%)	0 (0.0%)
		95% CI (Clopper-Pearson)	(0.0%, 70.8%)	(0.0%, 84.2%)

Safety Population: All treated patients
Percentages are based on the patients with the respective T315I status.

1.2.2.2 TEAE by SOC/PT and grade

1.2.2.2.1 Patients in CP, AP, or BP

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		34 (79.1%)	3 (7.0%)	37 (86.0%)	43 (100.0%)
Blood and lymphatic system disorders	All	15 (34.9%)	0 (0.0%)	15 (34.9%)	24 (55.8%)
	Thrombocytopenia	14 (32.6%)	0 (0.0%)	14 (32.6%)	16 (37.2%)
	Anaemia	2 (4.7%)	0 (0.0%)	2 (4.7%)	7 (16.3%)
	Neutropenia	4 (9.3%)	0 (0.0%)	4 (9.3%)	6 (14.0%)
Cardiac disorders	All	11 (25.6%)	0 (0.0%)	11 (25.6%)	28 (65.1%)
	Angina pectoris	1 (2.3%)	0 (0.0%)	1 (2.3%)	6 (14.0%)
	Tricuspid valve incompetence	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (14.0%)
	Atrial fibrillation	3 (7.0%)	0 (0.0%)	3 (7.0%)	5 (11.6%)
	Palpitations	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (11.6%)
	Pericardial effusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (11.6%)
Endocrine disorders	All	1 (2.3%)	0 (0.0%)	1 (2.3%)	6 (14.0%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Eye disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	19 (44.2%)
	Dry eye	0 (0.0%)	0 (0.0%)	0 (0.0%)	8 (18.6%)
Gastrointestinal disorders	All	15 (34.9%)	0 (0.0%)	15 (34.9%)	38 (88.4%)
	Constipation	1 (2.3%)	0 (0.0%)	1 (2.3%)	22 (51.2%)
	Nausea	0 (0.0%)	0 (0.0%)	0 (0.0%)	21 (48.8%)
	Abdominal pain	6 (14.0%)	0 (0.0%)	6 (14.0%)	20 (46.5%)
	Vomiting	0 (0.0%)	0 (0.0%)	0 (0.0%)	20 (46.5%)
	Abdominal pain upper	2 (4.7%)	0 (0.0%)	2 (4.7%)	11 (25.6%)
	Diarrhoea	0 (0.0%)	0 (0.0%)	0 (0.0%)	11 (25.6%)
	Dyspepsia	0 (0.0%)	0 (0.0%)	0 (0.0%)	10 (23.3%)
	Pancreatitis	2 (4.7%)	0 (0.0%)	2 (4.7%)	7 (16.3%)
	Abdominal distension	1 (2.3%)	0 (0.0%)	1 (2.3%)	6 (14.0%)
	Dry mouth	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (14.0%)
General disorders and administration site conditions	All	8 (18.6%)	0 (0.0%)	8 (18.6%)	37 (86.0%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Fatigue	3 (7.0%)	0 (0.0%)	3 (7.0%)	27 (62.8%)
	Oedema peripheral	0 (0.0%)	0 (0.0%)	0 (0.0%)	15 (34.9%)
	Pyrexia	0 (0.0%)	0 (0.0%)	0 (0.0%)	15 (34.9%)
	Chills	1 (2.3%)	0 (0.0%)	1 (2.3%)	12 (27.9%)
	Pain	1 (2.3%)	0 (0.0%)	1 (2.3%)	6 (14.0%)
	Asthenia	1 (2.3%)	0 (0.0%)	1 (2.3%)	5 (11.6%)
	Non-cardiac chest pain	1 (2.3%)	0 (0.0%)	1 (2.3%)	5 (11.6%)
Immune system disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (14.0%)
Infections and infestations	All	12 (27.9%)	1 (2.3%)	13 (30.2%)	35 (81.4%)
	Upper respiratory tract infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	17 (39.5%)
	Urinary tract infection	2 (4.7%)	0 (0.0%)	2 (4.7%)	13 (30.2%)
	Nasopharyngitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	11 (25.6%)
	Sinusitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	9 (20.9%)
	Pneumonia	4 (9.3%)	1 (2.3%)	5 (11.6%)	8 (18.6%)
	Bronchitis	1 (2.3%)	0 (0.0%)	1 (2.3%)	7 (16.3%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Gastroenteritis viral	1 (2.3%)	0 (0.0%)	1 (2.3%)	7 (16.3%)
	Influenza	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (14.0%)
	Cellulitis	2 (4.7%)	0 (0.0%)	2 (4.7%)	5 (11.6%)
Injury, poisoning and procedural complications	All	3 (7.0%)	0 (0.0%)	3 (7.0%)	19 (44.2%)
Investigations	All	20 (46.5%)	0 (0.0%)	20 (46.5%)	35 (81.4%)
	Lipase increased	8 (18.6%)	0 (0.0%)	8 (18.6%)	16 (37.2%)
	Alanine aminotransferase increased	3 (7.0%)	0 (0.0%)	3 (7.0%)	10 (23.3%)
	Blood triglycerides increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	10 (23.3%)
	Platelet count decreased	2 (4.7%)	0 (0.0%)	2 (4.7%)	7 (16.3%)
	Aspartate aminotransferase increased	1 (2.3%)	0 (0.0%)	1 (2.3%)	6 (14.0%)
	Blood creatinine increased	1 (2.3%)	0 (0.0%)	1 (2.3%)	6 (14.0%)
Metabolism and nutrition disorders	All	7 (16.3%)	0 (0.0%)	7 (16.3%)	28 (65.1%)
	Hypertriglyceridaemia	1 (2.3%)	0 (0.0%)	1 (2.3%)	9 (20.9%)
	Hyperkalaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (14.0%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Decreased appetite	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (11.6%)
	Hypokalaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (11.6%)
	Hypomagnesaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (11.6%)
Musculoskeletal and connective tissue disorders	All	4 (9.3%)	0 (0.0%)	4 (9.3%)	39 (90.7%)
	Arthralgia	1 (2.3%)	0 (0.0%)	1 (2.3%)	23 (53.5%)
	Back pain	1 (2.3%)	0 (0.0%)	1 (2.3%)	16 (37.2%)
	Muscle spasms	0 (0.0%)	0 (0.0%)	0 (0.0%)	16 (37.2%)
	Myalgia	0 (0.0%)	0 (0.0%)	0 (0.0%)	15 (34.9%)
	Pain in extremity	2 (4.7%)	0 (0.0%)	2 (4.7%)	13 (30.2%)
	Bone pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	12 (27.9%)
	Musculoskeletal pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	10 (23.3%)
	Musculoskeletal chest pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (11.6%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	All	6 (14.0%)	2 (4.7%)	8 (18.6%)	16 (37.2%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Nervous system disorders	All	13 (30.2%)	0 (0.0%)	13 (30.2%)	36 (83.7%)
	Headache	1 (2.3%)	0 (0.0%)	1 (2.3%)	25 (58.1%)
	Dizziness	2 (4.7%)	0 (0.0%)	2 (4.7%)	11 (25.6%)
	Somnolence	1 (2.3%)	0 (0.0%)	1 (2.3%)	5 (11.6%)
Psychiatric disorders	All	1 (2.3%)	0 (0.0%)	1 (2.3%)	17 (39.5%)
	Depression	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (14.0%)
	Insomnia	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (11.6%)
Renal and urinary disorders	All	4 (9.3%)	0 (0.0%)	4 (9.3%)	13 (30.2%)
Reproductive system and breast disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	8 (18.6%)
Respiratory, thoracic and mediastinal disorders	All	6 (14.0%)	1 (2.3%)	7 (16.3%)	27 (62.8%)
	Cough	0 (0.0%)	0 (0.0%)	0 (0.0%)	14 (32.6%)
	Dyspnoea	2 (4.7%)	1 (2.3%)	3 (7.0%)	9 (20.9%)
	Oropharyngeal pain	1 (2.3%)	0 (0.0%)	1 (2.3%)	8 (18.6%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Pleural effusion	3 (7.0%)	0 (0.0%)	3 (7.0%)	6 (14.0%)
Skin and subcutaneous tissue disorders	All	3 (7.0%)	0 (0.0%)	3 (7.0%)	36 (83.7%)
	Rash erythematous	0 (0.0%)	0 (0.0%)	0 (0.0%)	20 (46.5%)
	Dry skin	0 (0.0%)	0 (0.0%)	0 (0.0%)	19 (44.2%)
	Rash papular	0 (0.0%)	0 (0.0%)	0 (0.0%)	15 (34.9%)
	Dermatitis acneiform	1 (2.3%)	0 (0.0%)	1 (2.3%)	10 (23.3%)
	Rash	0 (0.0%)	0 (0.0%)	0 (0.0%)	9 (20.9%)
	Night sweats	0 (0.0%)	0 (0.0%)	0 (0.0%)	8 (18.6%)
	Pruritus	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (14.0%)
	Rash maculo-papular	1 (2.3%)	0 (0.0%)	1 (2.3%)	6 (14.0%)
	Rash pruritic	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (14.0%)
	Alopecia	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (11.6%)
Vascular disorders	All	11 (25.6%)	0 (0.0%)	11 (25.6%)	32 (74.4%)
	Hypertension	5 (11.6%)	0 (0.0%)	5 (11.6%)	20 (46.5%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Flushing	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (11.6%)
	Hypotension	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (11.6%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		4 (44.4%)	3 (33.3%)	7 (77.8%)	9 (100.0%)
Blood and lymphatic system disorders	All	2 (22.2%)	0 (0.0%)	2 (22.2%)	6 (66.7%)
	Thrombocytopenia	1 (11.1%)	0 (0.0%)	1 (11.1%)	3 (33.3%)
	Anaemia	1 (11.1%)	0 (0.0%)	1 (11.1%)	2 (22.2%)
	Leukocytosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Febrile neutropenia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Splenomegaly	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
Cardiac disorders	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	3 (33.3%)
	Diastolic dysfunction	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Tachycardia	1 (11.1%)	0 (0.0%)	1 (11.1%)	2 (22.2%)
Ear and labyrinth disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Ear pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Eye disorders	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	4 (44.4%)
	Photopsia	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Vision blurred	1 (11.1%)	0 (0.0%)	1 (11.1%)	2 (22.2%)
	Blepharospasm	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Cataract	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Eye discharge	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Eye pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Ocular hyperaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
Gastrointestinal disorders	All	3 (33.3%)	1 (11.1%)	4 (44.4%)	8 (88.9%)
	Diarrhoea	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (55.6%)
	Constipation	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (44.4%)
	Nausea	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (44.4%)
	Abdominal discomfort	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (33.3%)
	Abdominal pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (33.3%)
	Stomatitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (33.3%)
	Vomiting	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (33.3%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Abdominal distension	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Dyspepsia	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Flatulence	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Gingival bleeding	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Pancreatitis	2 (22.2%)	0 (0.0%)	2 (22.2%)	2 (22.2%)
	Pancreatitis acute	1 (11.1%)	0 (0.0%)	1 (11.1%)	2 (22.2%)
	Abdominal hernia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Abdominal pain upper	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Dry mouth	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Dysphagia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Faeces discoloured	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Gastrooesophageal reflux disease	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Hyperchlorhydria	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Intestinal ischaemia	0 (0.0%)	1 (11.1%)	1 (11.1%)	1 (11.1%)
	Lip disorder	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Mouth haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Oral pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
General disorders and administration site conditions	All	1 (11.1%)	2 (22.2%)	3 (33.3%)	8 (88.9%)
	Pyrexia	2 (22.2%)	0 (0.0%)	2 (22.2%)	7 (77.8%)
	Oedema peripheral	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (55.6%)
	Fatigue	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (33.3%)
	Multiple organ dysfunction syndrome	0 (0.0%)	2 (22.2%)	2 (22.2%)	2 (22.2%)
	Non-cardiac chest pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Peripheral swelling	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Asthenia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Chills	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Influenza like illness	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Malaise	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
Hepatobiliary disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Hepatic function abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Hyperbilirubinaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Infections and infestations	All	4 (44.4%)	1 (11.1%)	5 (55.6%)	6 (66.7%)
	Pneumonia	2 (22.2%)	0 (0.0%)	2 (22.2%)	3 (33.3%)
	Bronchitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Laryngitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Nasopharyngitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Rhinitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Bacteraemia	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Bacterial sepsis	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Cellulitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Clostridium difficile colitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Eye infection staphylococcal	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Localised infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Lower respiratory tract infection	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Lung infection	0 (0.0%)	1 (11.1%)	1 (11.1%)	1 (11.1%)
	Sepsis	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Septic shock	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Sinusitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Tinea cruris	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Upper respiratory tract infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Urinary tract infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Viral pharyngitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Viral upper respiratory tract infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
Injury, poisoning and procedural complications	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	4 (44.4%)
	Animal bite	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Contusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Laceration	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Procedural pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Sunburn	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Tendon rupture	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Tongue injury	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
Investigations	All	2 (22.2%)	0 (0.0%)	2 (22.2%)	6 (66.7%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Haemoglobin decreased	1 (11.1%)	0 (0.0%)	1 (11.1%)	2 (22.2%)
	Lipase increased	1 (11.1%)	0 (0.0%)	1 (11.1%)	2 (22.2%)
	Amylase increased	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Aspartate aminotransferase increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Blood chloride increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Blood creatinine increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Blood urea increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Blood uric acid decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Platelet count decreased	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Platelet count increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	White blood cell count decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	White blood cell count increased	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
Metabolism and nutrition disorders	All	2 (22.2%)	0 (0.0%)	2 (22.2%)	8 (88.9%)
	Decreased appetite	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (44.4%)
	Hypokalaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (44.4%)
	Hyperphosphataemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Hypocalcaemia	1 (11.1%)	0 (0.0%)	1 (11.1%)	2 (22.2%)
	Dehydration	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Fluid overload	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Glucose tolerance impaired	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Hyperkalaemia	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Hypomagnesaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Increased appetite	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Iron overload	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
Musculoskeletal and connective tissue disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (55.6%)
	Arthralgia	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (33.3%)
	Muscle spasms	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Musculoskeletal chest pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Musculoskeletal pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Myalgia	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Pain in extremity	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Joint stiffness	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Joint swelling	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Musculoskeletal discomfort	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Neck pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Pain in jaw	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Basal cell carcinoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Squamous cell carcinoma of skin	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
Nervous system disorders	All	2 (22.2%)	0 (0.0%)	2 (22.2%)	6 (66.7%)
	Headache	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (44.4%)
	Hypoaesthesia	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (33.3%)
	Neuropathy peripheral	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (33.3%)
	Cerebrovascular accident	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Dizziness	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Dizziness postural	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Memory impairment	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Sinus headache	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Syncope	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
Psychiatric disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (44.4%)
	Insomnia	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Anxiety	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Confusional state	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Depression	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
Renal and urinary disorders	All	2 (22.2%)	0 (0.0%)	2 (22.2%)	4 (44.4%)
	Pollakiuria	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Acute kidney injury	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Dysuria	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Incontinence	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Renal failure	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
Respiratory, thoracic and mediastinal disorders	All	3 (33.3%)	0 (0.0%)	3 (33.3%)	6 (66.7%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Dyspnoea	1 (11.1%)	0 (0.0%)	1 (11.1%)	4 (44.4%)
	Cough	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (33.3%)
	Pleural effusion	1 (11.1%)	0 (0.0%)	1 (11.1%)	3 (33.3%)
	Epistaxis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Hypoxia	2 (22.2%)	0 (0.0%)	2 (22.2%)	2 (22.2%)
	Sinus congestion	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Acute respiratory failure	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Allergic respiratory symptom	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Asthma	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Bronchospasm	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Chronic obstructive pulmonary disease	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Dysphonia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Lung infiltration	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Oropharyngeal pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Orthopnoea	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Pleuritic pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Pneumonitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Productive cough	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Pulmonary hypertension	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Pulmonary oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Rales	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Upper-airway cough syndrome	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Vocal cord disorder	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Wheezing	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
Skin and subcutaneous tissue disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (55.6%)
	Rash pruritic	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (33.3%)
	Pruritus	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Rash	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Rash erythematous	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Rash papular	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Actinic keratosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Decubitus ulcer	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Dermatitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Dermatitis contact	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Dry skin	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Ecchymosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Eczema	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Erythema	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Erythema nodosum	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Hyperhidrosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Nail disorder	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Nail ridging	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Night sweats	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Onychoclasis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Psoriasis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Rash macular	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Skin burning sensation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Skin exfoliation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Skin haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Skin mass	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Vascular disorders	All	2 (22.2%)	0 (0.0%)	2 (22.2%)	6 (66.7%)
	Hypertension	1 (11.1%)	0 (0.0%)	1 (11.1%)	4 (44.4%)
	Flushing	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Hot flush	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Peripheral artery occlusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Peripheral ischaemia	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (37.5%)	5 (62.5%)	8 (100.0%)	8 (100.0%)
Blood and lymphatic system disorders	All	5 (62.5%)	1 (12.5%)	6 (75.0%)	6 (75.0%)
	Febrile neutropenia	5 (62.5%)	0 (0.0%)	5 (62.5%)	5 (62.5%)
	Anaemia	1 (12.5%)	0 (0.0%)	1 (12.5%)	2 (25.0%)
	Thrombocytopenia	2 (25.0%)	0 (0.0%)	2 (25.0%)	2 (25.0%)
	Cytopenia	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Leukocytosis	0 (0.0%)	1 (12.5%)	1 (12.5%)	1 (12.5%)
	Lymph node pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Neutropenia	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
Cardiac disorders	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	4 (50.0%)
	Angina pectoris	1 (12.5%)	0 (0.0%)	1 (12.5%)	2 (25.0%)
	Palpitations	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (25.0%)
	Tachycardia	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (25.0%)
	Atrial fibrillation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Sinus arrest	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Sinus tachycardia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Ventricular tachycardia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
Ear and labyrinth disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (25.0%)
	Tinnitus	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Vertigo	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
Endocrine disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (25.0%)
	Cushingoid	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Hypothyroidism	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
Eye disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (37.5%)
	Conjunctival haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Eye inflammation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Eye pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Periorbital oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Photopsia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Retinal haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
Gastrointestinal disorders	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	6 (75.0%)
	Diarrhoea	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (50.0%)
	Abdominal tenderness	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (25.0%)
	Dry mouth	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (25.0%)
	Dyspepsia	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (25.0%)
	Nausea	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (25.0%)
	Vomiting	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (25.0%)
	Abdominal distension	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Abdominal pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Abdominal pain upper	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Colitis	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Constipation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Dysphagia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Lip haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Lip swelling	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Mouth haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Oral mucosal blistering	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Rectal haemorrhage	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Stomatitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Upper gastrointestinal haemorrhage	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
General disorders and administration site conditions	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	5 (62.5%)
	Fatigue	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (50.0%)
	Chills	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (37.5%)
	Oedema peripheral	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (37.5%)
	Pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (37.5%)
	Asthenia	1 (12.5%)	0 (0.0%)	1 (12.5%)	2 (25.0%)
	Pyrexia	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (25.0%)
	Catheter site pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Vessel puncture site rash	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Immune system disorders	Acute graft versus host disease in skin	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
Infections and infestations	All	4 (50.0%)	2 (25.0%)	6 (75.0%)	6 (75.0%)
	Enterobacter bacteraemia	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Neutropenic sepsis	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Oral candidiasis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Pneumonia	0 (0.0%)	1 (12.5%)	1 (12.5%)	1 (12.5%)
	Sepsis	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Septic shock	0 (0.0%)	1 (12.5%)	1 (12.5%)	1 (12.5%)
	Staphylococcal bacteraemia	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Upper respiratory tract infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Urinary tract infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Urinary tract infection enterococcal	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
Injury, poisoning and procedural complications	All	2 (25.0%)	0 (0.0%)	2 (25.0%)	3 (37.5%)
	Contusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (25.0%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Procedural pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (25.0%)
	Fall	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Limb injury	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Mouth injury	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Post-traumatic pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Subdural haematoma	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
Investigations	All	4 (50.0%)	0 (0.0%)	4 (50.0%)	6 (75.0%)
	Electrocardiogram QT prolonged	2 (25.0%)	0 (0.0%)	2 (25.0%)	3 (37.5%)
	Aspartate aminotransferase increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (25.0%)
	Alanine aminotransferase increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Blood creatinine decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Blood phosphorus increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Breath sounds abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Cardiac murmur	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Heart rate increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	International normalised ratio increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Liver palpable	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Monocyte count decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Neutrophil count increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Oxygen saturation decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Platelet count decreased	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Troponin increased	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
Metabolism and nutrition disorders	All	3 (37.5%)	0 (0.0%)	3 (37.5%)	6 (75.0%)
	Hypocalcaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (37.5%)
	Hypokalaemia	2 (25.0%)	0 (0.0%)	2 (25.0%)	3 (37.5%)
	Decreased appetite	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Dehydration	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Fluid retention	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Hyperglycaemia	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Hyperkalaemia	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Hypoalbuminaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Hypomagnesaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Hypovolaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Malnutrition	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
Musculoskeletal and connective tissue disorders	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	5 (62.5%)
	Pain in extremity	1 (12.5%)	0 (0.0%)	1 (12.5%)	4 (50.0%)
	Arthralgia	1 (12.5%)	0 (0.0%)	1 (12.5%)	3 (37.5%)
	Bone pain	1 (12.5%)	0 (0.0%)	1 (12.5%)	2 (25.0%)
	Muscle spasms	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (25.0%)
	Back pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Musculoskeletal pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Neck pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Periostitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	All	0 (0.0%)	2 (25.0%)	2 (25.0%)	3 (37.5%)
	Neoplasm progression	0 (0.0%)	2 (25.0%)	2 (25.0%)	2 (25.0%)
	Blast cell crisis	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Blast crisis in myelogenous leukaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
Nervous system disorders	All	1 (12.5%)	1 (12.5%)	2 (25.0%)	6 (75.0%)
	Dizziness	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (50.0%)
	Dysarthria	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Dysgeusia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Headache	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Hypoaesthesia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Metabolic encephalopathy	0 (0.0%)	1 (12.5%)	1 (12.5%)	1 (12.5%)
	Seizure	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Somnolence	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
Psychiatric disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (50.0%)
	Confusional state	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (37.5%)
	Insomnia	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (25.0%)
	Agitation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Renal and urinary disorders	Acute kidney injury	2 (25.0%)	0 (0.0%)	2 (25.0%)	2 (25.0%)
	All	2 (25.0%)	0 (0.0%)	2 (25.0%)	2 (25.0%)
	Anuria	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Bladder discomfort	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
Reproductive system and breast disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Menstruation irregular	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Vaginal haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
Respiratory, thoracic and mediastinal disorders	All	4 (50.0%)	0 (0.0%)	4 (50.0%)	5 (62.5%)
	Dyspnoea	2 (25.0%)	0 (0.0%)	2 (25.0%)	3 (37.5%)
	Oropharyngeal pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (25.0%)
	Cough	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Dyspnoea exertional	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Hypoxia	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Nasal congestion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Nasal dryness	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Productive cough	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Respiratory alkalosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Respiratory distress	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Respiratory failure	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Rhonchi	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Sinus congestion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Sputum discoloured	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Wheezing	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
Skin and subcutaneous tissue disorders	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	5 (62.5%)
	Petechiae	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (25.0%)
	Alopecia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Ecchymosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Night sweats	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Rash erythematous	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Skin exfoliation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 101)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Vascular disorders	All	3 (37.5%)	0 (0.0%)	3 (37.5%)	3 (37.5%)
	Hypertension	1 (12.5%)	0 (0.0%)	1 (12.5%)	2 (25.0%)
	Hypotension	1 (12.5%)	0 (0.0%)	1 (12.5%)	2 (25.0%)
	Deep vein thrombosis	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Thrombophlebitis superficial	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 201)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		221 (81.9%)	18 (6.7%)	239 (88.5%)	270 (100.0%)
Blood and lymphatic system disorders	All	105 (38.9%)	0 (0.0%)	105 (38.9%)	145 (53.7%)
	Thrombocytopenia	82 (30.4%)	0 (0.0%)	82 (30.4%)	108 (40.0%)
	Anaemia	25 (9.3%)	0 (0.0%)	25 (9.3%)	50 (18.5%)
	Neutropenia	40 (14.8%)	0 (0.0%)	40 (14.8%)	48 (17.8%)
Cardiac disorders	All	42 (15.6%)	5 (1.9%)	47 (17.4%)	81 (30.0%)
Ear and labyrinth disorders	All	3 (1.1%)	0 (0.0%)	3 (1.1%)	36 (13.3%)
Eye disorders	All	9 (3.3%)	0 (0.0%)	9 (3.3%)	87 (32.2%)
Gastrointestinal disorders	All	63 (23.3%)	0 (0.0%)	63 (23.3%)	227 (84.1%)
	Constipation	7 (2.6%)	0 (0.0%)	7 (2.6%)	112 (41.5%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Run Date/Time: 26MAY2020 11:09

Table 1.2.2.2.1 (Study 201)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Abdominal pain	21 (7.8%)	0 (0.0%)	21 (7.8%)	97 (35.9%)
	Nausea	2 (0.7%)	0 (0.0%)	2 (0.7%)	79 (29.3%)
	Abdominal pain upper	9 (3.3%)	0 (0.0%)	9 (3.3%)	54 (20.0%)
	Diarrhoea	2 (0.7%)	0 (0.0%)	2 (0.7%)	54 (20.0%)
	Vomiting	4 (1.5%)	0 (0.0%)	4 (1.5%)	50 (18.5%)
General disorders and administration site conditions	All	23 (8.5%)	0 (0.0%)	23 (8.5%)	190 (70.4%)
	Fatigue	6 (2.2%)	0 (0.0%)	6 (2.2%)	81 (30.0%)
	Pyrexia	3 (1.1%)	0 (0.0%)	3 (1.1%)	70 (25.9%)
	Asthenia	5 (1.9%)	0 (0.0%)	5 (1.9%)	49 (18.1%)
	Oedema peripheral	2 (0.7%)	0 (0.0%)	2 (0.7%)	44 (16.3%)
	Pain	2 (0.7%)	0 (0.0%)	2 (0.7%)	27 (10.0%)
Infections and infestations	All	39 (14.4%)	3 (1.1%)	42 (15.6%)	171 (63.3%)
	Upper respiratory tract infection	3 (1.1%)	0 (0.0%)	3 (1.1%)	37 (13.7%)
	Nasopharyngitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	33 (12.2%)
	Urinary tract infection	6 (2.2%)	0 (0.0%)	6 (2.2%)	31 (11.5%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 201)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Injury, poisoning and procedural complications	All	5 (1.9%)	1 (0.4%)	6 (2.2%)	65 (24.1%)
Investigations	All	84 (31.1%)	0 (0.0%)	84 (31.1%)	175 (64.8%)
	Lipase increased	34 (12.6%)	0 (0.0%)	34 (12.6%)	73 (27.0%)
	Alanine aminotransferase increased	14 (5.2%)	0 (0.0%)	14 (5.2%)	51 (18.9%)
	Aspartate aminotransferase increased	7 (2.6%)	0 (0.0%)	7 (2.6%)	42 (15.6%)
	Weight decreased	1 (0.4%)	0 (0.0%)	1 (0.4%)	28 (10.4%)
Metabolism and nutrition disorders	All	35 (13.0%)	0 (0.0%)	35 (13.0%)	118 (43.7%)
	Decreased appetite	1 (0.4%)	0 (0.0%)	1 (0.4%)	35 (13.0%)
Musculoskeletal and connective tissue disorders	All	32 (11.9%)	0 (0.0%)	32 (11.9%)	212 (78.5%)
	Arthralgia	8 (3.0%)	0 (0.0%)	8 (3.0%)	90 (33.3%)
	Myalgia	3 (1.1%)	0 (0.0%)	3 (1.1%)	65 (24.1%)
	Pain in extremity	8 (3.0%)	0 (0.0%)	8 (3.0%)	65 (24.1%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Run Date/Time: 26MAY2020 11:09

Table 1.2.2.2.1 (Study 201)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Back pain	3 (1.1%)	0 (0.0%)	3 (1.1%)	59 (21.9%)
	Bone pain	1 (0.4%)	0 (0.0%)	1 (0.4%)	38 (14.1%)
	Muscle spasms	0 (0.0%)	0 (0.0%)	0 (0.0%)	39 (14.4%)
	Musculoskeletal pain	4 (1.5%)	0 (0.0%)	4 (1.5%)	29 (10.7%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	All	12 (4.4%)	7 (2.6%)	19 (7.0%)	38 (14.1%)
Nervous system disorders	All	38 (14.1%)	2 (0.7%)	40 (14.8%)	186 (68.9%)
	Headache	9 (3.3%)	0 (0.0%)	9 (3.3%)	116 (43.0%)
	Dizziness	1 (0.4%)	0 (0.0%)	1 (0.4%)	46 (17.0%)
Psychiatric disorders	All	3 (1.1%)	0 (0.0%)	3 (1.1%)	55 (20.4%)
	Insomnia	0 (0.0%)	0 (0.0%)	0 (0.0%)	30 (11.1%)
Renal and urinary disorders	All	12 (4.4%)	0 (0.0%)	12 (4.4%)	49 (18.1%)
Reproductive system and breast disorders	All	3 (1.1%)	0 (0.0%)	3 (1.1%)	45 (16.7%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 201)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Respiratory, thoracic and mediastinal disorders	All	20 (7.4%)	0 (0.0%)	20 (7.4%)	135 (50.0%)
	Cough	0 (0.0%)	0 (0.0%)	0 (0.0%)	47 (17.4%)
	Dyspnoea	8 (3.0%)	0 (0.0%)	8 (3.0%)	47 (17.4%)
Skin and subcutaneous tissue disorders	All	30 (11.1%)	0 (0.0%)	30 (11.1%)	223 (82.6%)
	Dry skin	9 (3.3%)	0 (0.0%)	9 (3.3%)	114 (42.2%)
	Rash erythematous	7 (2.6%)	0 (0.0%)	7 (2.6%)	60 (22.2%)
	Pruritus	1 (0.4%)	0 (0.0%)	1 (0.4%)	35 (13.0%)
	Rash maculo-papular	3 (1.1%)	0 (0.0%)	3 (1.1%)	32 (11.9%)
	Rash	0 (0.0%)	0 (0.0%)	0 (0.0%)	31 (11.5%)
	Erythema	3 (1.1%)	0 (0.0%)	3 (1.1%)	28 (10.4%)
	Rash pruritic	0 (0.0%)	0 (0.0%)	0 (0.0%)	27 (10.0%)
Vascular disorders	All	61 (22.6%)	0 (0.0%)	61 (22.6%)	141 (52.2%)
	Hypertension	37 (13.7%)	0 (0.0%)	37 (13.7%)	98 (36.3%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 201)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		60 (70.6%)	18 (21.2%)	78 (91.8%)	85 (100.0%)
Blood and lymphatic system disorders	All	49 (57.6%)	0 (0.0%)	49 (57.6%)	57 (67.1%)
	Thrombocytopenia	33 (38.8%)	0 (0.0%)	33 (38.8%)	39 (45.9%)
	Anaemia	19 (22.4%)	0 (0.0%)	19 (22.4%)	31 (36.5%)
	Neutropenia	28 (32.9%)	0 (0.0%)	28 (32.9%)	28 (32.9%)
Cardiac disorders	All	8 (9.4%)	0 (0.0%)	8 (9.4%)	25 (29.4%)
Ear and labyrinth disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	9 (10.6%)
Eye disorders	All	4 (4.7%)	0 (0.0%)	4 (4.7%)	28 (32.9%)
Gastrointestinal disorders	All	17 (20.0%)	1 (1.2%)	18 (21.2%)	72 (84.7%)
	Abdominal pain	6 (7.1%)	0 (0.0%)	6 (7.1%)	30 (35.3%)
	Nausea	0 (0.0%)	0 (0.0%)	0 (0.0%)	27 (31.8%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 201)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Constipation	2 (2.4%)	0 (0.0%)	2 (2.4%)	25 (29.4%)
	Diarrhoea	2 (2.4%)	0 (0.0%)	2 (2.4%)	25 (29.4%)
	Vomiting	0 (0.0%)	0 (0.0%)	0 (0.0%)	23 (27.1%)
	Abdominal pain upper	1 (1.2%)	0 (0.0%)	1 (1.2%)	14 (16.5%)
General disorders and administration site conditions	All	12 (14.1%)	0 (0.0%)	12 (14.1%)	66 (77.6%)
	Pyrexia	6 (7.1%)	0 (0.0%)	6 (7.1%)	34 (40.0%)
	Fatigue	4 (4.7%)	0 (0.0%)	4 (4.7%)	32 (37.6%)
	Oedema peripheral	0 (0.0%)	0 (0.0%)	0 (0.0%)	15 (17.6%)
	Asthenia	3 (3.5%)	0 (0.0%)	3 (3.5%)	11 (12.9%)
	Pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	11 (12.9%)
	Chills	0 (0.0%)	0 (0.0%)	0 (0.0%)	10 (11.8%)
Hepatobiliary disorders	All	5 (5.9%)	0 (0.0%)	5 (5.9%)	13 (15.3%)
Infections and infestations	All	23 (27.1%)	4 (4.7%)	27 (31.8%)	65 (76.5%)
	Nasopharyngitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	15 (17.6%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 201)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Urinary tract infection	2 (2.4%)	0 (0.0%)	2 (2.4%)	12 (14.1%)
	Pneumonia	8 (9.4%)	0 (0.0%)	8 (9.4%)	11 (12.9%)
	Upper respiratory tract infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	11 (12.9%)
Injury, poisoning and procedural complications	All	6 (7.1%)	0 (0.0%)	6 (7.1%)	26 (30.6%)
Investigations	All	24 (28.2%)	0 (0.0%)	24 (28.2%)	45 (52.9%)
	Alanine aminotransferase increased	3 (3.5%)	0 (0.0%)	3 (3.5%)	20 (23.5%)
	Aspartate aminotransferase increased	4 (4.7%)	0 (0.0%)	4 (4.7%)	17 (20.0%)
	Lipase increased	11 (12.9%)	0 (0.0%)	11 (12.9%)	13 (15.3%)
	Blood alkaline phosphatase increased	2 (2.4%)	0 (0.0%)	2 (2.4%)	10 (11.8%)
	Gamma-glutamyltransferase increased	4 (4.7%)	0 (0.0%)	4 (4.7%)	10 (11.8%)
Metabolism and nutrition disorders	All	10 (11.8%)	0 (0.0%)	10 (11.8%)	44 (51.8%)
	Decreased appetite	1 (1.2%)	0 (0.0%)	1 (1.2%)	12 (14.1%)
	Hyperglycaemia	2 (2.4%)	0 (0.0%)	2 (2.4%)	9 (10.6%)
	Hypocalcaemia	3 (3.5%)	0 (0.0%)	3 (3.5%)	9 (10.6%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 201)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Musculoskeletal and connective tissue disorders	All	7 (8.2%)	0 (0.0%)	7 (8.2%)	62 (72.9%)
	Arthralgia	2 (2.4%)	0 (0.0%)	2 (2.4%)	29 (34.1%)
	Myalgia	0 (0.0%)	0 (0.0%)	0 (0.0%)	18 (21.2%)
	Pain in extremity	0 (0.0%)	0 (0.0%)	0 (0.0%)	17 (20.0%)
	Back pain	2 (2.4%)	0 (0.0%)	2 (2.4%)	13 (15.3%)
	Bone pain	1 (1.2%)	0 (0.0%)	1 (1.2%)	11 (12.9%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	All	5 (5.9%)	10 (11.8%)	15 (17.6%)	22 (25.9%)
	Neoplasm progression	3 (3.5%)	8 (9.4%)	11 (12.9%)	12 (14.1%)
Nervous system disorders	All	13 (15.3%)	0 (0.0%)	13 (15.3%)	52 (61.2%)
	Headache	1 (1.2%)	0 (0.0%)	1 (1.2%)	26 (30.6%)
	Dizziness	0 (0.0%)	0 (0.0%)	0 (0.0%)	9 (10.6%)
Psychiatric disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	32 (37.6%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 201)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Anxiety	0 (0.0%)	0 (0.0%)	0 (0.0%)	15 (17.6%)
	Insomnia	0 (0.0%)	0 (0.0%)	0 (0.0%)	11 (12.9%)
Renal and urinary disorders	All	2 (2.4%)	1 (1.2%)	3 (3.5%)	22 (25.9%)
Reproductive system and breast disorders	All	1 (1.2%)	0 (0.0%)	1 (1.2%)	14 (16.5%)
Respiratory, thoracic and mediastinal disorders	All	8 (9.4%)	1 (1.2%)	9 (10.6%)	47 (55.3%)
	Cough	0 (0.0%)	0 (0.0%)	0 (0.0%)	19 (22.4%)
	Dyspnoea	3 (3.5%)	0 (0.0%)	3 (3.5%)	17 (20.0%)
	Pleural effusion	2 (2.4%)	0 (0.0%)	2 (2.4%)	10 (11.8%)
Skin and subcutaneous tissue disorders	All	15 (17.6%)	0 (0.0%)	15 (17.6%)	68 (80.0%)
	Dry skin	1 (1.2%)	0 (0.0%)	1 (1.2%)	27 (31.8%)
	Rash	1 (1.2%)	0 (0.0%)	1 (1.2%)	13 (15.3%)
	Rash erythematous	2 (2.4%)	0 (0.0%)	2 (2.4%)	11 (12.9%)
	Alopecia	0 (0.0%)	0 (0.0%)	0 (0.0%)	9 (10.6%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 201)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Rash pruritic	2 (2.4%)	0 (0.0%)	2 (2.4%)	9 (10.6%)
Vascular disorders	All	14 (16.5%)	1 (1.2%)	15 (17.6%)	38 (44.7%)
	Hypertension	9 (10.6%)	0 (0.0%)	9 (10.6%)	22 (25.9%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 201)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		26 (41.9%)	32 (51.6%)	58 (93.5%)	62 (100.0%)
Blood and lymphatic system disorders	All	39 (62.9%)	1 (1.6%)	40 (64.5%)	42 (67.7%)
	Anaemia	20 (32.3%)	0 (0.0%)	20 (32.3%)	21 (33.9%)
	Thrombocytopenia	19 (30.6%)	0 (0.0%)	19 (30.6%)	20 (32.3%)
	Neutropenia	14 (22.6%)	0 (0.0%)	14 (22.6%)	16 (25.8%)
	Febrile neutropenia	8 (12.9%)	0 (0.0%)	8 (12.9%)	8 (12.9%)
Cardiac disorders	All	12 (19.4%)	2 (3.2%)	14 (22.6%)	20 (32.3%)
Eye disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	12 (19.4%)
Gastrointestinal disorders	All	13 (21.0%)	1 (1.6%)	14 (22.6%)	49 (79.0%)
	Nausea	1 (1.6%)	0 (0.0%)	1 (1.6%)	21 (33.9%)
	Constipation	0 (0.0%)	0 (0.0%)	0 (0.0%)	17 (27.4%)
	Vomiting	1 (1.6%)	0 (0.0%)	1 (1.6%)	17 (27.4%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 201)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Abdominal pain	4 (6.5%)	0 (0.0%)	4 (6.5%)	15 (24.2%)
	Diarrhoea	2 (3.2%)	0 (0.0%)	2 (3.2%)	15 (24.2%)
	Abdominal pain upper	1 (1.6%)	0 (0.0%)	1 (1.6%)	7 (11.3%)
General disorders and administration site conditions	All	9 (14.5%)	2 (3.2%)	11 (17.7%)	45 (72.6%)
	Pyrexia	2 (3.2%)	0 (0.0%)	2 (3.2%)	23 (37.1%)
	Fatigue	3 (4.8%)	0 (0.0%)	3 (4.8%)	16 (25.8%)
	Pain	2 (3.2%)	0 (0.0%)	2 (3.2%)	10 (16.1%)
	Asthenia	1 (1.6%)	0 (0.0%)	1 (1.6%)	9 (14.5%)
	Oedema peripheral	0 (0.0%)	0 (0.0%)	0 (0.0%)	9 (14.5%)
	Chills	1 (1.6%)	0 (0.0%)	1 (1.6%)	8 (12.9%)
Hepatobiliary disorders	All	6 (9.7%)	0 (0.0%)	6 (9.7%)	10 (16.1%)
Infections and infestations	All	16 (25.8%)	3 (4.8%)	19 (30.6%)	35 (56.5%)
	Pneumonia	7 (11.3%)	0 (0.0%)	7 (11.3%)	10 (16.1%)
	Upper respiratory tract infection	1 (1.6%)	0 (0.0%)	1 (1.6%)	8 (12.9%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 201)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Cellulitis	2 (3.2%)	0 (0.0%)	2 (3.2%)	7 (11.3%)
Injury, poisoning and procedural complications	All	1 (1.6%)	1 (1.6%)	2 (3.2%)	11 (17.7%)
Investigations	All	18 (29.0%)	0 (0.0%)	18 (29.0%)	31 (50.0%)
	Aspartate aminotransferase increased	4 (6.5%)	0 (0.0%)	4 (6.5%)	10 (16.1%)
	Lipase increased	8 (12.9%)	0 (0.0%)	8 (12.9%)	9 (14.5%)
	Alanine aminotransferase increased	4 (6.5%)	0 (0.0%)	4 (6.5%)	8 (12.9%)
Metabolism and nutrition disorders	All	11 (17.7%)	1 (1.6%)	12 (19.4%)	30 (48.4%)
	Hypokalaemia	4 (6.5%)	0 (0.0%)	4 (6.5%)	12 (19.4%)
	Hypocalcaemia	2 (3.2%)	0 (0.0%)	2 (3.2%)	7 (11.3%)
Musculoskeletal and connective tissue disorders	All	3 (4.8%)	0 (0.0%)	3 (4.8%)	37 (59.7%)
	Arthralgia	0 (0.0%)	0 (0.0%)	0 (0.0%)	12 (19.4%)
	Back pain	1 (1.6%)	0 (0.0%)	1 (1.6%)	12 (19.4%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 201)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Myalgia	0 (0.0%)	0 (0.0%)	0 (0.0%)	11 (17.7%)
	Pain in extremity	0 (0.0%)	0 (0.0%)	0 (0.0%)	8 (12.9%)
	Bone pain	2 (3.2%)	0 (0.0%)	2 (3.2%)	7 (11.3%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	All	4 (6.5%)	19 (30.6%)	23 (37.1%)	26 (41.9%)
	Neoplasm progression	2 (3.2%)	17 (27.4%)	19 (30.6%)	19 (30.6%)
Nervous system disorders	All	5 (8.1%)	2 (3.2%)	7 (11.3%)	31 (50.0%)
	Headache	2 (3.2%)	0 (0.0%)	2 (3.2%)	19 (30.6%)
Psychiatric disorders	All	1 (1.6%)	0 (0.0%)	1 (1.6%)	14 (22.6%)
	Insomnia	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (11.3%)
Renal and urinary disorders	All	3 (4.8%)	0 (0.0%)	3 (4.8%)	17 (27.4%)
Respiratory, thoracic and mediastinal disorders	All	9 (14.5%)	0 (0.0%)	9 (14.5%)	44 (71.0%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

Table 1.2.2.2.1 (Study 201)
Treatment-Emergent Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Cough	0 (0.0%)	0 (0.0%)	0 (0.0%)	12 (19.4%)
	Dyspnoea	3 (4.8%)	0 (0.0%)	3 (4.8%)	12 (19.4%)
	Oropharyngeal pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	9 (14.5%)
	Pleural effusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	8 (12.9%)
Skin and subcutaneous tissue disorders	All	5 (8.1%)	0 (0.0%)	5 (8.1%)	43 (69.4%)
	Dry skin	1 (1.6%)	0 (0.0%)	1 (1.6%)	16 (25.8%)
	Rash erythematous	1 (1.6%)	0 (0.0%)	1 (1.6%)	16 (25.8%)
Vascular disorders	All	10 (16.1%)	0 (0.0%)	10 (16.1%)	20 (32.3%)
	Hypertension	5 (8.1%)	0 (0.0%)	5 (8.1%)	13 (21.0%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 10% patients are listed.

1.2.2.3 Serious TEAE by SOC/PT and grade

1.2.2.3.1 Patients in CP, AP, or BP

Table 1.2.2.3.1 (Study 101)
Treatment-Emergent Serious Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		26 (60.5%)	3 (7.0%)	29 (67.4%)	33 (76.7%)
Blood and lymphatic system disorders	All	3 (7.0%)	0 (0.0%)	3 (7.0%)	3 (7.0%)
Cardiac disorders	All	11 (25.6%)	0 (0.0%)	11 (25.6%)	13 (30.2%)
	Atrial fibrillation	3 (7.0%)	0 (0.0%)	3 (7.0%)	4 (9.3%)
Gastrointestinal disorders	All	12 (27.9%)	0 (0.0%)	12 (27.9%)	15 (34.9%)
	Pancreatitis	2 (4.7%)	0 (0.0%)	2 (4.7%)	4 (9.3%)
General disorders and administration site conditions	All	3 (7.0%)	0 (0.0%)	3 (7.0%)	6 (14.0%)
	Pyrexia	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (7.0%)
Infections and infestations	All	10 (23.3%)	1 (2.3%)	11 (25.6%)	12 (27.9%)
	Pneumonia	2 (4.7%)	1 (2.3%)	3 (7.0%)	3 (7.0%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 5% patients are listed.

Table 1.2.2.3.1 (Study 101)
Treatment-Emergent Serious Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Injury, poisoning and procedural complications	All	3 (7.0%)	0 (0.0%)	3 (7.0%)	4 (9.3%)
Investigations	All	6 (14.0%)	0 (0.0%)	6 (14.0%)	6 (14.0%)
Metabolism and nutrition disorders	All	4 (9.3%)	0 (0.0%)	4 (9.3%)	5 (11.6%)
	Dehydration	2 (4.7%)	0 (0.0%)	2 (4.7%)	4 (9.3%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	All	6 (14.0%)	2 (4.7%)	8 (18.6%)	9 (20.9%)
	Malignant melanoma	3 (7.0%)	1 (2.3%)	4 (9.3%)	4 (9.3%)
	Squamous cell carcinoma of skin	2 (4.7%)	0 (0.0%)	2 (4.7%)	3 (7.0%)
Nervous system disorders	All	6 (14.0%)	0 (0.0%)	6 (14.0%)	7 (16.3%)
Psychiatric disorders	All	1 (2.3%)	0 (0.0%)	1 (2.3%)	3 (7.0%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 5% patients are listed.

Table 1.2.2.3.1 (Study 101)
Treatment-Emergent Serious Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Renal and urinary disorders	All	3 (7.0%)	0 (0.0%)	3 (7.0%)	3 (7.0%)
Respiratory, thoracic and mediastinal disorders	All	3 (7.0%)	1 (2.3%)	4 (9.3%)	7 (16.3%)
Vascular disorders	All	6 (14.0%)	0 (0.0%)	6 (14.0%)	8 (18.6%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 5% patients are listed.

Table 1.2.2.3.1 (Study 101)
Treatment-Emergent Serious Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		4 (44.4%)	3 (33.3%)	7 (77.8%)	8 (88.9%)
Blood and lymphatic system disorders	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	2 (22.2%)
	Febrile neutropenia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Splenomegaly	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
Cardiac disorders	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Tachycardia	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
Eye disorders	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Vision blurred	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
Gastrointestinal disorders	All	3 (33.3%)	1 (11.1%)	4 (44.4%)	4 (44.4%)
	Pancreatitis	2 (22.2%)	0 (0.0%)	2 (22.2%)	2 (22.2%)
	Pancreatitis acute	1 (11.1%)	0 (0.0%)	1 (11.1%)	2 (22.2%)
	Abdominal pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 5% patients are listed.

Table 1.2.2.3.1 (Study 101)
Treatment-Emergent Serious Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Constipation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Intestinal ischaemia	0 (0.0%)	1 (11.1%)	1 (11.1%)	1 (11.1%)
General disorders and administration site conditions	All	1 (11.1%)	2 (22.2%)	3 (33.3%)	6 (66.7%)
	Pyrexia	2 (22.2%)	0 (0.0%)	2 (22.2%)	5 (55.6%)
	Multiple organ dysfunction syndrome	0 (0.0%)	2 (22.2%)	2 (22.2%)	2 (22.2%)
Infections and infestations	All	3 (33.3%)	1 (11.1%)	4 (44.4%)	5 (55.6%)
	Pneumonia	2 (22.2%)	0 (0.0%)	2 (22.2%)	2 (22.2%)
	Bacteraemia	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Bacterial sepsis	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Eye infection staphylococcal	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Lung infection	0 (0.0%)	1 (11.1%)	1 (11.1%)	1 (11.1%)
	Sepsis	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Septic shock	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Viral upper respiratory tract infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 5% patients are listed.

Table 1.2.2.3.1 (Study 101)
Treatment-Emergent Serious Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Injury, poisoning and procedural complications	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Laceration	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
Nervous system disorders	All	2 (22.2%)	0 (0.0%)	2 (22.2%)	2 (22.2%)
	Cerebrovascular accident	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Syncope	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
Renal and urinary disorders	Acute kidney injury	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
Respiratory, thoracic and mediastinal disorders	All	2 (22.2%)	0 (0.0%)	2 (22.2%)	4 (44.4%)
	Dyspnoea	1 (11.1%)	0 (0.0%)	1 (11.1%)	3 (33.3%)
	Acute respiratory failure	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Hypoxia	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Pleural effusion	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Pneumonitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 5% patients are listed.

Table 1.2.2.3.1 (Study 101)
Treatment-Emergent Serious Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Vascular disorders	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Peripheral ischaemia	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 5% patients are listed.

Table 1.2.2.3.1 (Study 101)
Treatment-Emergent Serious Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (37.5%)	5 (62.5%)	8 (100.0%)	8 (100.0%)
Blood and lymphatic system disorders	All	3 (37.5%)	1 (12.5%)	4 (50.0%)	4 (50.0%)
	Febrile neutropenia	2 (25.0%)	0 (0.0%)	2 (25.0%)	2 (25.0%)
	Leukocytosis	0 (0.0%)	1 (12.5%)	1 (12.5%)	1 (12.5%)
	Thrombocytopenia	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
Cardiac disorders	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Angina pectoris	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Atrial fibrillation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Tachycardia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
Immune system disorders	Acute graft versus host disease in skin	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
Infections and infestations	All	2 (25.0%)	2 (25.0%)	4 (50.0%)	5 (62.5%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 5% patients are listed.

Table 1.2.2.3.1 (Study 101)
Treatment-Emergent Serious Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Neutropenic sepsis	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Pneumonia	0 (0.0%)	1 (12.5%)	1 (12.5%)	1 (12.5%)
	Sepsis	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Septic shock	0 (0.0%)	1 (12.5%)	1 (12.5%)	1 (12.5%)
	Upper respiratory tract infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
Injury, poisoning and procedural complications	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Subdural haematoma	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
Investigations	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	2 (25.0%)
	Oxygen saturation decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Troponin increased	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
Musculoskeletal and connective tissue disorders	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Bone pain	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Pain in extremity	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 5% patients are listed.

Table 1.2.2.3.1 (Study 101)
Treatment-Emergent Serious Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	All	0 (0.0%)	2 (25.0%)	2 (25.0%)	3 (37.5%)
	Neoplasm progression	0 (0.0%)	2 (25.0%)	2 (25.0%)	2 (25.0%)
	Blast cell crisis	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Blast crisis in myelogenous leukaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
Nervous system disorders	All	1 (12.5%)	1 (12.5%)	2 (25.0%)	2 (25.0%)
	Metabolic encephalopathy	0 (0.0%)	1 (12.5%)	1 (12.5%)	1 (12.5%)
	Seizure	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
Renal and urinary disorders	Acute kidney injury	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
Vascular disorders	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Deep vein thrombosis	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 5% patients are listed.

Table 1.2.2.3.1 (Study 201)
Treatment-Emergent Serious Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		131 (48.5%)	18 (6.7%)	149 (55.2%)	171 (63.3%)
Cardiac disorders	All	38 (14.1%)	5 (1.9%)	43 (15.9%)	56 (20.7%)
	Atrial fibrillation	10 (3.7%)	0 (0.0%)	10 (3.7%)	15 (5.6%)
	Angina pectoris	4 (1.5%)	0 (0.0%)	4 (1.5%)	14 (5.2%)
Gastrointestinal disorders	All	33 (12.2%)	0 (0.0%)	33 (12.2%)	40 (14.8%)
	Pancreatitis	13 (4.8%)	0 (0.0%)	13 (4.8%)	14 (5.2%)
General disorders and administration site conditions	All	11 (4.1%)	0 (0.0%)	11 (4.1%)	24 (8.9%)
Infections and infestations	All	34 (12.6%)	3 (1.1%)	37 (13.7%)	42 (15.6%)
	Pneumonia	10 (3.7%)	2 (0.7%)	12 (4.4%)	15 (5.6%)
Investigations	All	15 (5.6%)	0 (0.0%)	15 (5.6%)	19 (7.0%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 5% patients are listed.

Table 1.2.2.3.1 (Study 201)
Treatment-Emergent Serious Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	All	12 (4.4%)	7 (2.6%)	19 (7.0%)	27 (10.0%)
Nervous system disorders	All	23 (8.5%)	2 (0.7%)	25 (9.3%)	39 (14.4%)
Respiratory, thoracic and mediastinal disorders	All	13 (4.8%)	0 (0.0%)	13 (4.8%)	15 (5.6%)
Vascular disorders	All	31 (11.5%)	0 (0.0%)	31 (11.5%)	44 (16.3%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 5% patients are listed.

Table 1.2.2.3.1 (Study 201)
Treatment-Emergent Serious Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		32 (37.6%)	18 (21.2%)	50 (58.8%)	59 (69.4%)
Blood and lymphatic system disorders	All	9 (10.6%)	0 (0.0%)	9 (10.6%)	10 (11.8%)
Cardiac disorders	All	6 (7.1%)	0 (0.0%)	6 (7.1%)	11 (12.9%)
Gastrointestinal disorders	All	8 (9.4%)	1 (1.2%)	9 (10.6%)	16 (18.8%)
	Abdominal pain	2 (2.4%)	0 (0.0%)	2 (2.4%)	5 (5.9%)
General disorders and administration site conditions	All	7 (8.2%)	0 (0.0%)	7 (8.2%)	13 (15.3%)
	Pyrexia	4 (4.7%)	0 (0.0%)	4 (4.7%)	8 (9.4%)
Hepatobiliary disorders	All	4 (4.7%)	0 (0.0%)	4 (4.7%)	5 (5.9%)
Infections and infestations	All	22 (25.9%)	4 (4.7%)	26 (30.6%)	29 (34.1%)
	Pneumonia	7 (8.2%)	0 (0.0%)	7 (8.2%)	9 (10.6%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 5% patients are listed.

Table 1.2.2.3.1 (Study 201)
Treatment-Emergent Serious Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Injury, poisoning and procedural complications	All	4 (4.7%)	0 (0.0%)	4 (4.7%)	6 (7.1%)
Metabolism and nutrition disorders	All	3 (3.5%)	0 (0.0%)	3 (3.5%)	5 (5.9%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	All	4 (4.7%)	10 (11.8%)	14 (16.5%)	17 (20.0%)
	Neoplasm progression	2 (2.4%)	8 (9.4%)	10 (11.8%)	11 (12.9%)
Nervous system disorders	All	11 (12.9%)	0 (0.0%)	11 (12.9%)	14 (16.5%)
Respiratory, thoracic and mediastinal disorders	All	6 (7.1%)	1 (1.2%)	7 (8.2%)	8 (9.4%)
Vascular disorders	All	8 (9.4%)	1 (1.2%)	9 (10.6%)	9 (10.6%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 5% patients are listed.

Table 1.2.2.3.1 (Study 201)
Treatment-Emergent Serious Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		17 (27.4%)	32 (51.6%)	49 (79.0%)	53 (85.5%)
Blood and lymphatic system disorders	All	10 (16.1%)	1 (1.6%)	11 (17.7%)	12 (19.4%)
	Anaemia	3 (4.8%)	0 (0.0%)	3 (4.8%)	4 (6.5%)
Cardiac disorders	All	9 (14.5%)	2 (3.2%)	11 (17.7%)	11 (17.7%)
Gastrointestinal disorders	All	9 (14.5%)	1 (1.6%)	10 (16.1%)	14 (22.6%)
	Abdominal pain	2 (3.2%)	0 (0.0%)	2 (3.2%)	4 (6.5%)
General disorders and administration site conditions	All	3 (4.8%)	2 (3.2%)	5 (8.1%)	7 (11.3%)
Infections and infestations	All	15 (24.2%)	3 (4.8%)	18 (29.0%)	19 (30.6%)
	Pneumonia	7 (11.3%)	0 (0.0%)	7 (11.3%)	8 (12.9%)
Investigations	All	4 (6.5%)	0 (0.0%)	4 (6.5%)	7 (11.3%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 5% patients are listed.

Table 1.2.2.3.1 (Study 201)
Treatment-Emergent Serious Adverse Events by System Organ Class, Preferred Term and Maximum Grade
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Metabolism and nutrition disorders	All	3 (4.8%)	1 (1.6%)	4 (6.5%)	4 (6.5%)
Musculoskeletal and connective tissue disorders	All	2 (3.2%)	0 (0.0%)	2 (3.2%)	4 (6.5%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	All	2 (3.2%)	19 (30.6%)	21 (33.9%)	22 (35.5%)
	Neoplasm progression	1 (1.6%)	17 (27.4%)	18 (29.0%)	18 (29.0%)
Nervous system disorders	All	3 (4.8%)	2 (3.2%)	5 (8.1%)	6 (9.7%)
Respiratory, thoracic and mediastinal disorders	All	5 (8.1%)	0 (0.0%)	5 (8.1%)	8 (12.9%)
Vascular disorders	All	4 (6.5%)	0 (0.0%)	4 (6.5%)	5 (8.1%)

Safety Population: All treated patients
Percentages are based on the safety population.
Note: Only AEs occuring in at least 5% patients are listed.

1.2.2.4 TEAE leading to discontinuation by SOC/PT

Table 1.2.2.4.1 (Study 101)
Treatment-Emergent Adverse Events Leading to Premature Discontinuation by System Organ Class and Preferred Term
Safety Population - CML Patients

SOC	*Preferred term*	*CP-CML (N=43)*	*AP-CML (N=9)*	*BP-CML (N=8)*
Any AE		11 (25.6%)	4 (44.4%)	0 (0.0%)
Vascular disorders	All	3 (7.0%)	0 (0.0%)	0 (0.0%)
	Peripheral ischaemia	1 (2.3%)	0 (0.0%)	0 (0.0%)
	Peripheral vascular disorder	1 (2.3%)	0 (0.0%)	0 (0.0%)
	Visceral arterial ischaemia	1 (2.3%)	0 (0.0%)	0 (0.0%)
Cardiac disorders	All	2 (4.7%)	0 (0.0%)	0 (0.0%)
	Cardiac failure congestive	1 (2.3%)	0 (0.0%)	0 (0.0%)
	Myocardial infarction	1 (2.3%)	0 (0.0%)	0 (0.0%)
Gastrointestinal disorders	All	1 (2.3%)	1 (11.1%)	0 (0.0%)
	Intestinal ischaemia	0 (0.0%)	1 (11.1%)	0 (0.0%)
	Pancreatitis	1 (2.3%)	0 (0.0%)	0 (0.0%)
General disorders and administration site conditions	All	1 (2.3%)	1 (11.1%)	0 (0.0%)
	Pyrexia	1 (2.3%)	1 (11.1%)	0 (0.0%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.4.1 (Study 101)
Treatment-Emergent Adverse Events Leading to Premature Discontinuation by System Organ Class and Preferred Term
Safety Population - CML Patients

SOC	*Preferred term*	*CP-CML (N=43)*	*AP-CML (N=9)*	*BP-CML (N=8)*
Investigations	All	1 (2.3%)	1 (11.1%)	0 (0.0%)
	Blood creatinine increased	1 (2.3%)	0 (0.0%)	0 (0.0%)
	Lipase increased	0 (0.0%)	1 (11.1%)	0 (0.0%)
Nervous system disorders	All	2 (4.7%)	0 (0.0%)	0 (0.0%)
	Headache	1 (2.3%)	0 (0.0%)	0 (0.0%)
	Lacunar infarction	1 (2.3%)	0 (0.0%)	0 (0.0%)
Eye disorders	All	0 (0.0%)	1 (11.1%)	0 (0.0%)
	Vision blurred	0 (0.0%)	1 (11.1%)	0 (0.0%)
Renal and urinary disorders	All	1 (2.3%)	0 (0.0%)	0 (0.0%)
	Renal failure	1 (2.3%)	0 (0.0%)	0 (0.0%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.4.1 (Study 201)
Treatment-Emergent Adverse Events Leading to Premature Discontinuation by System Organ Class and Preferred Term
Safety Population - CML Patients

SOC	*Preferred term*	*CP-CML (N=270)*	*AP-CML (N=85)*	*BP-CML (N=62)*
Any AE		57 (21.1%)	10 (11.8%)	9 (14.5%)
Blood and lymphatic system disorders	All	12 (4.4%)	4 (4.7%)	2 (3.2%)
	Thrombocytopenia	12 (4.4%)	3 (3.5%)	1 (1.6%)
	Anaemia	1 (0.4%)	0 (0.0%)	0 (0.0%)
	Neutropenia	0 (0.0%)	1 (1.2%)	0 (0.0%)
	Pancytopenia	0 (0.0%)	0 (0.0%)	1 (1.6%)
Nervous system disorders	All	10 (3.7%)	0 (0.0%)	3 (4.8%)
	Cerebral infarction	3 (1.1%)	0 (0.0%)	0 (0.0%)
	Cerebral artery stenosis	2 (0.7%)	0 (0.0%)	0 (0.0%)
	Cerebral haemorrhage	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Cerebrovascular accident	1 (0.4%)	0 (0.0%)	0 (0.0%)
	Facial paralysis	1 (0.4%)	0 (0.0%)	0 (0.0%)
	Haemorrhage intracranial	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Headache	1 (0.4%)	0 (0.0%)	0 (0.0%)
	IVth nerve paralysis	1 (0.4%)	0 (0.0%)	0 (0.0%)

Safety Population: All treated patients
Percentages are based on the Safety Population.

Table 1.2.2.4.1 (Study 201)
Treatment-Emergent Adverse Events Leading to Premature Discontinuation by System Organ Class and Preferred Term
Safety Population - CML Patients

SOC	*Preferred term*	*CP-CML (N=270)*	*AP-CML (N=85)*	*BP-CML (N=62)*
	Lacunar infarction	1 (0.4%)	0 (0.0%)	0 (0.0%)
	Loss of consciousness	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Transient ischaemic attack	1 (0.4%)	0 (0.0%)	0 (0.0%)
Cardiac disorders	All	9 (3.3%)	2 (2.4%)	1 (1.6%)
	Coronary artery disease	3 (1.1%)	0 (0.0%)	0 (0.0%)
	Acute coronary syndrome	2 (0.7%)	0 (0.0%)	0 (0.0%)
	Cardiac failure	0 (0.0%)	1 (1.2%)	1 (1.6%)
	Pericardial effusion	1 (0.4%)	1 (1.2%)	0 (0.0%)
	Angina pectoris	1 (0.4%)	0 (0.0%)	0 (0.0%)
	Atrial fibrillation	1 (0.4%)	0 (0.0%)	0 (0.0%)
	Cardiac failure congestive	1 (0.4%)	0 (0.0%)	0 (0.0%)
Investigations	All	7 (2.6%)	1 (1.2%)	1 (1.6%)
	Platelet count decreased	2 (0.7%)	1 (1.2%)	0 (0.0%)
	Blood creatinine increased	1 (0.4%)	0 (0.0%)	0 (0.0%)
	Ejection fraction decreased	1 (0.4%)	0 (0.0%)	0 (0.0%)
	Gamma-glutamyltransferase increased	1 (0.4%)	0 (0.0%)	0 (0.0%)
	Lipase increased	1 (0.4%)	0 (0.0%)	0 (0.0%)

Safety Population: All treated patients
Percentages are based on the Safety Population.

Table 1.2.2.4.1 (Study 201)
Treatment-Emergent Adverse Events Leading to Premature Discontinuation by System Organ Class and Preferred Term
Safety Population - CML Patients

SOC	*Preferred term*	*CP-CML (N=270)*	*AP-CML (N=85)*	*BP-CML (N=62)*
	Liver function test increased	1 (0.4%)	0 (0.0%)	0 (0.0%)
	White blood cell count increased	0 (0.0%)	0 (0.0%)	1 (1.6%)
Infections and infestations	All	3 (1.1%)	1 (1.2%)	2 (3.2%)
	Pneumonia	2 (0.7%)	0 (0.0%)	1 (1.6%)
	Diverticulitis	1 (0.4%)	0 (0.0%)	0 (0.0%)
	Infectious colitis	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Sepsis	0 (0.0%)	1 (1.2%)	0 (0.0%)
General disorders and administration site conditions	All	3 (1.1%)	3 (3.5%)	0 (0.0%)
	Asthenia	0 (0.0%)	1 (1.2%)	0 (0.0%)
	General physical health deterioration	1 (0.4%)	0 (0.0%)	0 (0.0%)
	Non-cardiac chest pain	0 (0.0%)	1 (1.2%)	0 (0.0%)
	Pain	1 (0.4%)	0 (0.0%)	0 (0.0%)
	Pyrexia	0 (0.0%)	1 (1.2%)	0 (0.0%)
	Systemic inflammatory response syndrome	1 (0.4%)	0 (0.0%)	0 (0.0%)
Respiratory, thoracic and mediastinal disorders	All	3 (1.1%)	1 (1.2%)	0 (0.0%)
	Pulmonary embolism	2 (0.7%)	0 (0.0%)	0 (0.0%)

Safety Population: All treated patients
Percentages are based on the Safety Population.

Table 1.2.2.4.1 (Study 201)
Treatment-Emergent Adverse Events Leading to Premature Discontinuation by System Organ Class and Preferred Term
Safety Population - CML Patients

SOC	*Preferred term*	*CP-CML (N=270)*	*AP-CML (N=85)*	*BP-CML (N=62)*
	Dyspnoea	0 (0.0%)	1 (1.2%)	0 (0.0%)
	Pleural effusion	1 (0.4%)	0 (0.0%)	0 (0.0%)
Vascular disorders	All	3 (1.1%)	0 (0.0%)	0 (0.0%)
	Peripheral artery stenosis	2 (0.7%)	0 (0.0%)	0 (0.0%)
	Peripheral ischaemia	1 (0.4%)	0 (0.0%)	0 (0.0%)
Musculoskeletal and connective tissue disorders	All	2 (0.7%)	0 (0.0%)	1 (1.6%)
	Pain in extremity	2 (0.7%)	0 (0.0%)	0 (0.0%)
	Bone pain	0 (0.0%)	0 (0.0%)	1 (1.6%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	All	3 (1.1%)	0 (0.0%)	0 (0.0%)
	Myelodysplastic syndrome	2 (0.7%)	0 (0.0%)	0 (0.0%)
	Large cell lung cancer recurrent	1 (0.4%)	0 (0.0%)	0 (0.0%)
Eye disorders	All	2 (0.7%)	0 (0.0%)	0 (0.0%)
	Retinal vein occlusion	1 (0.4%)	0 (0.0%)	0 (0.0%)
	Retinal vein thrombosis	1 (0.4%)	0 (0.0%)	0 (0.0%)

Safety Population: All treated patients
Percentages are based on the Safety Population.

Table 1.2.2.4.1 (Study 201)
Treatment-Emergent Adverse Events Leading to Premature Discontinuation by System Organ Class and Preferred Term
Safety Population - CML Patients

SOC	*Preferred term*	*CP-CML (N=270)*	*AP-CML (N=85)*	*BP-CML (N=62)*
Skin and subcutaneous tissue disorders	All	1 (0.4%)	0 (0.0%)	0 (0.0%)
	Exfoliative rash	1 (0.4%)	0 (0.0%)	0 (0.0%)
Gastrointestinal disorders	All	1 (0.4%)	0 (0.0%)	0 (0.0%)
	Pancreatitis	1 (0.4%)	0 (0.0%)	0 (0.0%)
Metabolism and nutrition disorders	All	1 (0.4%)	0 (0.0%)	0 (0.0%)
	Hypocalcaemia	1 (0.4%)	0 (0.0%)	0 (0.0%)
Renal and urinary disorders	All	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Acute kidney injury	0 (0.0%)	0 (0.0%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the Safety Population.

1.2.2.5 Adverse Event of Special Interest, AESI

1.2.2.5.1 Patients in CP, AP, or BP

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		15 (34.9%)	0 (0.0%)	15 (34.9%)	19 (44.2%)
Cardiac disorders	All	7 (16.3%)	0 (0.0%)	7 (16.3%)	12 (27.9%)
	Angina pectoris	1 (2.3%)	0 (0.0%)	1 (2.3%)	6 (14.0%)
	Myocardial ischaemia	3 (7.0%)	0 (0.0%)	3 (7.0%)	3 (7.0%)
	Acute myocardial infarction	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Myocardial infarction	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Acute coronary syndrome	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Atrial thrombosis	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Coronary artery disease	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Coronary artery stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
General disorders and administration site conditions	All	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Ischaemic ulcer	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Investigations	All	4 (9.3%)	0 (0.0%)	4 (9.3%)	4 (9.3%)
	Troponin increased	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Blood creatine phosphokinase increased	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Electrocardiogram T wave inversion	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Troponin I increased	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
Nervous system disorders	All	3 (7.0%)	0 (0.0%)	3 (7.0%)	5 (11.6%)
	Aphasia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Carotid artery stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Embolic stroke	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Hemiparesis	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Hemiplegia	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Lacunar infarction	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Transient ischaemic attack	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
Renal and urinary disorders	All	1 (2.3%)	0 (0.0%)	1 (2.3%)	2 (4.7%)
	Renal artery stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Renal artery occlusion	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
Vascular disorders	All	4 (9.3%)	0 (0.0%)	4 (9.3%)	6 (14.0%)
	Peripheral vascular disorder	1 (2.3%)	0 (0.0%)	1 (2.3%)	3 (7.0%)
	Peripheral arterial occlusive disease	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Peripheral artery occlusion	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Peripheral ischaemia	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiovascular Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		10 (23.3%)	0 (0.0%)	10 (23.3%)	14 (32.6%)
Cardiac disorders	All	7 (16.3%)	0 (0.0%)	7 (16.3%)	12 (27.9%)
	Angina pectoris	1 (2.3%)	0 (0.0%)	1 (2.3%)	6 (14.0%)
	Myocardial ischaemia	3 (7.0%)	0 (0.0%)	3 (7.0%)	3 (7.0%)
	Acute myocardial infarction	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Myocardial infarction	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Acute coronary syndrome	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Atrial thrombosis	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Coronary artery disease	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Coronary artery stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
Investigations	All	4 (9.3%)	0 (0.0%)	4 (9.3%)	4 (9.3%)
	Troponin increased	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Blood creatine phosphokinase increased	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiovascular Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Electrocardiogram T wave inversion	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Troponin I increased	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cerebrovascular Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (7.0%)	0 (0.0%)	3 (7.0%)	5 (11.6%)
Nervous system disorders	All	3 (7.0%)	0 (0.0%)	3 (7.0%)	5 (11.6%)
	Aphasia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Carotid artery stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Embolic stroke	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Hemiparesis	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Hemiplegia	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Lacunar infarction	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Transient ischaemic attack	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Peripheral Vascular Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		5 (11.6%)	0 (0.0%)	5 (11.6%)	8 (18.6%)
General disorders and administration site conditions	All	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Ischaemic ulcer	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
Renal and urinary disorders	All	1 (2.3%)	0 (0.0%)	1 (2.3%)	2 (4.7%)
	Renal artery stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Renal artery occlusion	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
Vascular disorders	All	4 (9.3%)	0 (0.0%)	4 (9.3%)	6 (14.0%)
	Peripheral vascular disorder	1 (2.3%)	0 (0.0%)	1 (2.3%)	3 (7.0%)
	Peripheral arterial occlusive disease	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Peripheral artery occlusion	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Peripheral ischaemia	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Venous Thrombotic/Embolic Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (7.0%)
Vascular disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (7.0%)
	Deep vein thrombosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Venoocclusive disease	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Vascular Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		15 (34.9%)	0 (0.0%)	15 (34.9%)	20 (46.5%)
Cardiac disorders	All	7 (16.3%)	0 (0.0%)	7 (16.3%)	12 (27.9%)
	Angina pectoris	1 (2.3%)	0 (0.0%)	1 (2.3%)	6 (14.0%)
	Myocardial ischaemia	3 (7.0%)	0 (0.0%)	3 (7.0%)	3 (7.0%)
	Acute myocardial infarction	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Myocardial infarction	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Acute coronary syndrome	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Atrial thrombosis	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Coronary artery disease	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Coronary artery stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
General disorders and administration site conditions	All	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Ischaemic ulcer	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
Investigations	All	4 (9.3%)	0 (0.0%)	4 (9.3%)	4 (9.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Vascular Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Troponin increased	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Blood creatine phosphokinase increased	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Electrocardiogram T wave inversion	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Troponin I increased	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
Nervous system disorders	All	3 (7.0%)	0 (0.0%)	3 (7.0%)	5 (11.6%)
	Aphasia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Carotid artery stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Embolic stroke	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Hemiparesis	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Hemiplegia	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Lacunar infarction	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Transient ischaemic attack	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
Renal and urinary disorders	All	1 (2.3%)	0 (0.0%)	1 (2.3%)	2 (4.7%)
	Renal artery stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Renal artery occlusion	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Vascular Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Vascular disorders	All	4 (9.3%)	0 (0.0%)	4 (9.3%)	7 (16.3%)
	Peripheral vascular disorder	1 (2.3%)	0 (0.0%)	1 (2.3%)	3 (7.0%)
	Deep vein thrombosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Peripheral arterial occlusive disease	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Peripheral artery occlusion	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Peripheral ischaemia	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Venoocclusive disease	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Hepatoxicity
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		4 (9.3%)	0 (0.0%)	4 (9.3%)	14 (32.6%)
Investigations	All	4 (9.3%)	0 (0.0%)	4 (9.3%)	14 (32.6%)
	Alanine aminotransferase increased	3 (7.0%)	0 (0.0%)	3 (7.0%)	10 (23.3%)
	Aspartate aminotransferase increased	1 (2.3%)	0 (0.0%)	1 (2.3%)	6 (14.0%)
	Blood alkaline phosphatase increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (7.0%)
	Blood bilirubin increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	International normalised ratio increased	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiac Failure
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (7.0%)	0 (0.0%)	3 (7.0%)	5 (11.6%)
Cardiac disorders	All	3 (7.0%)	0 (0.0%)	3 (7.0%)	5 (11.6%)
	Left ventricular dysfunction	1 (2.3%)	0 (0.0%)	1 (2.3%)	4 (9.3%)
	Cardiac failure congestive	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
Investigations	All	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Ejection fraction decreased	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Skin and subcutaneous tissue disorders
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (7.0%)	0 (0.0%)	3 (7.0%)	36 (83.7%)
Skin and subcutaneous tissue disorders	All	3 (7.0%)	0 (0.0%)	3 (7.0%)	36 (83.7%)
	Rash erythematous	0 (0.0%)	0 (0.0%)	0 (0.0%)	20 (46.5%)
	Dry skin	0 (0.0%)	0 (0.0%)	0 (0.0%)	19 (44.2%)
	Rash papular	0 (0.0%)	0 (0.0%)	0 (0.0%)	15 (34.9%)
	Dermatitis acneiform	1 (2.3%)	0 (0.0%)	1 (2.3%)	10 (23.3%)
	Rash	0 (0.0%)	0 (0.0%)	0 (0.0%)	9 (20.9%)
	Night sweats	0 (0.0%)	0 (0.0%)	0 (0.0%)	8 (18.6%)
	Pruritus	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (14.0%)
	Rash maculo-papular	1 (2.3%)	0 (0.0%)	1 (2.3%)	6 (14.0%)
	Rash pruritic	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (14.0%)
	Alopecia	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (11.6%)
	Erythema	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (9.3%)
	Exfoliative rash	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (9.3%)
	Urticaria	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (9.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Skin and subcutaneous tissue disorders
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Erythema nodosum	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (7.0%)
	Hyperhidrosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (7.0%)
	Skin lesion	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (7.0%)
	Dermatitis contact	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Hyperkeratosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Pain of skin	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Petechiae	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Psoriasis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Rash follicular	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Rash macular	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Skin burning sensation	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Skin exfoliation	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Skin hyperpigmentation	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Skin mass	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Skin ulcer	1 (2.3%)	0 (0.0%)	1 (2.3%)	2 (4.7%)
	Actinic keratosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Dermatitis bullous	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Skin and subcutaneous tissue disorders
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Dermatitis psoriasiform	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Ecchymosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Hypohidrosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Papule	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Rosacea	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Seborrhoea	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Skin depigmentation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Skin discolouration	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Skin fissures	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Stasis dermatitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Xanthelasma	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		12 (27.9%)	1 (2.3%)	13 (30.2%)	35 (81.4%)
Infections and infestations	All	12 (27.9%)	1 (2.3%)	13 (30.2%)	35 (81.4%)
	Upper respiratory tract infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	17 (39.5%)
	Urinary tract infection	2 (4.7%)	0 (0.0%)	2 (4.7%)	13 (30.2%)
	Nasopharyngitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	11 (25.6%)
	Sinusitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	9 (20.9%)
	Pneumonia	4 (9.3%)	1 (2.3%)	5 (11.6%)	8 (18.6%)
	Bronchitis	1 (2.3%)	0 (0.0%)	1 (2.3%)	7 (16.3%)
	Gastroenteritis viral	1 (2.3%)	0 (0.0%)	1 (2.3%)	7 (16.3%)
	Influenza	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (14.0%)
	Cellulitis	2 (4.7%)	0 (0.0%)	2 (4.7%)	5 (11.6%)
	Rhinitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (7.0%)
	Eye infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Gastroenteritis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Herpes zoster	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Localised infection	1 (2.3%)	0 (0.0%)	1 (2.3%)	2 (4.7%)
	Lung infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Oral candidiasis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Urosepsis	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Wound infection	1 (2.3%)	0 (0.0%)	1 (2.3%)	2 (4.7%)
	Abscess oral	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Acute sinusitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Bacteraemia	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Clostridium difficile colitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Conjunctivitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Folliculitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Fungal infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Fungal skin infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Furuncle	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Gastrointestinal viral infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Herpes pharyngitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Hordeolum	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Laryngitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Oral herpes	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Pilonidal cyst	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Post procedural infection	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Rash pustular	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Septic shock	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Staphylococcal bacteraemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Staphylococcal infection	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Staphylococcal skin infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Streptococcal infection	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Tinea pedis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Viral infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Vulvovaginal mycotic infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Myelosuppression
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		16 (37.2%)	0 (0.0%)	16 (37.2%)	25 (58.1%)
Blood and lymphatic system disorders	All	15 (34.9%)	0 (0.0%)	15 (34.9%)	22 (51.2%)
	Thrombocytopenia	14 (32.6%)	0 (0.0%)	14 (32.6%)	16 (37.2%)
	Anaemia	2 (4.7%)	0 (0.0%)	2 (4.7%)	7 (16.3%)
	Neutropenia	4 (9.3%)	0 (0.0%)	4 (9.3%)	6 (14.0%)
	Febrile neutropenia	2 (4.7%)	0 (0.0%)	2 (4.7%)	4 (9.3%)
	Leukopenia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Lymphopenia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
Investigations	All	4 (9.3%)	0 (0.0%)	4 (9.3%)	9 (20.9%)
	Platelet count decreased	2 (4.7%)	0 (0.0%)	2 (4.7%)	7 (16.3%)
	Haemoglobin decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (9.3%)
	Neutrophil count decreased	3 (7.0%)	0 (0.0%)	3 (7.0%)	4 (9.3%)
	White blood cell count decreased	1 (2.3%)	0 (0.0%)	1 (2.3%)	3 (7.0%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Myelosuppression
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Lymphocyte count decreased	1 (2.3%)	0 (0.0%)	1 (2.3%)	2 (4.7%)
	Haematocrit decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Edema and Fluid Retention
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		4 (9.3%)	0 (0.0%)	4 (9.3%)	22 (51.2%)
Cardiac disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (11.6%)
	Pericardial effusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (11.6%)
General disorders and administration site conditions	All	1 (2.3%)	0 (0.0%)	1 (2.3%)	19 (44.2%)
	Oedema peripheral	0 (0.0%)	0 (0.0%)	0 (0.0%)	15 (34.9%)
	Peripheral swelling	1 (2.3%)	0 (0.0%)	1 (2.3%)	3 (7.0%)
	Generalised oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
Metabolism and nutrition disorders	All	1 (2.3%)	0 (0.0%)	1 (2.3%)	2 (4.7%)
	Fluid retention	1 (2.3%)	0 (0.0%)	1 (2.3%)	2 (4.7%)
	Fluid overload	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
Musculoskeletal and connective tissue disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Joint effusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Edema and Fluid Retention
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Joint swelling	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
Respiratory, thoracic and mediastinal disorders	All	3 (7.0%)	0 (0.0%)	3 (7.0%)	6 (14.0%)
	Pleural effusion	3 (7.0%)	0 (0.0%)	3 (7.0%)	6 (14.0%)
Vascular disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Lymphoedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Hypertension
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		5 (11.6%)	0 (0.0%)	5 (11.6%)	21 (48.8%)
Investigations	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Blood pressure increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
Vascular disorders	All	5 (11.6%)	0 (0.0%)	5 (11.6%)	20 (46.5%)
	Hypertension	5 (11.6%)	0 (0.0%)	5 (11.6%)	20 (46.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Eye disorder
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		0 (0.0%)	0 (0.0%)	0 (0.0%)	19 (44.2%)
Eye disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	19 (44.2%)
	Dry eye	0 (0.0%)	0 (0.0%)	0 (0.0%)	8 (18.6%)
	Visual impairment	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (9.3%)
	Vision blurred	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (7.0%)
	Conjunctival haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Diplopia	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Eye irritation	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Eye pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Iritis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Ocular hyperaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Periorbital oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Cataract	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Excessive eye blinking	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Eye pruritus	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Eye disorder
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Eye swelling	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Eyelid ptosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Glaucoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Ocular discomfort	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Photophobia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Photopsia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Scleritis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Uveitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Vitreous floaters	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Bleeding Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (7.0%)	0 (0.0%)	3 (7.0%)	17 (39.5%)
Blood and lymphatic system disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Increased tendency to bruise	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
Eye disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Conjunctival haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
Gastrointestinal disorders	All	2 (4.7%)	0 (0.0%)	2 (4.7%)	4 (9.3%)
	Gastrointestinal haemorrhage	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Gingival bleeding	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Peptic ulcer haemorrhage	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Rectal haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
General disorders and administration site conditions	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Catheter site haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Bleeding Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Infusion site haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Vessel puncture site bruise	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Vessel puncture site haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
Injury, poisoning and procedural complications	All	1 (2.3%)	0 (0.0%)	1 (2.3%)	3 (7.0%)
	Contusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Subdural haematoma	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
Investigations	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Blood urine present	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
Renal and urinary disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Haematuria	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
Reproductive system and breast disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Pelvic haematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Vaginal haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Bleeding Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Respiratory, thoracic and mediastinal disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (7.0%)
	Epistaxis	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (7.0%)
Skin and subcutaneous tissue disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (7.0%)
	Petechiae	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Ecchymosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Pancreatitis
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		10 (23.3%)	0 (0.0%)	10 (23.3%)	19 (44.2%)
Gastrointestinal disorders	All	3 (7.0%)	0 (0.0%)	3 (7.0%)	8 (18.6%)
	Pancreatitis	2 (4.7%)	0 (0.0%)	2 (4.7%)	7 (16.3%)
	Pancreatitis acute	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
Investigations	All	8 (18.6%)	0 (0.0%)	8 (18.6%)	16 (37.2%)
	Lipase increased	8 (18.6%)	0 (0.0%)	8 (18.6%)	16 (37.2%)
	Amylase increased	1 (2.3%)	0 (0.0%)	1 (2.3%)	3 (7.0%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Clinical Pancreatitis
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (7.0%)	0 (0.0%)	3 (7.0%)	8 (18.6%)
Gastrointestinal disorders	All	3 (7.0%)	0 (0.0%)	3 (7.0%)	8 (18.6%)
	Pancreatitis	2 (4.7%)	0 (0.0%)	2 (4.7%)	7 (16.3%)
	Pancreatitis acute	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Chemical Pancreatitis
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		8 (18.6%)	0 (0.0%)	8 (18.6%)	16 (37.2%)
Investigations	All	8 (18.6%)	0 (0.0%)	8 (18.6%)	16 (37.2%)
	Lipase increased	8 (18.6%)	0 (0.0%)	8 (18.6%)	16 (37.2%)
	Amylase increased	1 (2.3%)	0 (0.0%)	1 (2.3%)	3 (7.0%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiac Arrhythmias
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		5 (11.6%)	0 (0.0%)	5 (11.6%)	15 (34.9%)
Cardiac disorders	All	4 (9.3%)	0 (0.0%)	4 (9.3%)	14 (32.6%)
	Atrial fibrillation	3 (7.0%)	0 (0.0%)	3 (7.0%)	5 (11.6%)
	Palpitations	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (11.6%)
	Tachycardia	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (9.3%)
	Bradycardia	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Defect conduction intraventricular	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Sinus bradycardia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Sinus tachycardia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Supraventricular extrasystoles	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Tachyarrhythmia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Ventricular extrasystoles	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Ventricular tachycardia	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
Investigations	All	2 (4.7%)	0 (0.0%)	2 (4.7%)	4 (9.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiac Arrhythmias
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Electrocardiogram QT prolonged	2 (4.7%)	0 (0.0%)	2 (4.7%)	3 (7.0%)
	Heart rate increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Heart rate irregular	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
Nervous system disorders	All	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Syncope	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Hypothyroidism
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (9.3%)
Endocrine disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (9.3%)
	Hypothyroidism	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (9.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Arterial Occlusive Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		2 (22.2%)	0 (0.0%)	2 (22.2%)	2 (22.2%)
Nervous system disorders	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Cerebrovascular accident	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
Vascular disorders	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Peripheral artery occlusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Peripheral ischaemia	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cerebrovascular Arterial Occlusive Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
Nervous system disorders	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Cerebrovascular accident	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Peripheral Vascular Arterial Occlusive Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
Vascular disorders	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Peripheral artery occlusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Peripheral ischaemia	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Vascular Occlusive Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		2 (22.2%)	0 (0.0%)	2 (22.2%)	2 (22.2%)
Nervous system disorders	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Cerebrovascular accident	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
Vascular disorders	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Peripheral artery occlusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Peripheral ischaemia	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Hepatoxicity
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (33.3%)
Hepatobiliary disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Hepatic function abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Hyperbilirubinaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
Investigations	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Aspartate aminotransferase increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiac Failure
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
Respiratory, thoracic and mediastinal disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Pulmonary oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Skin and subcutaneous tissue disorders
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (55.6%)
Skin and subcutaneous tissue disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (55.6%)
	Rash pruritic	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (33.3%)
	Pruritus	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Rash	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Rash erythematous	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Rash papular	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Actinic keratosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Decubitus ulcer	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Dermatitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Dermatitis contact	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Dry skin	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Ecchymosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Eczema	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Erythema	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Skin and subcutaneous tissue disorders
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Erythema nodosum	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Hyperhidrosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Nail disorder	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Nail ridging	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Night sweats	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Onychoclasis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Psoriasis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Rash macular	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Skin burning sensation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Skin exfoliation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Skin haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Skin mass	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		4 (44.4%)	1 (11.1%)	5 (55.6%)	6 (66.7%)
Infections and infestations	All	4 (44.4%)	1 (11.1%)	5 (55.6%)	6 (66.7%)
	Pneumonia	2 (22.2%)	0 (0.0%)	2 (22.2%)	3 (33.3%)
	Bronchitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Laryngitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Nasopharyngitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Rhinitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Bacteraemia	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Bacterial sepsis	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Cellulitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Clostridium difficile colitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Eye infection staphylococcal	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Localised infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Lower respiratory tract infection	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Lung infection	0 (0.0%)	1 (11.1%)	1 (11.1%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Sepsis	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Septic shock	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Sinusitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Tinea cruris	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Upper respiratory tract infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Urinary tract infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Viral pharyngitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Viral upper respiratory tract infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Myelosuppression
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		2 (22.2%)	0 (0.0%)	2 (22.2%)	6 (66.7%)
Blood and lymphatic system disorders	All	2 (22.2%)	0 (0.0%)	2 (22.2%)	5 (55.6%)
	Thrombocytopenia	1 (11.1%)	0 (0.0%)	1 (11.1%)	3 (33.3%)
	Anaemia	1 (11.1%)	0 (0.0%)	1 (11.1%)	2 (22.2%)
	Febrile neutropenia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
Investigations	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	2 (22.2%)
	Haemoglobin decreased	1 (11.1%)	0 (0.0%)	1 (11.1%)	2 (22.2%)
	Platelet count decreased	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	White blood cell count decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Edema and Fluid Retention
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (11.1%)	0 (0.0%)	1 (11.1%)	5 (55.6%)
General disorders and administration site conditions	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (55.6%)
	Oedema peripheral	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (55.6%)
	Peripheral swelling	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
Metabolism and nutrition disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Fluid overload	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
Musculoskeletal and connective tissue disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Joint swelling	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
Respiratory, thoracic and mediastinal disorders	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	3 (33.3%)
	Pleural effusion	1 (11.1%)	0 (0.0%)	1 (11.1%)	3 (33.3%)
	Pulmonary oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Hypertension
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (11.1%)	0 (0.0%)	1 (11.1%)	4 (44.4%)
Vascular disorders	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	4 (44.4%)
	Hypertension	1 (11.1%)	0 (0.0%)	1 (11.1%)	4 (44.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Eye disorder
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (11.1%)	0 (0.0%)	1 (11.1%)	4 (44.4%)
Eye disorders	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	4 (44.4%)
	Photopsia	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Vision blurred	1 (11.1%)	0 (0.0%)	1 (11.1%)	2 (22.2%)
	Blepharospasm	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Cataract	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Eye discharge	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Eye pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Ocular hyperaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Bleeding Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
Gastrointestinal disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Gingival bleeding	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Mouth haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
Injury, poisoning and procedural complications	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Contusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
Respiratory, thoracic and mediastinal disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
	Epistaxis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (22.2%)
Skin and subcutaneous tissue disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Ecchymosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Skin haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Pancreatitis
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (33.3%)	0 (0.0%)	3 (33.3%)	3 (33.3%)
Gastrointestinal disorders	All	3 (33.3%)	0 (0.0%)	3 (33.3%)	3 (33.3%)
	Pancreatitis	2 (22.2%)	0 (0.0%)	2 (22.2%)	2 (22.2%)
	Pancreatitis acute	1 (11.1%)	0 (0.0%)	1 (11.1%)	2 (22.2%)
Investigations	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	2 (22.2%)
	Lipase increased	1 (11.1%)	0 (0.0%)	1 (11.1%)	2 (22.2%)
	Amylase increased	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Clinical Pancreatitis
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (33.3%)	0 (0.0%)	3 (33.3%)	3 (33.3%)
Gastrointestinal disorders	All	3 (33.3%)	0 (0.0%)	3 (33.3%)	3 (33.3%)
	Pancreatitis	2 (22.2%)	0 (0.0%)	2 (22.2%)	2 (22.2%)
	Pancreatitis acute	1 (11.1%)	0 (0.0%)	1 (11.1%)	2 (22.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Chemical Pancreatitis
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (11.1%)	0 (0.0%)	1 (11.1%)	2 (22.2%)
Investigations	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	2 (22.2%)
	Lipase increased	1 (11.1%)	0 (0.0%)	1 (11.1%)	2 (22.2%)
	Amylase increased	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiac Arrhythmias
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (11.1%)	0 (0.0%)	1 (11.1%)	2 (22.2%)
Cardiac disorders	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	2 (22.2%)
	Tachycardia	1 (11.1%)	0 (0.0%)	1 (11.1%)	2 (22.2%)
Nervous system disorders	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Syncope	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Arterial Occlusive Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (37.5%)	0 (0.0%)	3 (37.5%)	4 (50.0%)
Cardiac disorders	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	2 (25.0%)
	Angina pectoris	1 (12.5%)	0 (0.0%)	1 (12.5%)	2 (25.0%)
Investigations	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Troponin increased	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
Nervous system disorders	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Dysarthria	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiovascular Arterial Occlusive Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		2 (25.0%)	0 (0.0%)	2 (25.0%)	3 (37.5%)
Cardiac disorders	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	2 (25.0%)
	Angina pectoris	1 (12.5%)	0 (0.0%)	1 (12.5%)	2 (25.0%)
Investigations	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Troponin increased	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cerebrovascular Arterial Occlusive Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
Nervous system disorders	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Dysarthria	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Venous Thrombotic/Embolic Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
Vascular disorders	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Deep vein thrombosis	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Thrombophlebitis superficial	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Vascular Occlusive Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		4 (50.0%)	0 (0.0%)	4 (50.0%)	5 (62.5%)
Cardiac disorders	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	2 (25.0%)
	Angina pectoris	1 (12.5%)	0 (0.0%)	1 (12.5%)	2 (25.0%)
Investigations	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Troponin increased	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
Nervous system disorders	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Dysarthria	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
Vascular disorders	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Deep vein thrombosis	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Thrombophlebitis superficial	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Hepatoxicity
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (50.0%)
Investigations	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (37.5%)
	Aspartate aminotransferase increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (25.0%)
	Alanine aminotransferase increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	International normalised ratio increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Liver palpable	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
Metabolism and nutrition disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Hypoalbuminaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Skin and subcutaneous tissue disorders
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (12.5%)	0 (0.0%)	1 (12.5%)	5 (62.5%)
Skin and subcutaneous tissue disorders	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	5 (62.5%)
	Petechiae	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (25.0%)
	Alopecia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Ecchymosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Night sweats	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Rash erythematous	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Skin exfoliation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		4 (50.0%)	2 (25.0%)	6 (75.0%)	6 (75.0%)
Infections and infestations	All	4 (50.0%)	2 (25.0%)	6 (75.0%)	6 (75.0%)
	Enterobacter bacteraemia	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Neutropenic sepsis	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Oral candidiasis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Pneumonia	0 (0.0%)	1 (12.5%)	1 (12.5%)	1 (12.5%)
	Sepsis	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Septic shock	0 (0.0%)	1 (12.5%)	1 (12.5%)	1 (12.5%)
	Staphylococcal bacteraemia	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Upper respiratory tract infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Urinary tract infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Urinary tract infection enterococcal	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Myelosuppression
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		5 (62.5%)	0 (0.0%)	5 (62.5%)	5 (62.5%)
Blood and lymphatic system disorders	All	5 (62.5%)	0 (0.0%)	5 (62.5%)	5 (62.5%)
	Febrile neutropenia	5 (62.5%)	0 (0.0%)	5 (62.5%)	5 (62.5%)
	Anaemia	1 (12.5%)	0 (0.0%)	1 (12.5%)	2 (25.0%)
	Thrombocytopenia	2 (25.0%)	0 (0.0%)	2 (25.0%)	2 (25.0%)
	Cytopenia	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Neutropenia	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
Infections and infestations	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Neutropenic sepsis	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
Investigations	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	2 (25.0%)
	Monocyte count decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Platelet count decreased	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Edema and Fluid Retention
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (50.0%)
General disorders and administration site conditions	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (37.5%)
	Oedema peripheral	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (37.5%)
Metabolism and nutrition disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Fluid retention	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Hypertension
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (12.5%)	0 (0.0%)	1 (12.5%)	2 (25.0%)
Vascular disorders	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	2 (25.0%)
	Hypertension	1 (12.5%)	0 (0.0%)	1 (12.5%)	2 (25.0%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Eye disorder
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (37.5%)
Eye disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (37.5%)
	Conjunctival haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Eye inflammation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Eye pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Periorbital oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Photopsia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Retinal haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Bleeding Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		2 (25.0%)	0 (0.0%)	2 (25.0%)	4 (50.0%)
Eye disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Conjunctival haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Retinal haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
Gastrointestinal disorders	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Lip haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Mouth haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Rectal haemorrhage	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Upper gastrointestinal haemorrhage	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
Injury, poisoning and procedural complications	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	2 (25.0%)
	Contusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (25.0%)
	Subdural haematoma	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Bleeding Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Reproductive system and breast disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Vaginal haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
Skin and subcutaneous tissue disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (37.5%)
	Petechiae	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (25.0%)
	Ecchymosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiac Arrhythmias
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (37.5%)	0 (0.0%)	3 (37.5%)	6 (75.0%)
Cardiac disorders	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	4 (50.0%)
	Palpitations	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (25.0%)
	Tachycardia	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (25.0%)
	Atrial fibrillation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Sinus arrest	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Sinus tachycardia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Ventricular tachycardia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
Investigations	All	2 (25.0%)	0 (0.0%)	2 (25.0%)	4 (50.0%)
	Electrocardiogram QT prolonged	2 (25.0%)	0 (0.0%)	2 (25.0%)	3 (37.5%)
	Heart rate increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 101)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Hypothyroidism
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
Endocrine disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Hypothyroidism	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		49 (18.1%)	3 (1.1%)	52 (19.3%)	84 (31.1%)
Blood and lymphatic system disorders	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Splenic infarction	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Cardiac disorders	All	24 (8.9%)	1 (0.4%)	25 (9.3%)	40 (14.8%)
	Angina pectoris	5 (1.9%)	0 (0.0%)	5 (1.9%)	22 (8.1%)
	Coronary artery disease	9 (3.3%)	0 (0.0%)	9 (3.3%)	10 (3.7%)
	Myocardial infarction	7 (2.6%)	0 (0.0%)	7 (2.6%)	7 (2.6%)
	Acute coronary syndrome	5 (1.9%)	0 (0.0%)	5 (1.9%)	6 (2.2%)
	Acute myocardial infarction	2 (0.7%)	1 (0.4%)	3 (1.1%)	3 (1.1%)
	Angina unstable	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Coronary artery occlusion	4 (1.5%)	0 (0.0%)	4 (1.5%)	4 (1.5%)
	Coronary artery stenosis	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Ischaemic cardiomyopathy	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Myocardial ischaemia	1 (0.4%)	0 (0.0%)	1 (0.4%)	2 (0.7%)
	Arteriosclerosis coronary artery	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Arteriospasm coronary	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Cardiac discomfort	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Myocardial necrosis	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Eye disorders	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Retinal artery occlusion	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Injury, poisoning and procedural complications	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Coronary vascular graft occlusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
Investigations	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.5%)
	Blood creatine phosphokinase increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Electrocardiogram ST segment depression	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Electrocardiogram T wave inversion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Troponin increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Nervous system disorders	All	15 (5.6%)	2 (0.7%)	17 (6.3%)	34 (12.6%)
	Carotid artery stenosis	5 (1.9%)	0 (0.0%)	5 (1.9%)	7 (2.6%)
	Cerebral infarction	7 (2.6%)	0 (0.0%)	7 (2.6%)	8 (3.0%)
	Cerebrovascular accident	1 (0.4%)	1 (0.4%)	2 (0.7%)	9 (3.3%)
	Transient ischaemic attack	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (2.2%)
	Carotid artery occlusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Cerebral artery stenosis	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Dysarthria	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Aphasia	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Carotid arteriosclerosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Cerebral arteriosclerosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Cerebral ischaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Cerebrovascular disorder	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Cerebrovascular insufficiency	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Haemorrhagic cerebral infarction	0 (0.0%)	1 (0.4%)	1 (0.4%)	1 (0.4%)
	Haemorrhagic transformation stroke	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Hemiparesis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Hemiplegia	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Lacunar infarction	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Monoparesis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Vertebral artery stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
Renal and urinary disorders	All	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Renal artery stenosis	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
Vascular disorders	All	21 (7.8%)	0 (0.0%)	21 (7.8%)	35 (13.0%)
	Peripheral arterial occlusive disease	10 (3.7%)	0 (0.0%)	10 (3.7%)	18 (6.7%)
	Intermittent claudication	4 (1.5%)	0 (0.0%)	4 (1.5%)	11 (4.1%)
	Peripheral artery stenosis	8 (3.0%)	0 (0.0%)	8 (3.0%)	10 (3.7%)
	Peripheral artery occlusion	6 (2.2%)	0 (0.0%)	6 (2.2%)	7 (2.6%)
	Peripheral ischaemia	2 (0.7%)	0 (0.0%)	2 (0.7%)	5 (1.9%)
	Dry gangrene	1 (0.4%)	0 (0.0%)	1 (0.4%)	2 (0.7%)
	Extremity necrosis	1 (0.4%)	0 (0.0%)	1 (0.4%)	3 (1.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Peripheral vascular disorder	1 (0.4%)	0 (0.0%)	1 (0.4%)	3 (1.1%)
	Poor peripheral circulation	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiovascular Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		24 (8.9%)	1 (0.4%)	25 (9.3%)	42 (15.6%)
Cardiac disorders	All	24 (8.9%)	1 (0.4%)	25 (9.3%)	40 (14.8%)
	Angina pectoris	5 (1.9%)	0 (0.0%)	5 (1.9%)	22 (8.1%)
	Coronary artery disease	9 (3.3%)	0 (0.0%)	9 (3.3%)	10 (3.7%)
	Myocardial infarction	7 (2.6%)	0 (0.0%)	7 (2.6%)	7 (2.6%)
	Acute coronary syndrome	5 (1.9%)	0 (0.0%)	5 (1.9%)	6 (2.2%)
	Acute myocardial infarction	2 (0.7%)	1 (0.4%)	3 (1.1%)	3 (1.1%)
	Angina unstable	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Coronary artery occlusion	4 (1.5%)	0 (0.0%)	4 (1.5%)	4 (1.5%)
	Coronary artery stenosis	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Ischaemic cardiomyopathy	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Myocardial ischaemia	1 (0.4%)	0 (0.0%)	1 (0.4%)	2 (0.7%)
	Arteriosclerosis coronary artery	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Arteriospasm coronary	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Cardiac discomfort	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiovascular Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Myocardial necrosis	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Injury, poisoning and procedural complications	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Coronary vascular graft occlusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
Investigations	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.5%)
	Blood creatine phosphokinase increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Electrocardiogram ST segment depression	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Electrocardiogram T wave inversion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Troponin increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cerebrovascular Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		16 (5.9%)	2 (0.7%)	18 (6.7%)	35 (13.0%)
Eye disorders	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Retinal artery occlusion	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Nervous system disorders	All	15 (5.6%)	2 (0.7%)	17 (6.3%)	34 (12.6%)
	Carotid artery stenosis	5 (1.9%)	0 (0.0%)	5 (1.9%)	7 (2.6%)
	Cerebral infarction	7 (2.6%)	0 (0.0%)	7 (2.6%)	8 (3.0%)
	Cerebrovascular accident	1 (0.4%)	1 (0.4%)	2 (0.7%)	9 (3.3%)
	Transient ischaemic attack	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (2.2%)
	Carotid artery occlusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Cerebral artery stenosis	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Dysarthria	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Aphasia	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Carotid arteriosclerosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Cerebral arteriosclerosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cerebrovascular Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Cerebral ischaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Cerebrovascular disorder	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Cerebrovascular insufficiency	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Haemorrhagic cerebral infarction	0 (0.0%)	1 (0.4%)	1 (0.4%)	1 (0.4%)
	Haemorrhagic transformation stroke	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Hemiparesis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Hemiplegia	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Lacunar infarction	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Monoparesis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Vertebral artery stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Peripheral Vascular Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		24 (8.9%)	0 (0.0%)	24 (8.9%)	38 (14.1%)
Blood and lymphatic system disorders	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Splenic infarction	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Renal and urinary disorders	All	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Renal artery stenosis	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
Vascular disorders	All	21 (7.8%)	0 (0.0%)	21 (7.8%)	35 (13.0%)
	Peripheral arterial occlusive disease	10 (3.7%)	0 (0.0%)	10 (3.7%)	18 (6.7%)
	Intermittent claudication	4 (1.5%)	0 (0.0%)	4 (1.5%)	11 (4.1%)
	Peripheral artery stenosis	8 (3.0%)	0 (0.0%)	8 (3.0%)	10 (3.7%)
	Peripheral artery occlusion	6 (2.2%)	0 (0.0%)	6 (2.2%)	7 (2.6%)
	Peripheral ischaemia	2 (0.7%)	0 (0.0%)	2 (0.7%)	5 (1.9%)
	Dry gangrene	1 (0.4%)	0 (0.0%)	1 (0.4%)	2 (0.7%)
	Extremity necrosis	1 (0.4%)	0 (0.0%)	1 (0.4%)	3 (1.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Peripheral Vascular Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Peripheral vascular disorder	1 (0.4%)	0 (0.0%)	1 (0.4%)	3 (1.1%)
	Poor peripheral circulation	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Venous Thrombotic/Embolic Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		10 (3.7%)	0 (0.0%)	10 (3.7%)	15 (5.6%)
Eye disorders	All	2 (0.7%)	0 (0.0%)	2 (0.7%)	4 (1.5%)
	Retinal vein occlusion	1 (0.4%)	0 (0.0%)	1 (0.4%)	3 (1.1%)
	Retinal vein thrombosis	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Hepatobiliary disorders	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Venoocclusive liver disease	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Respiratory, thoracic and mediastinal disorders	All	4 (1.5%)	0 (0.0%)	4 (1.5%)	4 (1.5%)
	Pulmonary embolism	4 (1.5%)	0 (0.0%)	4 (1.5%)	4 (1.5%)
Vascular disorders	All	3 (1.1%)	0 (0.0%)	3 (1.1%)	6 (2.2%)
	Deep vein thrombosis	3 (1.1%)	0 (0.0%)	3 (1.1%)	6 (2.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Vascular Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		58 (21.5%)	3 (1.1%)	61 (22.6%)	92 (34.1%)
Blood and lymphatic system disorders	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Splenic infarction	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Cardiac disorders	All	24 (8.9%)	1 (0.4%)	25 (9.3%)	40 (14.8%)
	Angina pectoris	5 (1.9%)	0 (0.0%)	5 (1.9%)	22 (8.1%)
	Coronary artery disease	9 (3.3%)	0 (0.0%)	9 (3.3%)	10 (3.7%)
	Myocardial infarction	7 (2.6%)	0 (0.0%)	7 (2.6%)	7 (2.6%)
	Acute coronary syndrome	5 (1.9%)	0 (0.0%)	5 (1.9%)	6 (2.2%)
	Acute myocardial infarction	2 (0.7%)	1 (0.4%)	3 (1.1%)	3 (1.1%)
	Angina unstable	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Coronary artery occlusion	4 (1.5%)	0 (0.0%)	4 (1.5%)	4 (1.5%)
	Coronary artery stenosis	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Ischaemic cardiomyopathy	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Myocardial ischaemia	1 (0.4%)	0 (0.0%)	1 (0.4%)	2 (0.7%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Vascular Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Arteriosclerosis coronary artery	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Arteriospasm coronary	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Cardiac discomfort	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Myocardial necrosis	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Eye disorders	All	3 (1.1%)	0 (0.0%)	3 (1.1%)	5 (1.9%)
	Retinal vein occlusion	1 (0.4%)	0 (0.0%)	1 (0.4%)	3 (1.1%)
	Retinal artery occlusion	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Retinal vein thrombosis	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
General disorders and administration site conditions	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Vascular stent occlusion	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Hepatobiliary disorders	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Venoocclusive liver disease	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Vascular Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Injury, poisoning and procedural complications	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Coronary vascular graft occlusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
Investigations	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.5%)
	Blood creatine phosphokinase increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Electrocardiogram ST segment depression	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Electrocardiogram T wave inversion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Troponin increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
Nervous system disorders	All	15 (5.6%)	2 (0.7%)	17 (6.3%)	34 (12.6%)
	Carotid artery stenosis	5 (1.9%)	0 (0.0%)	5 (1.9%)	7 (2.6%)
	Cerebral infarction	7 (2.6%)	0 (0.0%)	7 (2.6%)	8 (3.0%)
	Cerebrovascular accident	1 (0.4%)	1 (0.4%)	2 (0.7%)	9 (3.3%)
	Transient ischaemic attack	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (2.2%)
	Carotid artery occlusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Cerebral artery stenosis	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Dysarthria	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Vascular Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Aphasia	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Carotid arteriosclerosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Cerebral arteriosclerosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Cerebral ischaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Cerebrovascular disorder	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Cerebrovascular insufficiency	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Haemorrhagic cerebral infarction	0 (0.0%)	1 (0.4%)	1 (0.4%)	1 (0.4%)
	Haemorrhagic transformation stroke	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Hemiparesis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Hemiplegia	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Lacunar infarction	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Monoparesis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Vertebral artery stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
Renal and urinary disorders	All	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Renal artery stenosis	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Vascular Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Respiratory, thoracic and mediastinal disorders	All	4 (1.5%)	0 (0.0%)	4 (1.5%)	4 (1.5%)
	Pulmonary embolism	4 (1.5%)	0 (0.0%)	4 (1.5%)	4 (1.5%)
Vascular disorders	All	24 (8.9%)	0 (0.0%)	24 (8.9%)	40 (14.8%)
	Peripheral arterial occlusive disease	10 (3.7%)	0 (0.0%)	10 (3.7%)	18 (6.7%)
	Intermittent claudication	4 (1.5%)	0 (0.0%)	4 (1.5%)	11 (4.1%)
	Peripheral artery stenosis	8 (3.0%)	0 (0.0%)	8 (3.0%)	10 (3.7%)
	Peripheral artery occlusion	6 (2.2%)	0 (0.0%)	6 (2.2%)	7 (2.6%)
	Deep vein thrombosis	3 (1.1%)	0 (0.0%)	3 (1.1%)	6 (2.2%)
	Peripheral ischaemia	2 (0.7%)	0 (0.0%)	2 (0.7%)	5 (1.9%)
	Dry gangrene	1 (0.4%)	0 (0.0%)	1 (0.4%)	2 (0.7%)
	Extremity necrosis	1 (0.4%)	0 (0.0%)	1 (0.4%)	3 (1.1%)
	Peripheral vascular disorder	1 (0.4%)	0 (0.0%)	1 (0.4%)	3 (1.1%)
	Poor peripheral circulation	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Hepatoxicity
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		25 (9.3%)	0 (0.0%)	25 (9.3%)	78 (28.9%)
Eye disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Ocular icterus	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
Gastrointestinal disorders	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Ascites	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Hepatobiliary disorders	All	4 (1.5%)	0 (0.0%)	4 (1.5%)	12 (4.4%)
	Hepatic pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Hepatic steatosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.5%)
	Hepatocellular injury	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Hyperbilirubinaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)
	Hepatotoxicity	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Non-alcoholic steatohepatitis	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Hepatoxicity
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Investigations	All	21 (7.8%)	0 (0.0%)	21 (7.8%)	66 (24.4%)
	Alanine aminotransferase increased	14 (5.2%)	0 (0.0%)	14 (5.2%)	51 (18.9%)
	Aspartate aminotransferase increased	7 (2.6%)	0 (0.0%)	7 (2.6%)	42 (15.6%)
	Blood alkaline phosphatase increased	1 (0.4%)	0 (0.0%)	1 (0.4%)	25 (9.3%)
	Gamma-glutamyltransferase increased	9 (3.3%)	0 (0.0%)	9 (3.3%)	21 (7.8%)
	Blood bilirubin increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)
	Transaminases increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)
	Bilirubin conjugated increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Hepatic enzyme increased	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	International normalised ratio increased	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Liver function test increased	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Metabolism and nutrition disorders	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	6 (2.2%)
	Hypoalbuminaemia	1 (0.4%)	0 (0.0%)	1 (0.4%)	6 (2.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiac Failure
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		14 (5.2%)	1 (0.4%)	15 (5.6%)	22 (8.1%)
Cardiac disorders	All	12 (4.4%)	1 (0.4%)	13 (4.8%)	16 (5.9%)
	Cardiac failure congestive	7 (2.6%)	1 (0.4%)	8 (3.0%)	10 (3.7%)
	Cardiac failure	2 (0.7%)	0 (0.0%)	2 (0.7%)	3 (1.1%)
	Acute left ventricular failure	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Cardiac failure acute	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Cardiac failure chronic	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Cardiogenic shock	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Left ventricular dysfunction	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Investigations	All	3 (1.1%)	0 (0.0%)	3 (1.1%)	8 (3.0%)
	Ejection fraction decreased	3 (1.1%)	0 (0.0%)	3 (1.1%)	7 (2.6%)
	Right ventricular ejection fraction decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiac Failure
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Respiratory, thoracic and mediastinal disorders	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Pulmonary oedema	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Skin and subcutaneous tissue disorders
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		30 (11.1%)	0 (0.0%)	30 (11.1%)	223 (82.6%)
Skin and subcutaneous tissue disorders	All	30 (11.1%)	0 (0.0%)	30 (11.1%)	223 (82.6%)
	Dry skin	9 (3.3%)	0 (0.0%)	9 (3.3%)	114 (42.2%)
	Rash erythematous	7 (2.6%)	0 (0.0%)	7 (2.6%)	60 (22.2%)
	Pruritus	1 (0.4%)	0 (0.0%)	1 (0.4%)	35 (13.0%)
	Rash maculo-papular	3 (1.1%)	0 (0.0%)	3 (1.1%)	32 (11.9%)
	Rash	0 (0.0%)	0 (0.0%)	0 (0.0%)	31 (11.5%)
	Erythema	3 (1.1%)	0 (0.0%)	3 (1.1%)	28 (10.4%)
	Rash pruritic	0 (0.0%)	0 (0.0%)	0 (0.0%)	27 (10.0%)
	Alopecia	0 (0.0%)	0 (0.0%)	0 (0.0%)	23 (8.5%)
	Hyperhidrosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	24 (8.9%)
	Night sweats	0 (0.0%)	0 (0.0%)	0 (0.0%)	25 (9.3%)
	Rash papular	0 (0.0%)	0 (0.0%)	0 (0.0%)	20 (7.4%)
	Skin exfoliation	0 (0.0%)	0 (0.0%)	0 (0.0%)	19 (7.0%)
	Rash macular	0 (0.0%)	0 (0.0%)	0 (0.0%)	13 (4.8%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Skin and subcutaneous tissue disorders
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Exfoliative rash	0 (0.0%)	0 (0.0%)	0 (0.0%)	9 (3.3%)
	Petechiae	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (2.6%)
	Skin ulcer	2 (0.7%)	0 (0.0%)	2 (0.7%)	7 (2.6%)
	Actinic keratosis	1 (0.4%)	0 (0.0%)	1 (0.4%)	5 (1.9%)
	Dermatitis allergic	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (1.9%)
	Hyperkeratosis	1 (0.4%)	0 (0.0%)	1 (0.4%)	5 (1.9%)
	Pain of skin	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (2.2%)
	Skin lesion	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (1.9%)
	Acne	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.5%)
	Blister	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)
	Dermal cyst	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)
	Dermatitis acneiform	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)
	Dermatitis contact	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Dermatitis exfoliative	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Dermatitis psoriasiform	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)
	Diabetic foot	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Drug eruption	1 (0.4%)	0 (0.0%)	1 (0.4%)	2 (0.7%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Skin and subcutaneous tissue disorders
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Ecchymosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)
	Eczema	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.5%)
	Erythema multiforme	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Generalised erythema	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Ichthyosis acquired	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Intertrigo	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Psoriasis	1 (0.4%)	0 (0.0%)	1 (0.4%)	2 (0.7%)
	Rash follicular	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)
	Skin discolouration	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)
	Skin disorder	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Skin hyperpigmentation	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)
	Skin hypertrophy	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Skin irritation	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Skin mass	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)
	Skin swelling	1 (0.4%)	0 (0.0%)	1 (0.4%)	3 (1.1%)
	Swelling face	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)
	Toxic skin eruption	1 (0.4%)	0 (0.0%)	1 (0.4%)	4 (1.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Skin and subcutaneous tissue disorders
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Acne cystic	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Acute febrile neutrophilic dermatosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Angioedema	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Butterfly rash	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Decubitus ulcer	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Eczema asteatotic	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Hair colour changes	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Hair texture abnormal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Hypotrichosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Keratosis pilaris	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Lentigo	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Lichenoid keratosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Nail disorder	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Nail dystrophy	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Parakeratosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Pigmentation disorder	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Pruritus generalised	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Skin and subcutaneous tissue disorders
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Rash generalised	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Rash morbilliform	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Rash vesicular	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Skin burning sensation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Skin depigmentation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Skin fissures	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Skin hypopigmentation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Skin necrosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Skin plaque	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Skin tightness	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Solar dermatitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Stasis dermatitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Sweat gland disorder	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		39 (14.4%)	3 (1.1%)	42 (15.6%)	171 (63.3%)
Infections and infestations	All	39 (14.4%)	3 (1.1%)	42 (15.6%)	171 (63.3%)
	Upper respiratory tract infection	3 (1.1%)	0 (0.0%)	3 (1.1%)	37 (13.7%)
	Nasopharyngitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	33 (12.2%)
	Urinary tract infection	6 (2.2%)	0 (0.0%)	6 (2.2%)	31 (11.5%)
	Bronchitis	1 (0.4%)	0 (0.0%)	1 (0.4%)	25 (9.3%)
	Sinusitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	24 (8.9%)
	Pneumonia	11 (4.1%)	2 (0.7%)	13 (4.8%)	17 (6.3%)
	Folliculitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	14 (5.2%)
	Cellulitis	5 (1.9%)	0 (0.0%)	5 (1.9%)	11 (4.1%)
	Conjunctivitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	12 (4.4%)
	Influenza	0 (0.0%)	0 (0.0%)	0 (0.0%)	12 (4.4%)
	Gastroenteritis	1 (0.4%)	0 (0.0%)	1 (0.4%)	7 (2.6%)
	Cystitis	1 (0.4%)	0 (0.0%)	1 (0.4%)	5 (1.9%)
	Localised infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (2.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Lower respiratory tract infection	1 (0.4%)	0 (0.0%)	1 (0.4%)	5 (1.9%)
	Oral candidiasis	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (1.9%)
	Tooth infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (2.2%)
	Clostridium difficile colitis	3 (1.1%)	0 (0.0%)	3 (1.1%)	4 (1.5%)
	Clostridium difficile infection	1 (0.4%)	0 (0.0%)	1 (0.4%)	2 (0.7%)
	Diverticulitis	2 (0.7%)	0 (0.0%)	2 (0.7%)	3 (1.1%)
	Ear infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Epididymitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Erysipelas	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Eye infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.5%)
	Fungal skin infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.5%)
	Gastroenteritis viral	1 (0.4%)	0 (0.0%)	1 (0.4%)	4 (1.5%)
	Gastrointestinal infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Genital herpes	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Gingivitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.5%)
	Helicobacter infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)
	Herpes zoster	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Hordeolum	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Lung infection	1 (0.4%)	0 (0.0%)	1 (0.4%)	2 (0.7%)
	Oral fungal infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Oral herpes	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.5%)
	Osteomyelitis	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Otitis externa	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Otitis media	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)
	Pharyngitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)
	Post procedural infection	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Respiratory tract infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Rhinitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)
	Sepsis	3 (1.1%)	0 (0.0%)	3 (1.1%)	4 (1.5%)
	Skin infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Tonsillitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.5%)
	Vaginal infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)
	Viral infection	1 (0.4%)	0 (0.0%)	1 (0.4%)	3 (1.1%)
	Viral upper respiratory tract infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Vulvitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Abdominal sepsis	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Abscess	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Acute sinusitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Arthritis bacterial	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Arthritis viral	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Bacteraemia	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Bacterial infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Cholecystitis infective	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Chronic sinusitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Dermatitis infected	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Dermatophytosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Dermo-hypodermitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Diarrhoea infectious	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Furuncle	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Genital infection bacterial	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Hand-foot-and-mouth disease	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Herpes dermatitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Herpes oesophagitis	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Herpes virus infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Infected skin ulcer	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Infusion site cellulitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Klebsiella bacteraemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Laryngitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Ophthalmic herpes simplex	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Otitis media acute	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Otitis media chronic	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Papilloma viral infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Parainfluenzae virus infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Periodontitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Peritonitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Pneumocystis jirovecii pneumonia	0 (0.0%)	1 (0.4%)	1 (0.4%)	1 (0.4%)
	Pneumonia mycoplasmal	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Pneumonia staphylococcal	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Post procedural pneumonia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Pyelonephritis	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Pyelonephritis acute	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Respiratory syncytial virus infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Respiratory tract infection viral	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Skin candida	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Staphylococcal bacteraemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Strongyloidiasis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Systemic infection	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Tinea cruris	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Tooth abscess	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Tracheitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Urinary tract infection bacterial	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Viral labyrinthitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Vulvovaginal candidiasis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Wound infection	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Wound infection staphylococcal	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Myelosuppression
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		117 (43.3%)	0 (0.0%)	117 (43.3%)	148 (54.8%)
Blood and lymphatic system disorders	All	102 (37.8%)	0 (0.0%)	102 (37.8%)	135 (50.0%)
	Thrombocytopenia	82 (30.4%)	0 (0.0%)	82 (30.4%)	108 (40.0%)
	Anaemia	25 (9.3%)	0 (0.0%)	25 (9.3%)	50 (18.5%)
	Neutropenia	40 (14.8%)	0 (0.0%)	40 (14.8%)	48 (17.8%)
	Leukopenia	4 (1.5%)	0 (0.0%)	4 (1.5%)	7 (2.6%)
	Febrile neutropenia	3 (1.1%)	0 (0.0%)	3 (1.1%)	3 (1.1%)
	Lymphopenia	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Pancytopenia	1 (0.4%)	0 (0.0%)	1 (0.4%)	2 (0.7%)
	Bone marrow failure	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Cytopenia	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Normochromic normocytic anaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
Investigations	All	25 (9.3%)	0 (0.0%)	25 (9.3%)	29 (10.7%)
	Platelet count decreased	15 (5.6%)	0 (0.0%)	15 (5.6%)	19 (7.0%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Myelosuppression
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Neutrophil count decreased	9 (3.3%)	0 (0.0%)	9 (3.3%)	10 (3.7%)
	White blood cell count decreased	4 (1.5%)	0 (0.0%)	4 (1.5%)	5 (1.9%)
	Haemoglobin decreased	3 (1.1%)	0 (0.0%)	3 (1.1%)	3 (1.1%)
	Lymphocyte count decreased	2 (0.7%)	0 (0.0%)	2 (0.7%)	3 (1.1%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	All	3 (1.1%)	0 (0.0%)	3 (1.1%)	3 (1.1%)
	Myelodysplastic syndrome	3 (1.1%)	0 (0.0%)	3 (1.1%)	3 (1.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Edema and Fluid Retention
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		11 (4.1%)	0 (0.0%)	11 (4.1%)	79 (29.3%)
Cardiac disorders	All	2 (0.7%)	0 (0.0%)	2 (0.7%)	9 (3.3%)
	Pericardial effusion	2 (0.7%)	0 (0.0%)	2 (0.7%)	9 (3.3%)
Gastrointestinal disorders	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Ascites	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
General disorders and administration site conditions	All	2 (0.7%)	0 (0.0%)	2 (0.7%)	54 (20.0%)
	Oedema peripheral	2 (0.7%)	0 (0.0%)	2 (0.7%)	44 (16.3%)
	Peripheral swelling	0 (0.0%)	0 (0.0%)	0 (0.0%)	9 (3.3%)
	Localised oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Generalised oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
Metabolism and nutrition disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Edema and Fluid Retention
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Fluid retention	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)
Musculoskeletal and connective tissue disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (1.9%)
	Joint swelling	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (1.9%)
Reproductive system and breast disorders	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Testicular swelling	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Respiratory, thoracic and mediastinal disorders	All	4 (1.5%)	0 (0.0%)	4 (1.5%)	15 (5.6%)
	Pleural effusion	3 (1.1%)	0 (0.0%)	3 (1.1%)	14 (5.2%)
	Pulmonary oedema	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Skin and subcutaneous tissue disorders	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	3 (1.1%)
	Skin swelling	1 (0.4%)	0 (0.0%)	1 (0.4%)	3 (1.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Hypertension
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		38 (14.1%)	0 (0.0%)	38 (14.1%)	100 (37.0%)
Investigations	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	3 (1.1%)
	Blood pressure increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)
	Blood pressure systolic increased	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Vascular disorders	All	37 (13.7%)	0 (0.0%)	37 (13.7%)	99 (36.7%)
	Hypertension	37 (13.7%)	0 (0.0%)	37 (13.7%)	98 (36.3%)
	Hypertensive crisis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Eye disorder
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		9 (3.3%)	0 (0.0%)	9 (3.3%)	87 (32.2%)
Eye disorders	All	9 (3.3%)	0 (0.0%)	9 (3.3%)	87 (32.2%)
	Dry eye	2 (0.7%)	0 (0.0%)	2 (0.7%)	21 (7.8%)
	Vision blurred	0 (0.0%)	0 (0.0%)	0 (0.0%)	20 (7.4%)
	Eye pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	12 (4.4%)
	Cataract	2 (0.7%)	0 (0.0%)	2 (0.7%)	9 (3.3%)
	Glaucoma	1 (0.4%)	0 (0.0%)	1 (0.4%)	6 (2.2%)
	Periorbital oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (2.2%)
	Blepharitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.5%)
	Conjunctival haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.5%)
	Conjunctival hyperaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Diplopia	1 (0.4%)	0 (0.0%)	1 (0.4%)	3 (1.1%)
	Eye haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Eye irritation	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)
	Eye swelling	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Eye disorder
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Eyelid oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.5%)
	Macular oedema	1 (0.4%)	0 (0.0%)	1 (0.4%)	3 (1.1%)
	Ocular hyperaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)
	Photophobia	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Retinal haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Retinal vein occlusion	1 (0.4%)	0 (0.0%)	1 (0.4%)	3 (1.1%)
	Visual acuity reduced	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Visual impairment	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)
	Asthenopia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Atrophy of globe	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Blepharospasm	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Blindness unilateral	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Cataract subcapsular	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Conjunctival irritation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Cystoid macular oedema	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Eye oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Eye pruritus	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Eye disorder
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Eyelid cyst	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Foreign body sensation in eyes	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Hyalosis asteroid	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Iridocyclitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Keratitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Lacrimation increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Ocular discomfort	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Ocular icterus	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Retinal artery occlusion	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Retinal vein thrombosis	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Ulcerative keratitis	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Uveitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Vitreous floaters	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Bleeding Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		8 (3.0%)	2 (0.7%)	10 (3.7%)	61 (22.6%)
Blood and lymphatic system disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Increased tendency to bruise	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
Ear and labyrinth disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Ear haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
Eye disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	8 (3.0%)
	Conjunctival haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.5%)
	Eye haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Retinal haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
Gastrointestinal disorders	All	3 (1.1%)	0 (0.0%)	3 (1.1%)	11 (4.1%)
	Gingival bleeding	1 (0.4%)	0 (0.0%)	1 (0.4%)	3 (1.1%)
	Haematochezia	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Bleeding Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Diarrhoea haemorrhagic	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Gastric ulcer haemorrhage	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Haematemesis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Haemorrhoidal haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Melaena	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Mouth haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Upper gastrointestinal haemorrhage	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
General disorders and administration site conditions	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Catheter site haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
Injury, poisoning and procedural complications	All	3 (1.1%)	1 (0.4%)	4 (1.5%)	14 (5.2%)
	Contusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (2.6%)
	Post procedural haematoma	1 (0.4%)	0 (0.0%)	1 (0.4%)	2 (0.7%)
	Post procedural haemorrhage	1 (0.4%)	0 (0.0%)	1 (0.4%)	2 (0.7%)
	Subdural haematoma	1 (0.4%)	1 (0.4%)	2 (0.7%)	2 (0.7%)
	Traumatic haematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Bleeding Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Nervous system disorders	All	1 (0.4%)	1 (0.4%)	2 (0.7%)	3 (1.1%)
	Haemorrhagic cerebral infarction	0 (0.0%)	1 (0.4%)	1 (0.4%)	1 (0.4%)
	Haemorrhagic transformation stroke	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Subarachnoid haemorrhage	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Renal and urinary disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.5%)
	Haematuria	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)
	Urinary bladder haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
Reproductive system and breast disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (2.6%)
	Menorrhagia	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Metrorrhagia	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.7%)
	Vaginal haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)
Respiratory, thoracic and mediastinal disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	21 (7.8%)
	Epistaxis	0 (0.0%)	0 (0.0%)	0 (0.0%)	19 (7.0%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Bleeding Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Bronchial haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Haemoptysis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
Skin and subcutaneous tissue disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	10 (3.7%)
	Petechiae	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (2.6%)
	Ecchymosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)
Vascular disorders	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	4 (1.5%)
	Haematoma	1 (0.4%)	0 (0.0%)	1 (0.4%)	4 (1.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Pancreatitis
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		50 (18.5%)	0 (0.0%)	50 (18.5%)	86 (31.9%)
Gastrointestinal disorders	All	19 (7.0%)	0 (0.0%)	19 (7.0%)	21 (7.8%)
	Pancreatitis	13 (4.8%)	0 (0.0%)	13 (4.8%)	16 (5.9%)
	Pancreatitis acute	6 (2.2%)	0 (0.0%)	6 (2.2%)	6 (2.2%)
Investigations	All	37 (13.7%)	0 (0.0%)	37 (13.7%)	76 (28.1%)
	Lipase increased	34 (12.6%)	0 (0.0%)	34 (12.6%)	73 (27.0%)
	Amylase increased	8 (3.0%)	0 (0.0%)	8 (3.0%)	21 (7.8%)
Metabolism and nutrition disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Hyperlipasaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Clinical Pancreatitis
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		19 (7.0%)	0 (0.0%)	19 (7.0%)	21 (7.8%)
Gastrointestinal disorders	All	19 (7.0%)	0 (0.0%)	19 (7.0%)	21 (7.8%)
	Pancreatitis	13 (4.8%)	0 (0.0%)	13 (4.8%)	16 (5.9%)
	Pancreatitis acute	6 (2.2%)	0 (0.0%)	6 (2.2%)	6 (2.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Chemical Pancreatitis
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		37 (13.7%)	0 (0.0%)	37 (13.7%)	77 (28.5%)
Investigations	All	37 (13.7%)	0 (0.0%)	37 (13.7%)	76 (28.1%)
	Lipase increased	34 (12.6%)	0 (0.0%)	34 (12.6%)	73 (27.0%)
	Amylase increased	8 (3.0%)	0 (0.0%)	8 (3.0%)	21 (7.8%)
Metabolism and nutrition disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Hyperlipasaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiac Arrhythmias
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		18 (6.7%)	3 (1.1%)	21 (7.8%)	52 (19.3%)
Cardiac disorders	All	14 (5.2%)	3 (1.1%)	17 (6.3%)	44 (16.3%)
	Atrial fibrillation	11 (4.1%)	0 (0.0%)	11 (4.1%)	23 (8.5%)
	Palpitations	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (2.6%)
	Sinus bradycardia	1 (0.4%)	0 (0.0%)	1 (0.4%)	5 (1.9%)
	Tachycardia	1 (0.4%)	0 (0.0%)	1 (0.4%)	5 (1.9%)
	Atrial flutter	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (1.1%)
	Bradycardia	2 (0.7%)	0 (0.0%)	2 (0.7%)	4 (1.5%)
	Cardiac arrest	0 (0.0%)	3 (1.1%)	3 (1.1%)	3 (1.1%)
	Ventricular tachycardia	1 (0.4%)	0 (0.0%)	1 (0.4%)	2 (0.7%)
	Arrhythmia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Arrhythmia supraventricular	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Atrial tachycardia	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Atrioventricular block first degree	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Cardio-respiratory arrest	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiac Arrhythmias
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Extrasystoles	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Sinus node dysfunction	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Sinus tachycardia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Supraventricular extrasystoles	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Ventricular extrasystoles	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
Investigations	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	5 (1.9%)
	Electrocardiogram QT prolonged	1 (0.4%)	0 (0.0%)	1 (0.4%)	4 (1.5%)
	Heart rate irregular	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
Nervous system disorders	All	5 (1.9%)	0 (0.0%)	5 (1.9%)	8 (3.0%)
	Syncope	5 (1.9%)	0 (0.0%)	5 (1.9%)	8 (3.0%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
QT Prolongation
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		7 (2.6%)	3 (1.1%)	10 (3.7%)	17 (6.3%)
Cardiac disorders	All	2 (0.7%)	3 (1.1%)	5 (1.9%)	6 (2.2%)
	Cardiac arrest	0 (0.0%)	3 (1.1%)	3 (1.1%)	3 (1.1%)
	Ventricular tachycardia	1 (0.4%)	0 (0.0%)	1 (0.4%)	2 (0.7%)
	Cardio-respiratory arrest	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Investigations	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	4 (1.5%)
	Electrocardiogram QT prolonged	1 (0.4%)	0 (0.0%)	1 (0.4%)	4 (1.5%)
Nervous system disorders	All	5 (1.9%)	0 (0.0%)	5 (1.9%)	8 (3.0%)
	Syncope	5 (1.9%)	0 (0.0%)	5 (1.9%)	8 (3.0%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Hypothyroidism
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		0 (0.0%)	0 (0.0%)	0 (0.0%)	9 (3.3%)
Endocrine disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	9 (3.3%)
	Hypothyroidism	0 (0.0%)	0 (0.0%)	0 (0.0%)	9 (3.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Arterial Occlusive Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		11 (12.9%)	0 (0.0%)	11 (12.9%)	17 (20.0%)
Cardiac disorders	All	6 (7.1%)	0 (0.0%)	6 (7.1%)	12 (14.1%)
	Acute myocardial infarction	2 (2.4%)	0 (0.0%)	2 (2.4%)	3 (3.5%)
	Angina pectoris	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.5%)
	Coronary artery disease	2 (2.4%)	0 (0.0%)	2 (2.4%)	3 (3.5%)
	Myocardial infarction	1 (1.2%)	0 (0.0%)	1 (1.2%)	2 (2.4%)
	Acute coronary syndrome	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Coronary artery occlusion	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Ischaemic cardiomyopathy	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Stress cardiomyopathy	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
Nervous system disorders	All	3 (3.5%)	0 (0.0%)	3 (3.5%)	5 (5.9%)
	Cerebrovascular accident	1 (1.2%)	0 (0.0%)	1 (1.2%)	2 (2.4%)
	Aphasia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Cerebellar infarction	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Arterial Occlusive Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Cerebral ischaemia	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Vertebral artery stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
Vascular disorders	All	3 (3.5%)	0 (0.0%)	3 (3.5%)	5 (5.9%)
	Peripheral arterial occlusive disease	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
	Peripheral vascular disorder	1 (1.2%)	0 (0.0%)	1 (1.2%)	2 (2.4%)
	Extremity necrosis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Peripheral ischaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Subclavian artery stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiovascular Arterial Occlusive Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		6 (7.1%)	0 (0.0%)	6 (7.1%)	12 (14.1%)
Cardiac disorders	All	6 (7.1%)	0 (0.0%)	6 (7.1%)	12 (14.1%)
	Acute myocardial infarction	2 (2.4%)	0 (0.0%)	2 (2.4%)	3 (3.5%)
	Angina pectoris	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.5%)
	Coronary artery disease	2 (2.4%)	0 (0.0%)	2 (2.4%)	3 (3.5%)
	Myocardial infarction	1 (1.2%)	0 (0.0%)	1 (1.2%)	2 (2.4%)
	Acute coronary syndrome	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Coronary artery occlusion	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Ischaemic cardiomyopathy	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Stress cardiomyopathy	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cerebrovascular Arterial Occlusive Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (3.5%)	0 (0.0%)	3 (3.5%)	5 (5.9%)
Nervous system disorders	All	3 (3.5%)	0 (0.0%)	3 (3.5%)	5 (5.9%)
	Cerebrovascular accident	1 (1.2%)	0 (0.0%)	1 (1.2%)	2 (2.4%)
	Aphasia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Cerebellar infarction	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Cerebral ischaemia	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Vertebral artery stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Peripheral Vascular Arterial Occlusive Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (3.5%)	0 (0.0%)	3 (3.5%)	5 (5.9%)
Vascular disorders	All	3 (3.5%)	0 (0.0%)	3 (3.5%)	5 (5.9%)
	Peripheral arterial occlusive disease	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
	Peripheral vascular disorder	1 (1.2%)	0 (0.0%)	1 (1.2%)	2 (2.4%)
	Extremity necrosis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Peripheral ischaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Subclavian artery stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Venous Thrombotic/Embolic Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (1.2%)	0 (0.0%)	1 (1.2%)	3 (3.5%)
Eye disorders	All	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Retinal vein thrombosis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
Respiratory, thoracic and mediastinal disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Pulmonary embolism	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
Vascular disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
	Deep vein thrombosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Thrombophlebitis superficial	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Vascular Occlusive Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		11 (12.9%)	0 (0.0%)	11 (12.9%)	19 (22.4%)
Cardiac disorders	All	6 (7.1%)	0 (0.0%)	6 (7.1%)	12 (14.1%)
	Acute myocardial infarction	2 (2.4%)	0 (0.0%)	2 (2.4%)	3 (3.5%)
	Angina pectoris	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.5%)
	Coronary artery disease	2 (2.4%)	0 (0.0%)	2 (2.4%)	3 (3.5%)
	Myocardial infarction	1 (1.2%)	0 (0.0%)	1 (1.2%)	2 (2.4%)
	Acute coronary syndrome	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Coronary artery occlusion	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Ischaemic cardiomyopathy	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Stress cardiomyopathy	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
Eye disorders	All	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Retinal vein thrombosis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
Nervous system disorders	All	3 (3.5%)	0 (0.0%)	3 (3.5%)	5 (5.9%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Vascular Occlusive Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Cerebrovascular accident	1 (1.2%)	0 (0.0%)	1 (1.2%)	2 (2.4%)
	Aphasia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Cerebellar infarction	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Cerebral ischaemia	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Vertebral artery stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
Respiratory, thoracic and mediastinal disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Pulmonary embolism	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
Vascular disorders	All	3 (3.5%)	0 (0.0%)	3 (3.5%)	7 (8.2%)
	Peripheral arterial occlusive disease	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
	Peripheral vascular disorder	1 (1.2%)	0 (0.0%)	1 (1.2%)	2 (2.4%)
	Deep vein thrombosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Extremity necrosis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Peripheral ischaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Subclavian artery stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Thrombophlebitis superficial	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Hepatoxicity
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		11 (12.9%)	0 (0.0%)	11 (12.9%)	31 (36.5%)
Gastrointestinal disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
	Ascites	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
Hepatobiliary disorders	All	2 (2.4%)	0 (0.0%)	2 (2.4%)	6 (7.1%)
	Hyperbilirubinaemia	1 (1.2%)	0 (0.0%)	1 (1.2%)	4 (4.7%)
	Hepatic steatosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Hepatotoxicity	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Jaundice	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
Investigations	All	10 (11.8%)	0 (0.0%)	10 (11.8%)	25 (29.4%)
	Alanine aminotransferase increased	3 (3.5%)	0 (0.0%)	3 (3.5%)	20 (23.5%)
	Aspartate aminotransferase increased	4 (4.7%)	0 (0.0%)	4 (4.7%)	17 (20.0%)
	Blood alkaline phosphatase increased	2 (2.4%)	0 (0.0%)	2 (2.4%)	10 (11.8%)
	Gamma-glutamyltransferase increased	4 (4.7%)	0 (0.0%)	4 (4.7%)	10 (11.8%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Hepatoxicity
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Blood bilirubin increased	2 (2.4%)	0 (0.0%)	2 (2.4%)	6 (7.1%)
	Transaminases increased	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
Metabolism and nutrition disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.5%)
	Hypoalbuminaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiac Failure
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		4 (4.7%)	0 (0.0%)	4 (4.7%)	6 (7.1%)
Cardiac disorders	All	4 (4.7%)	0 (0.0%)	4 (4.7%)	5 (5.9%)
	Cardiac failure	2 (2.4%)	0 (0.0%)	2 (2.4%)	3 (3.5%)
	Cardiac failure chronic	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Cardiac failure congestive	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Cardiopulmonary failure	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Left ventricular dysfunction	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
Investigations	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Ejection fraction decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Skin and subcutaneous tissue disorders
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		15 (17.6%)	0 (0.0%)	15 (17.6%)	68 (80.0%)
Skin and subcutaneous tissue disorders	All	15 (17.6%)	0 (0.0%)	15 (17.6%)	68 (80.0%)
	Dry skin	1 (1.2%)	0 (0.0%)	1 (1.2%)	27 (31.8%)
	Rash	1 (1.2%)	0 (0.0%)	1 (1.2%)	13 (15.3%)
	Rash erythematous	2 (2.4%)	0 (0.0%)	2 (2.4%)	11 (12.9%)
	Alopecia	0 (0.0%)	0 (0.0%)	0 (0.0%)	9 (10.6%)
	Rash pruritic	2 (2.4%)	0 (0.0%)	2 (2.4%)	9 (10.6%)
	Erythema	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (8.2%)
	Pruritus	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (8.2%)
	Exfoliative rash	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (7.1%)
	Rash papular	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (7.1%)
	Ecchymosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (5.9%)
	Hyperhidrosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (5.9%)
	Hyperkeratosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (5.9%)
	Night sweats	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (5.9%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Skin and subcutaneous tissue disorders
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Rash maculo-papular	1 (1.2%)	0 (0.0%)	1 (1.2%)	5 (5.9%)
	Skin lesion	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (4.7%)
	Petechiae	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.5%)
	Skin exfoliation	1 (1.2%)	0 (0.0%)	1 (1.2%)	3 (3.5%)
	Skin hyperpigmentation	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.5%)
	Rash generalised	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
	Skin ulcer	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
	Urticaria	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
	Actinic keratosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Acute febrile neutrophilic dermatosis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Angioedema	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Blister	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Dermatitis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Dermatitis acneiform	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Dermatitis allergic	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Dermatitis contact	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Dermatitis exfoliative	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Skin and subcutaneous tissue disorders
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Diabetic foot	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Eczema	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Erythema multiforme	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Erythema nodosum	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Erythrosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Generalised erythema	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Keratosis pilaris	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Mucocutaneous haemorrhage	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Pain of skin	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Photosensitivity reaction	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Pityriasis rubra pilaris	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Psoriasis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Rash macular	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Seborrhoea	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Skin discolouration	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Skin disorder	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Skin hypertrophy	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		23 (27.1%)	4 (4.7%)	27 (31.8%)	65 (76.5%)
Infections and infestations	All	23 (27.1%)	4 (4.7%)	27 (31.8%)	65 (76.5%)
	Nasopharyngitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	15 (17.6%)
	Urinary tract infection	2 (2.4%)	0 (0.0%)	2 (2.4%)	12 (14.1%)
	Pneumonia	8 (9.4%)	0 (0.0%)	8 (9.4%)	11 (12.9%)
	Upper respiratory tract infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	11 (12.9%)
	Cellulitis	3 (3.5%)	0 (0.0%)	3 (3.5%)	7 (8.2%)
	Tooth infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (5.9%)
	Bronchitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (4.7%)
	Conjunctivitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (4.7%)
	Folliculitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (4.7%)
	Sepsis	2 (2.4%)	2 (2.4%)	4 (4.7%)	4 (4.7%)
	Clostridium difficile colitis	2 (2.4%)	0 (0.0%)	2 (2.4%)	3 (3.5%)
	Ear infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.5%)
	Gastroenteritis	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Infection	2 (2.4%)	0 (0.0%)	2 (2.4%)	3 (3.5%)
	Respiratory tract infection	1 (1.2%)	0 (0.0%)	1 (1.2%)	3 (3.5%)
	Sinusitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.5%)
	Tooth abscess	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.5%)
	Appendicitis	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
	Bacteraemia	1 (1.2%)	0 (0.0%)	1 (1.2%)	2 (2.4%)
	Cystitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
	Gingivitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
	Influenza	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
	Oesophageal candidiasis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
	Oral candidiasis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
	Oral herpes	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
	Pharyngitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
	Skin infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
	Body tinea	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Breast cellulitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Bronchopulmonary aspergillosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Diverticulitis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Escherichia urinary tract infection	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Eye infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Fungaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Fungal skin infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Furuncle	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Gangrene	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Gastroenteritis norovirus	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Herpes zoster	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Hordeolum	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Kidney infection	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Lip infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Localised infection	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Lower respiratory tract infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Lung infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Mastitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Mastoiditis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Nail infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Neutropenic sepsis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Orchitis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Otitis externa	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Otitis media acute	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Periodontitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Pharyngitis streptococcal	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Pneumonia fungal	0 (0.0%)	1 (1.2%)	1 (1.2%)	1 (1.2%)
	Pulmonary tuberculosis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Rash pustular	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Rhinitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Septic shock	0 (0.0%)	1 (1.2%)	1 (1.2%)	1 (1.2%)
	Splenic abscess	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Tongue fungal infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Tonsillitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Urosepsis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Vaginal infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Vulval abscess	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Myelosuppression
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		52 (61.2%)	0 (0.0%)	52 (61.2%)	60 (70.6%)
Blood and lymphatic system disorders	All	49 (57.6%)	0 (0.0%)	49 (57.6%)	57 (67.1%)
	Thrombocytopenia	33 (38.8%)	0 (0.0%)	33 (38.8%)	39 (45.9%)
	Anaemia	19 (22.4%)	0 (0.0%)	19 (22.4%)	31 (36.5%)
	Neutropenia	28 (32.9%)	0 (0.0%)	28 (32.9%)	28 (32.9%)
	Leukopenia	6 (7.1%)	0 (0.0%)	6 (7.1%)	7 (8.2%)
	Febrile neutropenia	4 (4.7%)	0 (0.0%)	4 (4.7%)	4 (4.7%)
	Pancytopenia	2 (2.4%)	0 (0.0%)	2 (2.4%)	3 (3.5%)
	Lymphopenia	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
Infections and infestations	All	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Neutropenic sepsis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
Investigations	All	7 (8.2%)	0 (0.0%)	7 (8.2%)	10 (11.8%)
	Platelet count decreased	5 (5.9%)	0 (0.0%)	5 (5.9%)	7 (8.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Myelosuppression
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Neutrophil count decreased	4 (4.7%)	0 (0.0%)	4 (4.7%)	4 (4.7%)
	White blood cell count decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.5%)
	Haemoglobin decreased	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	All	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Myelodysplastic syndrome	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Edema and Fluid Retention
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		2 (2.4%)	0 (0.0%)	2 (2.4%)	30 (35.3%)
Cardiac disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.5%)
	Pericardial effusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.5%)
Gastrointestinal disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
	Ascites	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
General disorders and administration site conditions	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	22 (25.9%)
	Oedema peripheral	0 (0.0%)	0 (0.0%)	0 (0.0%)	15 (17.6%)
	Peripheral swelling	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (8.2%)
	Generalised oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Localised oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
Metabolism and nutrition disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Fluid retention	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Edema and Fluid Retention
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Musculoskeletal and connective tissue disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
	Joint swelling	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
Respiratory, thoracic and mediastinal disorders	All	2 (2.4%)	0 (0.0%)	2 (2.4%)	10 (11.8%)
	Pleural effusion	2 (2.4%)	0 (0.0%)	2 (2.4%)	10 (11.8%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Hypertension
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		10 (11.8%)	0 (0.0%)	10 (11.8%)	22 (25.9%)
Vascular disorders	All	10 (11.8%)	0 (0.0%)	10 (11.8%)	22 (25.9%)
	Hypertension	9 (10.6%)	0 (0.0%)	9 (10.6%)	22 (25.9%)
	Hypertensive crisis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Eye disorder
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		4 (4.7%)	0 (0.0%)	4 (4.7%)	28 (32.9%)
Eye disorders	All	4 (4.7%)	0 (0.0%)	4 (4.7%)	28 (32.9%)
	Dry eye	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (8.2%)
	Vision blurred	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (4.7%)
	Blepharitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.5%)
	Cataract	2 (2.4%)	0 (0.0%)	2 (2.4%)	3 (3.5%)
	Visual acuity reduced	1 (1.2%)	0 (0.0%)	1 (1.2%)	3 (3.5%)
	Conjunctival haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
	Eye pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
	Iritis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
	Vitreous floaters	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
	Conjunctival hyperaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Corneal erosion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Diplopia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Eye discharge	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Eye disorder
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Eye haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Eye swelling	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Eyelid disorder	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Eyelid oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Eyelid thickening	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Iridocyclitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Lacrimation increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Macular fibrosis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Ocular hyperaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Periorbital oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Retinal vein thrombosis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Visual impairment	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Bleeding Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		10 (11.8%)	1 (1.2%)	11 (12.9%)	32 (37.6%)
Ear and labyrinth disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Ear haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
Eye disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.5%)
	Conjunctival haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
	Eye haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
Gastrointestinal disorders	All	4 (4.7%)	1 (1.2%)	5 (5.9%)	13 (15.3%)
	Gastrointestinal haemorrhage	2 (2.4%)	1 (1.2%)	3 (3.5%)	4 (4.7%)
	Haemorrhoidal haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.5%)
	Gingival bleeding	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
	Rectal haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
	Retroperitoneal haematoma	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
	Gastric ulcer haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Bleeding Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Haematochezia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Melaena	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Mouth haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Peritoneal haemorrhage	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
General disorders and administration site conditions	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Catheter site haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
Injury, poisoning and procedural complications	All	2 (2.4%)	0 (0.0%)	2 (2.4%)	7 (8.2%)
	Post procedural haematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
	Post procedural haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
	Subdural haematoma	1 (1.2%)	0 (0.0%)	1 (1.2%)	2 (2.4%)
	Subcutaneous haematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Traumatic haematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Traumatic intracranial haemorrhage	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Bleeding Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Musculoskeletal and connective tissue disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Muscle haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
Nervous system disorders	All	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Cerebral haemorrhage	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
Renal and urinary disorders	All	1 (1.2%)	0 (0.0%)	1 (1.2%)	4 (4.7%)
	Haematuria	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.5%)
	Cystitis haemorrhagic	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
Reproductive system and breast disorders	All	1 (1.2%)	0 (0.0%)	1 (1.2%)	3 (3.5%)
	Menorrhagia	1 (1.2%)	0 (0.0%)	1 (1.2%)	2 (2.4%)
	Haemorrhagic ovarian cyst	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Metrorrhagia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Vaginal haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
Respiratory, thoracic and mediastinal disorders	All	1 (1.2%)	0 (0.0%)	1 (1.2%)	7 (8.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Bleeding Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Epistaxis	1 (1.2%)	0 (0.0%)	1 (1.2%)	7 (8.2%)
Skin and subcutaneous tissue disorders	All	1 (1.2%)	0 (0.0%)	1 (1.2%)	7 (8.2%)
	Ecchymosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (5.9%)
	Petechiae	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.5%)
	Mucocutaneous haemorrhage	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
Vascular disorders	All	1 (1.2%)	0 (0.0%)	1 (1.2%)	3 (3.5%)
	Haematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Haemorrhagic vasculitis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Pancreatitis
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		13 (15.3%)	0 (0.0%)	13 (15.3%)	19 (22.4%)
Gastrointestinal disorders	All	5 (5.9%)	0 (0.0%)	5 (5.9%)	7 (8.2%)
	Pancreatitis	2 (2.4%)	0 (0.0%)	2 (2.4%)	4 (4.7%)
	Pancreatitis acute	3 (3.5%)	0 (0.0%)	3 (3.5%)	3 (3.5%)
Investigations	All	11 (12.9%)	0 (0.0%)	11 (12.9%)	15 (17.6%)
	Lipase increased	11 (12.9%)	0 (0.0%)	11 (12.9%)	13 (15.3%)
	Amylase increased	3 (3.5%)	0 (0.0%)	3 (3.5%)	7 (8.2%)
Metabolism and nutrition disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Hyperamylasaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Clinical Pancreatitis
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		5 (5.9%)	0 (0.0%)	5 (5.9%)	7 (8.2%)
Gastrointestinal disorders	All	5 (5.9%)	0 (0.0%)	5 (5.9%)	7 (8.2%)
	Pancreatitis	2 (2.4%)	0 (0.0%)	2 (2.4%)	4 (4.7%)
	Pancreatitis acute	3 (3.5%)	0 (0.0%)	3 (3.5%)	3 (3.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Chemical Pancreatitis
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		11 (12.9%)	0 (0.0%)	11 (12.9%)	16 (18.8%)
Investigations	All	11 (12.9%)	0 (0.0%)	11 (12.9%)	15 (17.6%)
	Lipase increased	11 (12.9%)	0 (0.0%)	11 (12.9%)	13 (15.3%)
	Amylase increased	3 (3.5%)	0 (0.0%)	3 (3.5%)	7 (8.2%)
Metabolism and nutrition disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Hyperamylasaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiac Arrhythmias
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		4 (4.7%)	0 (0.0%)	4 (4.7%)	14 (16.5%)
Cardiac disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	9 (10.6%)
	Palpitations	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (3.5%)
	Atrial fibrillation	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
	Bradycardia	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
	Sinus tachycardia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Supraventricular tachycardia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Tachycardia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
Investigations	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Electrocardiogram QT prolonged	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
Nervous system disorders	All	4 (4.7%)	0 (0.0%)	4 (4.7%)	4 (4.7%)
	Syncope	4 (4.7%)	0 (0.0%)	4 (4.7%)	4 (4.7%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
QT Prolongation
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		4 (4.7%)	0 (0.0%)	4 (4.7%)	5 (5.9%)
Investigations	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Electrocardiogram QT prolonged	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
Nervous system disorders	All	4 (4.7%)	0 (0.0%)	4 (4.7%)	4 (4.7%)
	Syncope	4 (4.7%)	0 (0.0%)	4 (4.7%)	4 (4.7%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Hypothyroidism
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (4.7%)
Endocrine disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (4.7%)
	Hypothyroidism	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (4.7%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Tumour lysis syndrome
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
Metabolism and nutrition disorders	All	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
	Tumour lysis syndrome	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Arterial Occlusive Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		5 (8.1%)	0 (0.0%)	5 (8.1%)	7 (11.3%)
Blood and lymphatic system disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Splenic infarction	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
Cardiac disorders	All	3 (4.8%)	0 (0.0%)	3 (4.8%)	4 (6.5%)
	Angina pectoris	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (4.8%)
	Acute myocardial infarction	2 (3.2%)	0 (0.0%)	2 (3.2%)	2 (3.2%)
	Coronary artery disease	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Myocardial infarction	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
Renal and urinary disorders	All	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Renal artery stenosis	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
Vascular disorders	All	2 (3.2%)	0 (0.0%)	2 (3.2%)	2 (3.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Arterial Occlusive Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Embolism arterial	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Peripheral arterial occlusive disease	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiovascular Arterial Occlusive Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (4.8%)	0 (0.0%)	3 (4.8%)	4 (6.5%)
Cardiac disorders	All	3 (4.8%)	0 (0.0%)	3 (4.8%)	4 (6.5%)
	Angina pectoris	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (4.8%)
	Acute myocardial infarction	2 (3.2%)	0 (0.0%)	2 (3.2%)	2 (3.2%)
	Coronary artery disease	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Myocardial infarction	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Peripheral Vascular Arterial Occlusive Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (1.6%)	0 (0.0%)	1 (1.6%)	2 (3.2%)
Blood and lymphatic system disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Splenic infarction	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
Renal and urinary disorders	All	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Renal artery stenosis	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
Vascular disorders	All	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Peripheral arterial occlusive disease	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Venous Thrombotic/Embolic Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		5 (8.1%)	0 (0.0%)	5 (8.1%)	6 (9.7%)
Hepatobiliary disorders	All	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Portal vein thrombosis	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
Respiratory, thoracic and mediastinal disorders	All	3 (4.8%)	0 (0.0%)	3 (4.8%)	3 (4.8%)
	Pulmonary embolism	3 (4.8%)	0 (0.0%)	3 (4.8%)	3 (4.8%)
Vascular disorders	All	1 (1.6%)	0 (0.0%)	1 (1.6%)	3 (4.8%)
	Thrombophlebitis superficial	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.2%)
	Deep vein thrombosis	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Vascular Occlusive Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		9 (14.5%)	0 (0.0%)	9 (14.5%)	11 (17.7%)
Blood and lymphatic system disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Splenic infarction	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
Cardiac disorders	All	3 (4.8%)	0 (0.0%)	3 (4.8%)	4 (6.5%)
	Angina pectoris	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (4.8%)
	Acute myocardial infarction	2 (3.2%)	0 (0.0%)	2 (3.2%)	2 (3.2%)
	Coronary artery disease	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Myocardial infarction	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
Hepatobiliary disorders	All	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Portal vein thrombosis	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
Renal and urinary disorders	All	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Renal artery stenosis	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Vascular Occlusive Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Respiratory, thoracic and mediastinal disorders	All	3 (4.8%)	0 (0.0%)	3 (4.8%)	3 (4.8%)
	Pulmonary embolism	3 (4.8%)	0 (0.0%)	3 (4.8%)	3 (4.8%)
Vascular disorders	All	3 (4.8%)	0 (0.0%)	3 (4.8%)	5 (8.1%)
	Thrombophlebitis superficial	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.2%)
	Deep vein thrombosis	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Embolism arterial	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Peripheral arterial occlusive disease	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Hepatoxicity
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		12 (19.4%)	0 (0.0%)	12 (19.4%)	20 (32.3%)
Gastrointestinal disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.2%)
	Ascites	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.2%)
Hepatobiliary disorders	All	5 (8.1%)	0 (0.0%)	5 (8.1%)	8 (12.9%)
	Hyperbilirubinaemia	2 (3.2%)	0 (0.0%)	2 (3.2%)	2 (3.2%)
	Cholestasis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Hepatic lesion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Hepatic pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Hepatitis	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Hepatocellular injury	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Liver disorder	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Non-alcoholic fatty liver	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
Investigations	All	7 (11.3%)	0 (0.0%)	7 (11.3%)	13 (21.0%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Hepatoxicity
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Aspartate aminotransferase increased	4 (6.5%)	0 (0.0%)	4 (6.5%)	10 (16.1%)
	Alanine aminotransferase increased	4 (6.5%)	0 (0.0%)	4 (6.5%)	8 (12.9%)
	Blood alkaline phosphatase increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (4.8%)
	Gamma-glutamyltransferase increased	2 (3.2%)	0 (0.0%)	2 (3.2%)	2 (3.2%)
	Blood bilirubin increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
Metabolism and nutrition disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Hypoalbuminaemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiac Failure
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		5 (8.1%)	2 (3.2%)	7 (11.3%)	9 (14.5%)
Cardiac disorders	All	4 (6.5%)	2 (3.2%)	6 (9.7%)	6 (9.7%)
	Cardiac failure	2 (3.2%)	1 (1.6%)	3 (4.8%)	3 (4.8%)
	Cardiac failure congestive	0 (0.0%)	1 (1.6%)	1 (1.6%)	2 (3.2%)
	Cardiogenic shock	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Left ventricular failure	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Right ventricular failure	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
Investigations	All	4 (6.5%)	0 (0.0%)	4 (6.5%)	5 (8.1%)
	Ejection fraction decreased	4 (6.5%)	0 (0.0%)	4 (6.5%)	5 (8.1%)
Respiratory, thoracic and mediastinal disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.2%)
	Pulmonary oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Skin and subcutaneous tissue disorders
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		5 (8.1%)	0 (0.0%)	5 (8.1%)	43 (69.4%)
Skin and subcutaneous tissue disorders	All	5 (8.1%)	0 (0.0%)	5 (8.1%)	43 (69.4%)
	Dry skin	1 (1.6%)	0 (0.0%)	1 (1.6%)	16 (25.8%)
	Rash erythematous	1 (1.6%)	0 (0.0%)	1 (1.6%)	16 (25.8%)
	Alopecia	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (8.1%)
	Erythema	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (8.1%)
	Urticaria	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (6.5%)
	Hyperhidrosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (4.8%)
	Night sweats	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (4.8%)
	Petechiae	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (4.8%)
	Pruritus	1 (1.6%)	0 (0.0%)	1 (1.6%)	3 (4.8%)
	Rash	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (4.8%)
	Rash maculo-papular	2 (3.2%)	0 (0.0%)	2 (3.2%)	3 (4.8%)
	Ecchymosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.2%)
	Ichthyosis acquired	1 (1.6%)	0 (0.0%)	1 (1.6%)	2 (3.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Skin and subcutaneous tissue disorders
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Rash macular	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.2%)
	Rash papular	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.2%)
	Skin exfoliation	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.2%)
	Skin lesion	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.2%)
	Skin ulcer	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.2%)
	Decubitus ulcer	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Dermatitis exfoliative	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Exfoliative rash	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Interstitial granulomatous dermatitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Purpura	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Rash pruritic	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Seborrhoeic dermatitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Skin hyperpigmentation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Skin mass	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		16 (25.8%)	3 (4.8%)	19 (30.6%)	35 (56.5%)
Infections and infestations	All	16 (25.8%)	3 (4.8%)	19 (30.6%)	35 (56.5%)
	Pneumonia	7 (11.3%)	0 (0.0%)	7 (11.3%)	10 (16.1%)
	Upper respiratory tract infection	1 (1.6%)	0 (0.0%)	1 (1.6%)	8 (12.9%)
	Cellulitis	2 (3.2%)	0 (0.0%)	2 (3.2%)	7 (11.3%)
	Bacteraemia	1 (1.6%)	0 (0.0%)	1 (1.6%)	4 (6.5%)
	Oral candidiasis	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (6.5%)
	Gastroenteritis	2 (3.2%)	0 (0.0%)	2 (3.2%)	3 (4.8%)
	Clostridium difficile colitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.2%)
	Clostridium difficile infection	1 (1.6%)	0 (0.0%)	1 (1.6%)	2 (3.2%)
	Herpes zoster	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.2%)
	Klebsiella sepsis	2 (3.2%)	0 (0.0%)	2 (3.2%)	2 (3.2%)
	Nasopharyngitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.2%)
	Sepsis	0 (0.0%)	2 (3.2%)	2 (3.2%)	2 (3.2%)
	Sinusitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Tongue fungal infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.2%)
	Abscess	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Bronchitis	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Catheter site cellulitis	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Clostridial infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Device related infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Escherichia bacteraemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Escherichia urinary tract infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Folliculitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Fungal skin infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Groin abscess	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Herpes virus infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Incision site infection	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Infectious colitis	0 (0.0%)	1 (1.6%)	1 (1.6%)	1 (1.6%)
	Influenza	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Oral herpes	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Oral infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Perirectal abscess	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Pneumonia respiratory syncytial viral	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Pneumonia staphylococcal	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Septic shock	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Skin infection	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Staphylococcal bacteraemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Streptococcal bacteraemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Tooth abscess	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Urinary tract infection	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Myelosuppression
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		41 (66.1%)	0 (0.0%)	41 (66.1%)	42 (67.7%)
Blood and lymphatic system disorders	All	40 (64.5%)	0 (0.0%)	40 (64.5%)	41 (66.1%)
	Anaemia	20 (32.3%)	0 (0.0%)	20 (32.3%)	21 (33.9%)
	Thrombocytopenia	19 (30.6%)	0 (0.0%)	19 (30.6%)	20 (32.3%)
	Neutropenia	14 (22.6%)	0 (0.0%)	14 (22.6%)	16 (25.8%)
	Febrile neutropenia	8 (12.9%)	0 (0.0%)	8 (12.9%)	8 (12.9%)
	Pancytopenia	4 (6.5%)	0 (0.0%)	4 (6.5%)	4 (6.5%)
Investigations	All	8 (12.9%)	0 (0.0%)	8 (12.9%)	10 (16.1%)
	Neutrophil count decreased	4 (6.5%)	0 (0.0%)	4 (6.5%)	6 (9.7%)
	Platelet count decreased	4 (6.5%)	0 (0.0%)	4 (6.5%)	5 (8.1%)
	Haemoglobin decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Edema and Fluid Retention
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (4.8%)	1 (1.6%)	4 (6.5%)	20 (32.3%)
Cardiac disorders	All	2 (3.2%)	0 (0.0%)	2 (3.2%)	4 (6.5%)
	Pericardial effusion	2 (3.2%)	0 (0.0%)	2 (3.2%)	4 (6.5%)
Gastrointestinal disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.2%)
	Ascites	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.2%)
General disorders and administration site conditions	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	12 (19.4%)
	Oedema peripheral	0 (0.0%)	0 (0.0%)	0 (0.0%)	9 (14.5%)
	Generalised oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.2%)
	Peripheral swelling	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
Metabolism and nutrition disorders	All	1 (1.6%)	0 (0.0%)	1 (1.6%)	2 (3.2%)
	Fluid overload	1 (1.6%)	0 (0.0%)	1 (1.6%)	2 (3.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Edema and Fluid Retention
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Nervous system disorders	All	0 (0.0%)	1 (1.6%)	1 (1.6%)	1 (1.6%)
	Brain oedema	0 (0.0%)	1 (1.6%)	1 (1.6%)	1 (1.6%)
Respiratory, thoracic and mediastinal disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	10 (16.1%)
	Pleural effusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	8 (12.9%)
	Pulmonary oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Hypertension
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		5 (8.1%)	0 (0.0%)	5 (8.1%)	14 (22.6%)
Endocrine disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Hyperaldosteronism	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
Vascular disorders	All	5 (8.1%)	0 (0.0%)	5 (8.1%)	13 (21.0%)
	Hypertension	5 (8.1%)	0 (0.0%)	5 (8.1%)	13 (21.0%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Eye disorder
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		0 (0.0%)	0 (0.0%)	0 (0.0%)	12 (19.4%)
Eye disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	12 (19.4%)
	Dry eye	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (8.1%)
	Periorbital oedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.2%)
	Cataract	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Eye pain	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Glaucoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Lacrimation increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Papilloedema	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Photophobia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Retinal haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Vision blurred	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Visual impairment	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Bleeding Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		4 (6.5%)	3 (4.8%)	7 (11.3%)	23 (37.1%)
Eye disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Retinal haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
Gastrointestinal disorders	All	2 (3.2%)	1 (1.6%)	3 (4.8%)	10 (16.1%)
	Gingival bleeding	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (4.8%)
	Gastrointestinal haemorrhage	1 (1.6%)	0 (0.0%)	1 (1.6%)	2 (3.2%)
	Gastritis haemorrhagic	0 (0.0%)	1 (1.6%)	1 (1.6%)	1 (1.6%)
	Haematemesis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Haematochezia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Haemorrhoidal haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Intra-abdominal haemorrhage	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Melaena	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Oral mucosa haematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Tongue haematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Bleeding Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Upper gastrointestinal haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
Injury, poisoning and procedural complications	All	1 (1.6%)	1 (1.6%)	2 (3.2%)	5 (8.1%)
	Contusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.2%)
	Subcutaneous haematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Subdural haematoma	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Traumatic intracranial haemorrhage	0 (0.0%)	1 (1.6%)	1 (1.6%)	1 (1.6%)
Nervous system disorders	All	1 (1.6%)	1 (1.6%)	2 (3.2%)	2 (3.2%)
	Cerebral haemorrhage	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Haemorrhage intracranial	0 (0.0%)	1 (1.6%)	1 (1.6%)	1 (1.6%)
Reproductive system and breast disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Vaginal haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
Respiratory, thoracic and mediastinal disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	7 (11.3%)
	Epistaxis	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (9.7%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Bleeding Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Haemoptysis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Pharyngeal haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
Skin and subcutaneous tissue disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	6 (9.7%)
	Petechiae	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (4.8%)
	Ecchymosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.2%)
	Purpura	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Pancreatitis
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		10 (16.1%)	0 (0.0%)	10 (16.1%)	12 (19.4%)
Gastrointestinal disorders	All	2 (3.2%)	0 (0.0%)	2 (3.2%)	3 (4.8%)
	Pancreatitis acute	2 (3.2%)	0 (0.0%)	2 (3.2%)	2 (3.2%)
	Pancreatitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
Investigations	All	8 (12.9%)	0 (0.0%)	8 (12.9%)	9 (14.5%)
	Lipase increased	8 (12.9%)	0 (0.0%)	8 (12.9%)	9 (14.5%)
	Amylase increased	3 (4.8%)	0 (0.0%)	3 (4.8%)	4 (6.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Clinical Pancreatitis
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		2 (3.2%)	0 (0.0%)	2 (3.2%)	3 (4.8%)
Gastrointestinal disorders	All	2 (3.2%)	0 (0.0%)	2 (3.2%)	3 (4.8%)
	Pancreatitis acute	2 (3.2%)	0 (0.0%)	2 (3.2%)	2 (3.2%)
	Pancreatitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Chemical Pancreatitis
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		8 (12.9%)	0 (0.0%)	8 (12.9%)	9 (14.5%)
Investigations	All	8 (12.9%)	0 (0.0%)	8 (12.9%)	9 (14.5%)
	Lipase increased	8 (12.9%)	0 (0.0%)	8 (12.9%)	9 (14.5%)
	Amylase increased	3 (4.8%)	0 (0.0%)	3 (4.8%)	4 (6.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiac Arrhythmias
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		5 (8.1%)	0 (0.0%)	5 (8.1%)	15 (24.2%)
Cardiac disorders	All	4 (6.5%)	0 (0.0%)	4 (6.5%)	13 (21.0%)
	Tachycardia	1 (1.6%)	0 (0.0%)	1 (1.6%)	5 (8.1%)
	Atrial fibrillation	2 (3.2%)	0 (0.0%)	2 (3.2%)	4 (6.5%)
	Supraventricular tachycardia	1 (1.6%)	0 (0.0%)	1 (1.6%)	3 (4.8%)
	Atrial flutter	1 (1.6%)	0 (0.0%)	1 (1.6%)	2 (3.2%)
	Arrhythmia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Atrioventricular block complete	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Bradycardia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Bundle branch block right	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Palpitations	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Sinus tachycardia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
Investigations	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Electrocardiogram QT prolonged	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiac Arrhythmias
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Nervous system disorders	All	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Loss of consciousness	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
QT Prolongation
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (1.6%)	0 (0.0%)	1 (1.6%)	2 (3.2%)
Investigations	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Electrocardiogram QT prolonged	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
Nervous system disorders	All	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Loss of consciousness	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Hypothyroidism
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
Endocrine disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Hypothyroidism	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.1 (Study 201)
Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Tumour lysis syndrome
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
Metabolism and nutrition disorders	All	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Tumour lysis syndrome	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		14 (32.6%)	0 (0.0%)	14 (32.6%)	16 (37.2%)
Cardiac disorders	All	7 (16.3%)	0 (0.0%)	7 (16.3%)	8 (18.6%)
	Acute myocardial infarction	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Myocardial infarction	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Myocardial ischaemia	1 (2.3%)	0 (0.0%)	1 (2.3%)	2 (4.7%)
	Acute coronary syndrome	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Atrial thrombosis	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Coronary artery stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
General disorders and administration site conditions	All	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Ischaemic ulcer	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
Investigations	All	3 (7.0%)	0 (0.0%)	3 (7.0%)	3 (7.0%)
	Troponin increased	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Electrocardiogram T wave inversion	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Troponin I increased	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
Nervous system disorders	All	3 (7.0%)	0 (0.0%)	3 (7.0%)	4 (9.3%)
	Carotid artery stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Embolic stroke	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Hemiparesis	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Hemiplegia	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Lacunar infarction	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Transient ischaemic attack	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
Renal and urinary disorders	All	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Renal artery occlusion	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
Vascular disorders	All	4 (9.3%)	0 (0.0%)	4 (9.3%)	5 (11.6%)
	Peripheral arterial occlusive disease	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Peripheral vascular disorder	1 (2.3%)	0 (0.0%)	1 (2.3%)	2 (4.7%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Peripheral artery occlusion	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Peripheral ischaemia	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiovascular Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		9 (20.9%)	0 (0.0%)	9 (20.9%)	10 (23.3%)
Cardiac disorders	All	7 (16.3%)	0 (0.0%)	7 (16.3%)	8 (18.6%)
	Acute myocardial infarction	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Myocardial infarction	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Myocardial ischaemia	1 (2.3%)	0 (0.0%)	1 (2.3%)	2 (4.7%)
	Acute coronary syndrome	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Atrial thrombosis	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Coronary artery stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
Investigations	All	3 (7.0%)	0 (0.0%)	3 (7.0%)	3 (7.0%)
	Troponin increased	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Electrocardiogram T wave inversion	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Troponin I increased	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cerebrovascular Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (7.0%)	0 (0.0%)	3 (7.0%)	4 (9.3%)
Nervous system disorders	All	3 (7.0%)	0 (0.0%)	3 (7.0%)	4 (9.3%)
	Carotid artery stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Embolic stroke	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Hemiparesis	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Hemiplegia	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Lacunar infarction	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Transient ischaemic attack	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Peripheral Vascular Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		5 (11.6%)	0 (0.0%)	5 (11.6%)	6 (14.0%)
General disorders and administration site conditions	All	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Ischaemic ulcer	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
Renal and urinary disorders	All	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Renal artery occlusion	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
Vascular disorders	All	4 (9.3%)	0 (0.0%)	4 (9.3%)	5 (11.6%)
	Peripheral arterial occlusive disease	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Peripheral vascular disorder	1 (2.3%)	0 (0.0%)	1 (2.3%)	2 (4.7%)
	Peripheral artery occlusion	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Peripheral ischaemia	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Venous Thrombotic/Embolic Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
Vascular disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Venoocclusive disease	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Vascular Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		14 (32.6%)	0 (0.0%)	14 (32.6%)	16 (37.2%)
Cardiac disorders	All	7 (16.3%)	0 (0.0%)	7 (16.3%)	8 (18.6%)
	Acute myocardial infarction	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Myocardial infarction	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Myocardial ischaemia	1 (2.3%)	0 (0.0%)	1 (2.3%)	2 (4.7%)
	Acute coronary syndrome	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Atrial thrombosis	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Coronary artery stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
General disorders and administration site conditions	All	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Ischaemic ulcer	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
Investigations	All	3 (7.0%)	0 (0.0%)	3 (7.0%)	3 (7.0%)
	Troponin increased	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Electrocardiogram T wave inversion	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Vascular Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Troponin I increased	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
Nervous system disorders	All	3 (7.0%)	0 (0.0%)	3 (7.0%)	4 (9.3%)
	Carotid artery stenosis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Embolic stroke	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Hemiparesis	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Hemiplegia	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Lacunar infarction	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Transient ischaemic attack	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
Renal and urinary disorders	All	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Renal artery occlusion	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
Vascular disorders	All	4 (9.3%)	0 (0.0%)	4 (9.3%)	5 (11.6%)
	Peripheral arterial occlusive disease	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Peripheral vascular disorder	1 (2.3%)	0 (0.0%)	1 (2.3%)	2 (4.7%)
	Peripheral artery occlusion	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Vascular Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Peripheral ischaemia	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Venoocclusive disease	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Hepatoxicity
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
Investigations	All	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Alanine aminotransferase increased	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Aspartate aminotransferase increased	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiac Failure
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
Cardiac disorders	All	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Cardiac failure congestive	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Left ventricular dysfunction	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
Investigations	All	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Ejection fraction decreased	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Skin and subcutaneous tissue disorders
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
Skin and subcutaneous tissue disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (4.7%)
	Erythema nodosum	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Stasis dermatitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		10 (23.3%)	1 (2.3%)	11 (25.6%)	12 (27.9%)
Infections and infestations	All	10 (23.3%)	1 (2.3%)	11 (25.6%)	12 (27.9%)
	Pneumonia	2 (4.7%)	1 (2.3%)	3 (7.0%)	3 (7.0%)
	Bronchitis	1 (2.3%)	0 (0.0%)	1 (2.3%)	2 (4.7%)
	Cellulitis	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Urinary tract infection	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Bacteraemia	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Gastroenteritis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Gastroenteritis viral	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Localised infection	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Post procedural infection	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Septic shock	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Streptococcal infection	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Urosepsis	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Wound infection	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Myelosuppression
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (7.0%)	0 (0.0%)	3 (7.0%)	3 (7.0%)
Blood and lymphatic system disorders	All	3 (7.0%)	0 (0.0%)	3 (7.0%)	3 (7.0%)
	Febrile neutropenia	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Thrombocytopenia	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
Investigations	All	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Platelet count decreased	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Edema and Fluid Retention
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
Respiratory, thoracic and mediastinal disorders	All	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Pleural effusion	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Hypertension
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
Vascular disorders	All	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Hypertension	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Eye disorder
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
Eye disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
	Uveitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Bleeding Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (7.0%)	0 (0.0%)	3 (7.0%)	3 (7.0%)
Gastrointestinal disorders	All	2 (4.7%)	0 (0.0%)	2 (4.7%)	2 (4.7%)
	Gastrointestinal haemorrhage	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Peptic ulcer haemorrhage	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
Injury, poisoning and procedural complications	All	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)
	Subdural haematoma	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Pancreatitis
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		2 (4.7%)	0 (0.0%)	2 (4.7%)	4 (9.3%)
Gastrointestinal disorders	All	2 (4.7%)	0 (0.0%)	2 (4.7%)	4 (9.3%)
	Pancreatitis	2 (4.7%)	0 (0.0%)	2 (4.7%)	4 (9.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Clinical Pancreatitis
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		2 (4.7%)	0 (0.0%)	2 (4.7%)	4 (9.3%)
Gastrointestinal disorders	All	2 (4.7%)	0 (0.0%)	2 (4.7%)	4 (9.3%)
	Pancreatitis	2 (4.7%)	0 (0.0%)	2 (4.7%)	4 (9.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiac Arrhythmias
Safety Population - CP-CML Patients

		CP-CML Patients (N=43)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		4 (9.3%)	0 (0.0%)	4 (9.3%)	5 (11.6%)
Cardiac disorders	All	4 (9.3%)	0 (0.0%)	4 (9.3%)	5 (11.6%)
	Atrial fibrillation	3 (7.0%)	0 (0.0%)	3 (7.0%)	4 (9.3%)
	Ventricular tachycardia	1 (2.3%)	0 (0.0%)	1 (2.3%)	1 (2.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Arterial Occlusive Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		2 (22.2%)	0 (0.0%)	2 (22.2%)	2 (22.2%)
Nervous system disorders	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Cerebrovascular accident	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
Vascular disorders	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Peripheral ischaemia	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cerebrovascular Arterial Occlusive Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
Nervous system disorders	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Cerebrovascular accident	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Peripheral Vascular Arterial Occlusive Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
Vascular disorders	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Peripheral ischaemia	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Vascular Occlusive Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		2 (22.2%)	0 (0.0%)	2 (22.2%)	2 (22.2%)
Nervous system disorders	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Cerebrovascular accident	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
Vascular disorders	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Peripheral ischaemia	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (33.3%)	1 (11.1%)	4 (44.4%)	5 (55.6%)
Infections and infestations	All	3 (33.3%)	1 (11.1%)	4 (44.4%)	5 (55.6%)
	Pneumonia	2 (22.2%)	0 (0.0%)	2 (22.2%)	2 (22.2%)
	Bacteraemia	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Bacterial sepsis	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Eye infection staphylococcal	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Lung infection	0 (0.0%)	1 (11.1%)	1 (11.1%)	1 (11.1%)
	Sepsis	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Septic shock	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Viral upper respiratory tract infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Myelosuppression
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
Blood and lymphatic system disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)
	Febrile neutropenia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Edema and Fluid Retention
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
Respiratory, thoracic and mediastinal disorders	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Pleural effusion	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Eye disorder
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
Eye disorders	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Vision blurred	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Pancreatitis
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (33.3%)	0 (0.0%)	3 (33.3%)	3 (33.3%)
Gastrointestinal disorders	All	3 (33.3%)	0 (0.0%)	3 (33.3%)	3 (33.3%)
	Pancreatitis	2 (22.2%)	0 (0.0%)	2 (22.2%)	2 (22.2%)
	Pancreatitis acute	1 (11.1%)	0 (0.0%)	1 (11.1%)	2 (22.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Clinical Pancreatitis
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (33.3%)	0 (0.0%)	3 (33.3%)	3 (33.3%)
Gastrointestinal disorders	All	3 (33.3%)	0 (0.0%)	3 (33.3%)	3 (33.3%)
	Pancreatitis	2 (22.2%)	0 (0.0%)	2 (22.2%)	2 (22.2%)
	Pancreatitis acute	1 (11.1%)	0 (0.0%)	1 (11.1%)	2 (22.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiac Arrhythmias
Safety Population - AP-CML Patients

		AP-CML Patients (N=9)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
Cardiac disorders	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Tachycardia	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
Nervous system disorders	All	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)
	Syncope	1 (11.1%)	0 (0.0%)	1 (11.1%)	1 (11.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Arterial Occlusive Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		2 (25.0%)	0 (0.0%)	2 (25.0%)	2 (25.0%)
Cardiac disorders	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Angina pectoris	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
Investigations	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Troponin increased	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiovascular Arterial Occlusive Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		2 (25.0%)	0 (0.0%)	2 (25.0%)	2 (25.0%)
Cardiac disorders	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Angina pectoris	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
Investigations	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Troponin increased	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Venous Thrombotic/Embolic Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
Vascular disorders	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Deep vein thrombosis	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Vascular Occlusive Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (37.5%)	0 (0.0%)	3 (37.5%)	3 (37.5%)
Cardiac disorders	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Angina pectoris	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
Investigations	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Troponin increased	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
Vascular disorders	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Deep vein thrombosis	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		2 (25.0%)	2 (25.0%)	4 (50.0%)	5 (62.5%)
Infections and infestations	All	2 (25.0%)	2 (25.0%)	4 (50.0%)	5 (62.5%)
	Neutropenic sepsis	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Pneumonia	0 (0.0%)	1 (12.5%)	1 (12.5%)	1 (12.5%)
	Sepsis	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Septic shock	0 (0.0%)	1 (12.5%)	1 (12.5%)	1 (12.5%)
	Upper respiratory tract infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Myelosuppression
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (37.5%)	0 (0.0%)	3 (37.5%)	3 (37.5%)
Blood and lymphatic system disorders	All	3 (37.5%)	0 (0.0%)	3 (37.5%)	3 (37.5%)
	Febrile neutropenia	2 (25.0%)	0 (0.0%)	2 (25.0%)	2 (25.0%)
	Thrombocytopenia	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
Infections and infestations	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Neutropenic sepsis	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Bleeding Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
Injury, poisoning and procedural complications	All	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)
	Subdural haematoma	1 (12.5%)	0 (0.0%)	1 (12.5%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 101)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiac Arrhythmias
Safety Population - BP-CML Patients

		BP-CML Patients (N=8)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
Cardiac disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Atrial fibrillation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)
	Tachycardia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		45 (16.7%)	3 (1.1%)	48 (17.8%)	69 (25.6%)
Blood and lymphatic system disorders	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Splenic infarction	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Cardiac disorders	All	22 (8.1%)	1 (0.4%)	23 (8.5%)	33 (12.2%)
	Angina pectoris	4 (1.5%)	0 (0.0%)	4 (1.5%)	14 (5.2%)
	Coronary artery disease	9 (3.3%)	0 (0.0%)	9 (3.3%)	10 (3.7%)
	Myocardial infarction	7 (2.6%)	0 (0.0%)	7 (2.6%)	7 (2.6%)
	Acute coronary syndrome	5 (1.9%)	0 (0.0%)	5 (1.9%)	6 (2.2%)
	Acute myocardial infarction	2 (0.7%)	1 (0.4%)	3 (1.1%)	3 (1.1%)
	Coronary artery occlusion	3 (1.1%)	0 (0.0%)	3 (1.1%)	3 (1.1%)
	Coronary artery stenosis	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Angina unstable	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Arteriosclerosis coronary artery	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Arteriospasm coronary	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Cardiac discomfort	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Ischaemic cardiomyopathy	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Eye disorders	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Retinal artery occlusion	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Nervous system disorders	All	15 (5.6%)	2 (0.7%)	17 (6.3%)	27 (10.0%)
	Cerebral infarction	7 (2.6%)	0 (0.0%)	7 (2.6%)	8 (3.0%)
	Cerebrovascular accident	1 (0.4%)	1 (0.4%)	2 (0.7%)	9 (3.3%)
	Carotid artery stenosis	5 (1.9%)	0 (0.0%)	5 (1.9%)	6 (2.2%)
	Cerebral artery stenosis	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Transient ischaemic attack	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.5%)
	Carotid artery occlusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Cerebrovascular disorder	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Haemorrhagic cerebral infarction	0 (0.0%)	1 (0.4%)	1 (0.4%)	1 (0.4%)
	Haemorrhagic transformation stroke	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Lacunar infarction	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Renal and urinary disorders	All	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Renal artery stenosis	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
Vascular disorders	All	19 (7.0%)	0 (0.0%)	19 (7.0%)	28 (10.4%)
	Peripheral arterial occlusive disease	9 (3.3%)	0 (0.0%)	9 (3.3%)	13 (4.8%)
	Peripheral artery stenosis	7 (2.6%)	0 (0.0%)	7 (2.6%)	8 (3.0%)
	Peripheral artery occlusion	5 (1.9%)	0 (0.0%)	5 (1.9%)	5 (1.9%)
	Dry gangrene	1 (0.4%)	0 (0.0%)	1 (0.4%)	2 (0.7%)
	Peripheral ischaemia	2 (0.7%)	0 (0.0%)	2 (0.7%)	3 (1.1%)
	Peripheral vascular disorder	1 (0.4%)	0 (0.0%)	1 (0.4%)	3 (1.1%)
	Intermittent claudication	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiovascular Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		22 (8.1%)	1 (0.4%)	23 (8.5%)	33 (12.2%)
Cardiac disorders	All	22 (8.1%)	1 (0.4%)	23 (8.5%)	33 (12.2%)
	Angina pectoris	4 (1.5%)	0 (0.0%)	4 (1.5%)	14 (5.2%)
	Coronary artery disease	9 (3.3%)	0 (0.0%)	9 (3.3%)	10 (3.7%)
	Myocardial infarction	7 (2.6%)	0 (0.0%)	7 (2.6%)	7 (2.6%)
	Acute coronary syndrome	5 (1.9%)	0 (0.0%)	5 (1.9%)	6 (2.2%)
	Acute myocardial infarction	2 (0.7%)	1 (0.4%)	3 (1.1%)	3 (1.1%)
	Coronary artery occlusion	3 (1.1%)	0 (0.0%)	3 (1.1%)	3 (1.1%)
	Coronary artery stenosis	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Angina unstable	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Arteriosclerosis coronary artery	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Arteriospasm coronary	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Cardiac discomfort	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Ischaemic cardiomyopathy	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cerebrovascular Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		16 (5.9%)	2 (0.7%)	18 (6.7%)	28 (10.4%)
Eye disorders	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Retinal artery occlusion	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Nervous system disorders	All	15 (5.6%)	2 (0.7%)	17 (6.3%)	27 (10.0%)
	Cerebral infarction	7 (2.6%)	0 (0.0%)	7 (2.6%)	8 (3.0%)
	Cerebrovascular accident	1 (0.4%)	1 (0.4%)	2 (0.7%)	9 (3.3%)
	Carotid artery stenosis	5 (1.9%)	0 (0.0%)	5 (1.9%)	6 (2.2%)
	Cerebral artery stenosis	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Transient ischaemic attack	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.5%)
	Carotid artery occlusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Cerebrovascular disorder	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Haemorrhagic cerebral infarction	0 (0.0%)	1 (0.4%)	1 (0.4%)	1 (0.4%)
	Haemorrhagic transformation stroke	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Lacunar infarction	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Peripheral Vascular Arterial Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		22 (8.1%)	0 (0.0%)	22 (8.1%)	31 (11.5%)
Blood and lymphatic system disorders	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Splenic infarction	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Renal and urinary disorders	All	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Renal artery stenosis	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
Vascular disorders	All	19 (7.0%)	0 (0.0%)	19 (7.0%)	28 (10.4%)
	Peripheral arterial occlusive disease	9 (3.3%)	0 (0.0%)	9 (3.3%)	13 (4.8%)
	Peripheral artery stenosis	7 (2.6%)	0 (0.0%)	7 (2.6%)	8 (3.0%)
	Peripheral artery occlusion	5 (1.9%)	0 (0.0%)	5 (1.9%)	5 (1.9%)
	Dry gangrene	1 (0.4%)	0 (0.0%)	1 (0.4%)	2 (0.7%)
	Peripheral ischaemia	2 (0.7%)	0 (0.0%)	2 (0.7%)	3 (1.1%)
	Peripheral vascular disorder	1 (0.4%)	0 (0.0%)	1 (0.4%)	3 (1.1%)
	Intermittent claudication	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Venous Thrombotic/Embolic Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		8 (3.0%)	0 (0.0%)	8 (3.0%)	13 (4.8%)
Eye disorders	All	2 (0.7%)	0 (0.0%)	2 (0.7%)	4 (1.5%)
	Retinal vein occlusion	1 (0.4%)	0 (0.0%)	1 (0.4%)	3 (1.1%)
	Retinal vein thrombosis	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Hepatobiliary disorders	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Venoocclusive liver disease	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Respiratory, thoracic and mediastinal disorders	All	3 (1.1%)	0 (0.0%)	3 (1.1%)	3 (1.1%)
	Pulmonary embolism	3 (1.1%)	0 (0.0%)	3 (1.1%)	3 (1.1%)
Vascular disorders	All	2 (0.7%)	0 (0.0%)	2 (0.7%)	5 (1.9%)
	Deep vein thrombosis	2 (0.7%)	0 (0.0%)	2 (0.7%)	5 (1.9%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Vascular Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		53 (19.6%)	3 (1.1%)	56 (20.7%)	78 (28.9%)
Blood and lymphatic system disorders	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Splenic infarction	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Cardiac disorders	All	22 (8.1%)	1 (0.4%)	23 (8.5%)	33 (12.2%)
	Angina pectoris	4 (1.5%)	0 (0.0%)	4 (1.5%)	14 (5.2%)
	Coronary artery disease	9 (3.3%)	0 (0.0%)	9 (3.3%)	10 (3.7%)
	Myocardial infarction	7 (2.6%)	0 (0.0%)	7 (2.6%)	7 (2.6%)
	Acute coronary syndrome	5 (1.9%)	0 (0.0%)	5 (1.9%)	6 (2.2%)
	Acute myocardial infarction	2 (0.7%)	1 (0.4%)	3 (1.1%)	3 (1.1%)
	Coronary artery occlusion	3 (1.1%)	0 (0.0%)	3 (1.1%)	3 (1.1%)
	Coronary artery stenosis	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Angina unstable	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Arteriosclerosis coronary artery	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Arteriospasm coronary	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Vascular Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Cardiac discomfort	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Ischaemic cardiomyopathy	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Eye disorders	All	3 (1.1%)	0 (0.0%)	3 (1.1%)	5 (1.9%)
	Retinal vein occlusion	1 (0.4%)	0 (0.0%)	1 (0.4%)	3 (1.1%)
	Retinal artery occlusion	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Retinal vein thrombosis	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
General disorders and administration site conditions	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Vascular stent occlusion	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Hepatobiliary disorders	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Venoocclusive liver disease	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Nervous system disorders	All	15 (5.6%)	2 (0.7%)	17 (6.3%)	27 (10.0%)
	Cerebral infarction	7 (2.6%)	0 (0.0%)	7 (2.6%)	8 (3.0%)
	Cerebrovascular accident	1 (0.4%)	1 (0.4%)	2 (0.7%)	9 (3.3%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Vascular Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Carotid artery stenosis	5 (1.9%)	0 (0.0%)	5 (1.9%)	6 (2.2%)
	Cerebral artery stenosis	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Transient ischaemic attack	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.5%)
	Carotid artery occlusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Cerebrovascular disorder	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Haemorrhagic cerebral infarction	0 (0.0%)	1 (0.4%)	1 (0.4%)	1 (0.4%)
	Haemorrhagic transformation stroke	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Lacunar infarction	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Renal and urinary disorders	All	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Renal artery stenosis	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
Respiratory, thoracic and mediastinal disorders	All	3 (1.1%)	0 (0.0%)	3 (1.1%)	3 (1.1%)
	Pulmonary embolism	3 (1.1%)	0 (0.0%)	3 (1.1%)	3 (1.1%)
Vascular disorders	All	21 (7.8%)	0 (0.0%)	21 (7.8%)	32 (11.9%)
	Peripheral arterial occlusive disease	9 (3.3%)	0 (0.0%)	9 (3.3%)	13 (4.8%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Vascular Occlusive Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Peripheral artery stenosis	7 (2.6%)	0 (0.0%)	7 (2.6%)	8 (3.0%)
	Deep vein thrombosis	2 (0.7%)	0 (0.0%)	2 (0.7%)	5 (1.9%)
	Peripheral artery occlusion	5 (1.9%)	0 (0.0%)	5 (1.9%)	5 (1.9%)
	Dry gangrene	1 (0.4%)	0 (0.0%)	1 (0.4%)	2 (0.7%)
	Peripheral ischaemia	2 (0.7%)	0 (0.0%)	2 (0.7%)	3 (1.1%)
	Peripheral vascular disorder	1 (0.4%)	0 (0.0%)	1 (0.4%)	3 (1.1%)
	Intermittent claudication	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Hepatoxicity
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		7 (2.6%)	0 (0.0%)	7 (2.6%)	7 (2.6%)
Hepatobiliary disorders	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Non-alcoholic steatohepatitis	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Investigations	All	6 (2.2%)	0 (0.0%)	6 (2.2%)	6 (2.2%)
	Alanine aminotransferase increased	2 (0.7%)	0 (0.0%)	2 (0.7%)	3 (1.1%)
	Aspartate aminotransferase increased	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Blood alkaline phosphatase increased	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Gamma-glutamyltransferase increased	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Hepatic enzyme increased	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	International normalised ratio increased	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Liver function test increased	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiac Failure
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		12 (4.4%)	1 (0.4%)	13 (4.8%)	13 (4.8%)
Cardiac disorders	All	11 (4.1%)	1 (0.4%)	12 (4.4%)	12 (4.4%)
	Cardiac failure congestive	7 (2.6%)	1 (0.4%)	8 (3.0%)	8 (3.0%)
	Acute left ventricular failure	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Cardiac failure	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Cardiac failure acute	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Cardiogenic shock	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Left ventricular dysfunction	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Investigations	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Ejection fraction decreased	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Skin and subcutaneous tissue disorders
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		4 (1.5%)	0 (0.0%)	4 (1.5%)	8 (3.0%)
Skin and subcutaneous tissue disorders	All	4 (1.5%)	0 (0.0%)	4 (1.5%)	8 (3.0%)
	Skin ulcer	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Angioedema	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Erythema	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Erythema multiforme	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Hyperkeratosis	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Rash maculo-papular	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Skin swelling	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		34 (12.6%)	3 (1.1%)	37 (13.7%)	42 (15.6%)
Infections and infestations	All	34 (12.6%)	3 (1.1%)	37 (13.7%)	42 (15.6%)
	Pneumonia	10 (3.7%)	2 (0.7%)	12 (4.4%)	15 (5.6%)
	Urinary tract infection	6 (2.2%)	0 (0.0%)	6 (2.2%)	7 (2.6%)
	Cellulitis	4 (1.5%)	0 (0.0%)	4 (1.5%)	5 (1.9%)
	Clostridium difficile colitis	2 (0.7%)	0 (0.0%)	2 (0.7%)	3 (1.1%)
	Diverticulitis	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Osteomyelitis	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Post procedural infection	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Sepsis	2 (0.7%)	0 (0.0%)	2 (0.7%)	3 (1.1%)
	Upper respiratory tract infection	3 (1.1%)	0 (0.0%)	3 (1.1%)	3 (1.1%)
	Abdominal sepsis	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Arthritis bacterial	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Arthritis viral	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Bacteraemia	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Bacterial infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Bronchitis	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Cholecystitis infective	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Clostridium difficile infection	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Gastroenteritis	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Genital infection bacterial	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Herpes oesophagitis	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Lung infection	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Otitis media chronic	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Peritonitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Pneumocystis jirovecii pneumonia	0 (0.0%)	1 (0.4%)	1 (0.4%)	1 (0.4%)
	Pneumonia mycoplasmal	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Pneumonia staphylococcal	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Pyelonephritis	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Pyelonephritis acute	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Respiratory syncytial virus infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Systemic infection	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Viral infection	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Wound infection	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Wound infection staphylococcal	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Myelosuppression
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		16 (5.9%)	0 (0.0%)	16 (5.9%)	17 (6.3%)
Blood and lymphatic system disorders	All	8 (3.0%)	0 (0.0%)	8 (3.0%)	10 (3.7%)
	Anaemia	5 (1.9%)	0 (0.0%)	5 (1.9%)	7 (2.6%)
	Thrombocytopenia	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Febrile neutropenia	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Pancytopenia	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Investigations	All	5 (1.9%)	0 (0.0%)	5 (1.9%)	5 (1.9%)
	Neutrophil count decreased	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Platelet count decreased	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Haemoglobin decreased	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	All	3 (1.1%)	0 (0.0%)	3 (1.1%)	3 (1.1%)
	Myelodysplastic syndrome	3 (1.1%)	0 (0.0%)	3 (1.1%)	3 (1.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Edema and Fluid Retention
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		4 (1.5%)	0 (0.0%)	4 (1.5%)	9 (3.3%)
Cardiac disorders	All	2 (0.7%)	0 (0.0%)	2 (0.7%)	4 (1.5%)
	Pericardial effusion	2 (0.7%)	0 (0.0%)	2 (0.7%)	4 (1.5%)
General disorders and administration site conditions	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Oedema peripheral	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Respiratory, thoracic and mediastinal disorders	All	1 (0.4%)	0 (0.0%)	1 (0.4%)	3 (1.1%)
	Pleural effusion	1 (0.4%)	0 (0.0%)	1 (0.4%)	3 (1.1%)
Skin and subcutaneous tissue disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Skin swelling	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Hypertension
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		8 (3.0%)	0 (0.0%)	8 (3.0%)	11 (4.1%)
Vascular disorders	All	8 (3.0%)	0 (0.0%)	8 (3.0%)	11 (4.1%)
	Hypertension	8 (3.0%)	0 (0.0%)	8 (3.0%)	11 (4.1%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Eye disorder
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		5 (1.9%)	0 (0.0%)	5 (1.9%)	8 (3.0%)
Eye disorders	All	5 (1.9%)	0 (0.0%)	5 (1.9%)	8 (3.0%)
	Retinal vein occlusion	1 (0.4%)	0 (0.0%)	1 (0.4%)	3 (1.1%)
	Cataract	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Cystoid macular oedema	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Retinal artery occlusion	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Retinal vein thrombosis	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Ulcerative keratitis	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Vision blurred	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Bleeding Events
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		6 (2.2%)	2 (0.7%)	8 (3.0%)	9 (3.3%)
Gastrointestinal disorders	All	2 (0.7%)	0 (0.0%)	2 (0.7%)	2 (0.7%)
	Gastric ulcer haemorrhage	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Upper gastrointestinal haemorrhage	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Injury, poisoning and procedural complications	All	3 (1.1%)	1 (0.4%)	4 (1.5%)	4 (1.5%)
	Subdural haematoma	1 (0.4%)	1 (0.4%)	2 (0.7%)	2 (0.7%)
	Post procedural haematoma	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Post procedural haemorrhage	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Nervous system disorders	All	1 (0.4%)	1 (0.4%)	2 (0.7%)	3 (1.1%)
	Haemorrhagic cerebral infarction	0 (0.0%)	1 (0.4%)	1 (0.4%)	1 (0.4%)
	Haemorrhagic transformation stroke	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Subarachnoid haemorrhage	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Pancreatitis
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		22 (8.1%)	0 (0.0%)	22 (8.1%)	23 (8.5%)
Gastrointestinal disorders	All	19 (7.0%)	0 (0.0%)	19 (7.0%)	19 (7.0%)
	Pancreatitis	13 (4.8%)	0 (0.0%)	13 (4.8%)	14 (5.2%)
	Pancreatitis acute	6 (2.2%)	0 (0.0%)	6 (2.2%)	6 (2.2%)
Investigations	All	5 (1.9%)	0 (0.0%)	5 (1.9%)	7 (2.6%)
	Lipase increased	5 (1.9%)	0 (0.0%)	5 (1.9%)	7 (2.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Clinical Pancreatitis
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		19 (7.0%)	0 (0.0%)	19 (7.0%)	19 (7.0%)
Gastrointestinal disorders	All	19 (7.0%)	0 (0.0%)	19 (7.0%)	19 (7.0%)
	Pancreatitis	13 (4.8%)	0 (0.0%)	13 (4.8%)	14 (5.2%)
	Pancreatitis acute	6 (2.2%)	0 (0.0%)	6 (2.2%)	6 (2.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Chemical Pancreatitis
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		5 (1.9%)	0 (0.0%)	5 (1.9%)	7 (2.6%)
Investigations	All	5 (1.9%)	0 (0.0%)	5 (1.9%)	7 (2.6%)
	Lipase increased	5 (1.9%)	0 (0.0%)	5 (1.9%)	7 (2.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiac Arrhythmias
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		13 (4.8%)	3 (1.1%)	16 (5.9%)	23 (8.5%)
Cardiac disorders	All	13 (4.8%)	3 (1.1%)	16 (5.9%)	22 (8.1%)
	Atrial fibrillation	10 (3.7%)	0 (0.0%)	10 (3.7%)	15 (5.6%)
	Cardiac arrest	0 (0.0%)	3 (1.1%)	3 (1.1%)	3 (1.1%)
	Arrhythmia supraventricular	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Atrial tachycardia	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Bradycardia	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Cardio-respiratory arrest	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Sinus node dysfunction	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Sinus tachycardia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
	Tachycardia	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Ventricular tachycardia	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Nervous system disorders	All	2 (0.7%)	0 (0.0%)	2 (0.7%)	4 (1.5%)
	Syncope	2 (0.7%)	0 (0.0%)	2 (0.7%)	4 (1.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
QT Prolongation
Safety Population - CP-CML Patients

		CP-CML Patients (N=270)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (1.1%)	3 (1.1%)	6 (2.2%)	8 (3.0%)
Cardiac disorders	All	2 (0.7%)	3 (1.1%)	5 (1.9%)	5 (1.9%)
	Cardiac arrest	0 (0.0%)	3 (1.1%)	3 (1.1%)	3 (1.1%)
	Cardio-respiratory arrest	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
	Ventricular tachycardia	1 (0.4%)	0 (0.0%)	1 (0.4%)	1 (0.4%)
Nervous system disorders	All	2 (0.7%)	0 (0.0%)	2 (0.7%)	4 (1.5%)
	Syncope	2 (0.7%)	0 (0.0%)	2 (0.7%)	4 (1.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Arterial Occlusive Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		10 (11.8%)	0 (0.0%)	10 (11.8%)	13 (15.3%)
Cardiac disorders	All	5 (5.9%)	0 (0.0%)	5 (5.9%)	8 (9.4%)
	Acute myocardial infarction	2 (2.4%)	0 (0.0%)	2 (2.4%)	3 (3.5%)
	Coronary artery disease	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
	Myocardial infarction	1 (1.2%)	0 (0.0%)	1 (1.2%)	2 (2.4%)
	Acute coronary syndrome	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Coronary artery occlusion	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Ischaemic cardiomyopathy	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
Nervous system disorders	All	3 (3.5%)	0 (0.0%)	3 (3.5%)	4 (4.7%)
	Cerebrovascular accident	1 (1.2%)	0 (0.0%)	1 (1.2%)	2 (2.4%)
	Cerebellar infarction	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Cerebral ischaemia	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
Vascular disorders	All	3 (3.5%)	0 (0.0%)	3 (3.5%)	3 (3.5%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Arterial Occlusive Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Peripheral arterial occlusive disease	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
	Extremity necrosis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Peripheral vascular disorder	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiovascular Arterial Occlusive Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		5 (5.9%)	0 (0.0%)	5 (5.9%)	8 (9.4%)
Cardiac disorders	All	5 (5.9%)	0 (0.0%)	5 (5.9%)	8 (9.4%)
	Acute myocardial infarction	2 (2.4%)	0 (0.0%)	2 (2.4%)	3 (3.5%)
	Coronary artery disease	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
	Myocardial infarction	1 (1.2%)	0 (0.0%)	1 (1.2%)	2 (2.4%)
	Acute coronary syndrome	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Coronary artery occlusion	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Ischaemic cardiomyopathy	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cerebrovascular Arterial Occlusive Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (3.5%)	0 (0.0%)	3 (3.5%)	4 (4.7%)
Nervous system disorders	All	3 (3.5%)	0 (0.0%)	3 (3.5%)	4 (4.7%)
	Cerebrovascular accident	1 (1.2%)	0 (0.0%)	1 (1.2%)	2 (2.4%)
	Cerebellar infarction	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Cerebral ischaemia	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Peripheral Vascular Arterial Occlusive Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (3.5%)	0 (0.0%)	3 (3.5%)	3 (3.5%)
Vascular disorders	All	3 (3.5%)	0 (0.0%)	3 (3.5%)	3 (3.5%)
	Peripheral arterial occlusive disease	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
	Extremity necrosis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Peripheral vascular disorder	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Venous Thrombotic/Embolic Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (1.2%)	0 (0.0%)	1 (1.2%)	2 (2.4%)
Eye disorders	All	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Retinal vein thrombosis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
Respiratory, thoracic and mediastinal disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Pulmonary embolism	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Vascular Occlusive Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		10 (11.8%)	0 (0.0%)	10 (11.8%)	14 (16.5%)
Cardiac disorders	All	5 (5.9%)	0 (0.0%)	5 (5.9%)	8 (9.4%)
	Acute myocardial infarction	2 (2.4%)	0 (0.0%)	2 (2.4%)	3 (3.5%)
	Coronary artery disease	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
	Myocardial infarction	1 (1.2%)	0 (0.0%)	1 (1.2%)	2 (2.4%)
	Acute coronary syndrome	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Coronary artery occlusion	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Ischaemic cardiomyopathy	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
Eye disorders	All	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Retinal vein thrombosis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
Nervous system disorders	All	3 (3.5%)	0 (0.0%)	3 (3.5%)	4 (4.7%)
	Cerebrovascular accident	1 (1.2%)	0 (0.0%)	1 (1.2%)	2 (2.4%)
	Cerebellar infarction	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Vascular Occlusive Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Cerebral ischaemia	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
Respiratory, thoracic and mediastinal disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Pulmonary embolism	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
Vascular disorders	All	3 (3.5%)	0 (0.0%)	3 (3.5%)	3 (3.5%)
	Peripheral arterial occlusive disease	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
	Extremity necrosis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Peripheral vascular disorder	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Hepatoxicity
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (3.5%)	0 (0.0%)	3 (3.5%)	4 (4.7%)
Gastrointestinal disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Ascites	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
Hepatobiliary disorders	All	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Hyperbilirubinaemia	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
Investigations	All	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
	Gamma-glutamyltransferase increased	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
	Alanine aminotransferase increased	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Aspartate aminotransferase increased	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Blood alkaline phosphatase increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Blood bilirubin increased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiac Failure
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (3.5%)	0 (0.0%)	3 (3.5%)	5 (5.9%)
Cardiac disorders	All	3 (3.5%)	0 (0.0%)	3 (3.5%)	5 (5.9%)
	Cardiac failure	1 (1.2%)	0 (0.0%)	1 (1.2%)	2 (2.4%)
	Cardiac failure chronic	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Cardiac failure congestive	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Cardiopulmonary failure	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Skin and subcutaneous tissue disorders
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		4 (4.7%)	0 (0.0%)	4 (4.7%)	4 (4.7%)
Skin and subcutaneous tissue disorders	All	4 (4.7%)	0 (0.0%)	4 (4.7%)	4 (4.7%)
	Acute febrile neutrophilic dermatosis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Angioedema	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Diabetic foot	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Mucocutaneous haemorrhage	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		22 (25.9%)	4 (4.7%)	26 (30.6%)	29 (34.1%)
Infections and infestations	All	22 (25.9%)	4 (4.7%)	26 (30.6%)	29 (34.1%)
	Pneumonia	7 (8.2%)	0 (0.0%)	7 (8.2%)	9 (10.6%)
	Sepsis	2 (2.4%)	2 (2.4%)	4 (4.7%)	4 (4.7%)
	Cellulitis	3 (3.5%)	0 (0.0%)	3 (3.5%)	3 (3.5%)
	Appendicitis	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
	Bacteraemia	1 (1.2%)	0 (0.0%)	1 (1.2%)	2 (2.4%)
	Clostridium difficile colitis	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
	Infection	1 (1.2%)	0 (0.0%)	1 (1.2%)	2 (2.4%)
	Breast cellulitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Diverticulitis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Gangrene	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Gastroenteritis norovirus	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Kidney infection	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Localised infection	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Lung infection	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Oesophageal candidiasis	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Pharyngitis streptococcal	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Pneumonia fungal	0 (0.0%)	1 (1.2%)	1 (1.2%)	1 (1.2%)
	Pulmonary tuberculosis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Respiratory tract infection	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Septic shock	0 (0.0%)	1 (1.2%)	1 (1.2%)	1 (1.2%)
	Splenic abscess	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Urinary tract infection	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Urosepsis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Myelosuppression
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		12 (14.1%)	0 (0.0%)	12 (14.1%)	13 (15.3%)
Blood and lymphatic system disorders	All	9 (10.6%)	0 (0.0%)	9 (10.6%)	10 (11.8%)
	Anaemia	3 (3.5%)	0 (0.0%)	3 (3.5%)	4 (4.7%)
	Thrombocytopenia	4 (4.7%)	0 (0.0%)	4 (4.7%)	4 (4.7%)
	Febrile neutropenia	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
	Pancytopenia	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
Investigations	All	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
	Platelet count decreased	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
	Neutrophil count decreased	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	All	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Myelodysplastic syndrome	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Edema and Fluid Retention
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		2 (2.4%)	0 (0.0%)	2 (2.4%)	4 (4.7%)
Cardiac disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Pericardial effusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
Gastrointestinal disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Ascites	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
Respiratory, thoracic and mediastinal disorders	All	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
	Pleural effusion	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Hypertension
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (3.5%)	0 (0.0%)	3 (3.5%)	3 (3.5%)
Vascular disorders	All	3 (3.5%)	0 (0.0%)	3 (3.5%)	3 (3.5%)
	Hypertension	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
	Hypertensive crisis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Eye disorder
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
Eye disorders	All	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
	Cataract	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Macular fibrosis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Retinal vein thrombosis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Bleeding Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		7 (8.2%)	1 (1.2%)	8 (9.4%)	11 (12.9%)
Gastrointestinal disorders	All	3 (3.5%)	1 (1.2%)	4 (4.7%)	5 (5.9%)
	Gastrointestinal haemorrhage	1 (1.2%)	1 (1.2%)	2 (2.4%)	2 (2.4%)
	Haemorrhoidal haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (2.4%)
	Retroperitoneal haematoma	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
	Peritoneal haemorrhage	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Rectal haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
Injury, poisoning and procedural complications	All	2 (2.4%)	0 (0.0%)	2 (2.4%)	4 (4.7%)
	Subdural haematoma	1 (1.2%)	0 (0.0%)	1 (1.2%)	2 (2.4%)
	Post procedural haematoma	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Post procedural haemorrhage	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Traumatic intracranial haemorrhage	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
Nervous system disorders	All	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Bleeding Events
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Cerebral haemorrhage	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
Renal and urinary disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Haematuria	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
Reproductive system and breast disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Haemorrhagic ovarian cyst	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
Respiratory, thoracic and mediastinal disorders	All	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Epistaxis	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
Skin and subcutaneous tissue disorders	All	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Mucocutaneous haemorrhage	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Pancreatitis
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		5 (5.9%)	0 (0.0%)	5 (5.9%)	6 (7.1%)
Gastrointestinal disorders	All	4 (4.7%)	0 (0.0%)	4 (4.7%)	5 (5.9%)
	Pancreatitis	2 (2.4%)	0 (0.0%)	2 (2.4%)	3 (3.5%)
	Pancreatitis acute	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
Investigations	All	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Lipase increased	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Clinical Pancreatitis
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		4 (4.7%)	0 (0.0%)	4 (4.7%)	5 (5.9%)
Gastrointestinal disorders	All	4 (4.7%)	0 (0.0%)	4 (4.7%)	5 (5.9%)
	Pancreatitis	2 (2.4%)	0 (0.0%)	2 (2.4%)	3 (3.5%)
	Pancreatitis acute	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Chemical Pancreatitis
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
Investigations	All	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Lipase increased	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiac Arrhythmias
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		2 (2.4%)	0 (0.0%)	2 (2.4%)	3 (3.5%)
Cardiac disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
	Bradycardia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
Nervous system disorders	All	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
	Syncope	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
QT Prolongation
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
Nervous system disorders	All	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)
	Syncope	2 (2.4%)	0 (0.0%)	2 (2.4%)	2 (2.4%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Tumour lysis syndrome
Safety Population - AP-CML Patients

		AP-CML Patients (N=85)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
Metabolism and nutrition disorders	All	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)
	Tumour lysis syndrome	1 (1.2%)	0 (0.0%)	1 (1.2%)	1 (1.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Arterial Occlusive Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		5 (8.1%)	0 (0.0%)	5 (8.1%)	5 (8.1%)
Cardiac disorders	All	3 (4.8%)	0 (0.0%)	3 (4.8%)	3 (4.8%)
	Acute myocardial infarction	2 (3.2%)	0 (0.0%)	2 (3.2%)	2 (3.2%)
	Angina pectoris	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Myocardial infarction	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
Renal and urinary disorders	All	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Renal artery stenosis	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
Vascular disorders	All	2 (3.2%)	0 (0.0%)	2 (3.2%)	2 (3.2%)
	Embolism arterial	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Peripheral arterial occlusive disease	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiovascular Arterial Occlusive Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (4.8%)	0 (0.0%)	3 (4.8%)	3 (4.8%)
Cardiac disorders	All	3 (4.8%)	0 (0.0%)	3 (4.8%)	3 (4.8%)
	Acute myocardial infarction	2 (3.2%)	0 (0.0%)	2 (3.2%)	2 (3.2%)
	Angina pectoris	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Myocardial infarction	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Peripheral Vascular Arterial Occlusive Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
Renal and urinary disorders	All	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Renal artery stenosis	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
Vascular disorders	All	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Peripheral arterial occlusive disease	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Venous Thrombotic/Embolic Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		5 (8.1%)	0 (0.0%)	5 (8.1%)	6 (9.7%)
Hepatobiliary disorders	All	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Portal vein thrombosis	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
Respiratory, thoracic and mediastinal disorders	All	3 (4.8%)	0 (0.0%)	3 (4.8%)	3 (4.8%)
	Pulmonary embolism	3 (4.8%)	0 (0.0%)	3 (4.8%)	3 (4.8%)
Vascular disorders	All	1 (1.6%)	0 (0.0%)	1 (1.6%)	2 (3.2%)
	Deep vein thrombosis	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Thrombophlebitis superficial	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Vascular Occlusive Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		9 (14.5%)	0 (0.0%)	9 (14.5%)	10 (16.1%)
Cardiac disorders	All	3 (4.8%)	0 (0.0%)	3 (4.8%)	3 (4.8%)
	Acute myocardial infarction	2 (3.2%)	0 (0.0%)	2 (3.2%)	2 (3.2%)
	Angina pectoris	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Myocardial infarction	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
Hepatobiliary disorders	All	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Portal vein thrombosis	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
Renal and urinary disorders	All	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Renal artery stenosis	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
Respiratory, thoracic and mediastinal disorders	All	3 (4.8%)	0 (0.0%)	3 (4.8%)	3 (4.8%)
	Pulmonary embolism	3 (4.8%)	0 (0.0%)	3 (4.8%)	3 (4.8%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Vascular Occlusive Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Vascular disorders	All	3 (4.8%)	0 (0.0%)	3 (4.8%)	4 (6.5%)
	Deep vein thrombosis	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Embolism arterial	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Peripheral arterial occlusive disease	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Thrombophlebitis superficial	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Hepatoxicity
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
Gastrointestinal disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Ascites	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiac Failure
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		5 (8.1%)	2 (3.2%)	7 (11.3%)	8 (12.9%)
Cardiac disorders	All	4 (6.5%)	2 (3.2%)	6 (9.7%)	6 (9.7%)
	Cardiac failure	2 (3.2%)	1 (1.6%)	3 (4.8%)	3 (4.8%)
	Cardiac failure congestive	0 (0.0%)	1 (1.6%)	1 (1.6%)	1 (1.6%)
	Cardiogenic shock	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Left ventricular failure	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Right ventricular failure	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
Investigations	All	2 (3.2%)	0 (0.0%)	2 (3.2%)	3 (4.8%)
	Ejection fraction decreased	2 (3.2%)	0 (0.0%)	2 (3.2%)	3 (4.8%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Skin and subcutaneous tissue disorders
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		2 (3.2%)	0 (0.0%)	2 (3.2%)	2 (3.2%)
Skin and subcutaneous tissue disorders	All	2 (3.2%)	0 (0.0%)	2 (3.2%)	2 (3.2%)
	Rash erythematous	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Rash maculo-papular	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		15 (24.2%)	3 (4.8%)	18 (29.0%)	19 (30.6%)
Infections and infestations	All	15 (24.2%)	3 (4.8%)	18 (29.0%)	19 (30.6%)
	Pneumonia	7 (11.3%)	0 (0.0%)	7 (11.3%)	8 (12.9%)
	Cellulitis	2 (3.2%)	0 (0.0%)	2 (3.2%)	2 (3.2%)
	Clostridium difficile colitis	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (3.2%)
	Gastroenteritis	2 (3.2%)	0 (0.0%)	2 (3.2%)	2 (3.2%)
	Klebsiella sepsis	2 (3.2%)	0 (0.0%)	2 (3.2%)	2 (3.2%)
	Sepsis	0 (0.0%)	2 (3.2%)	2 (3.2%)	2 (3.2%)
	Bacteraemia	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Bronchitis	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Catheter site cellulitis	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Clostridium difficile infection	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Incision site infection	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Infectious colitis	0 (0.0%)	1 (1.6%)	1 (1.6%)	1 (1.6%)
	Pneumonia respiratory syncytial viral	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Infections and infestations
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
	Staphylococcal bacteraemia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Upper respiratory tract infection	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Urinary tract infection	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Myelosuppression
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		11 (17.7%)	0 (0.0%)	11 (17.7%)	12 (19.4%)
Blood and lymphatic system disorders	All	10 (16.1%)	0 (0.0%)	10 (16.1%)	11 (17.7%)
	Anaemia	3 (4.8%)	0 (0.0%)	3 (4.8%)	4 (6.5%)
	Febrile neutropenia	3 (4.8%)	0 (0.0%)	3 (4.8%)	3 (4.8%)
	Neutropenia	3 (4.8%)	0 (0.0%)	3 (4.8%)	3 (4.8%)
	Pancytopenia	3 (4.8%)	0 (0.0%)	3 (4.8%)	3 (4.8%)
	Thrombocytopenia	2 (3.2%)	0 (0.0%)	2 (3.2%)	2 (3.2%)
Investigations	All	1 (1.6%)	0 (0.0%)	1 (1.6%)	2 (3.2%)
	Haemoglobin decreased	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Platelet count decreased	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Edema and Fluid Retention
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (4.8%)	1 (1.6%)	4 (6.5%)	4 (6.5%)
Cardiac disorders	All	2 (3.2%)	0 (0.0%)	2 (3.2%)	2 (3.2%)
	Pericardial effusion	2 (3.2%)	0 (0.0%)	2 (3.2%)	2 (3.2%)
Gastrointestinal disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Ascites	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
Metabolism and nutrition disorders	All	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Fluid overload	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
Nervous system disorders	All	0 (0.0%)	1 (1.6%)	1 (1.6%)	1 (1.6%)
	Brain oedema	0 (0.0%)	1 (1.6%)	1 (1.6%)	1 (1.6%)
Respiratory, thoracic and mediastinal disorders	All	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Pleural effusion	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Bleeding Events
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		2 (3.2%)	3 (4.8%)	5 (8.1%)	5 (8.1%)
Gastrointestinal disorders	All	1 (1.6%)	1 (1.6%)	2 (3.2%)	2 (3.2%)
	Gastritis haemorrhagic	0 (0.0%)	1 (1.6%)	1 (1.6%)	1 (1.6%)
	Gastrointestinal haemorrhage	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
Injury, poisoning and procedural complications	All	0 (0.0%)	1 (1.6%)	1 (1.6%)	1 (1.6%)
	Traumatic intracranial haemorrhage	0 (0.0%)	1 (1.6%)	1 (1.6%)	1 (1.6%)
Nervous system disorders	All	1 (1.6%)	1 (1.6%)	2 (3.2%)	2 (3.2%)
	Cerebral haemorrhage	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Haemorrhage intracranial	0 (0.0%)	1 (1.6%)	1 (1.6%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Pancreatitis
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (4.8%)	0 (0.0%)	3 (4.8%)	3 (4.8%)
Gastrointestinal disorders	All	2 (3.2%)	0 (0.0%)	2 (3.2%)	2 (3.2%)
	Pancreatitis acute	2 (3.2%)	0 (0.0%)	2 (3.2%)	2 (3.2%)
Investigations	All	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Lipase increased	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Clinical Pancreatitis
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		2 (3.2%)	0 (0.0%)	2 (3.2%)	2 (3.2%)
Gastrointestinal disorders	All	2 (3.2%)	0 (0.0%)	2 (3.2%)	2 (3.2%)
	Pancreatitis acute	2 (3.2%)	0 (0.0%)	2 (3.2%)	2 (3.2%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Chemical Pancreatitis
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
Investigations	All	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Lipase increased	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Cardiac Arrhythmias
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		3 (4.8%)	0 (0.0%)	3 (4.8%)	6 (9.7%)
Cardiac disorders	All	2 (3.2%)	0 (0.0%)	2 (3.2%)	5 (8.1%)
	Atrial fibrillation	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Atrial flutter	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Atrioventricular block complete	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Bundle branch block right	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
	Tachycardia	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (1.6%)
Nervous system disorders	All	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Loss of consciousness	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
QT Prolongation
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
Nervous system disorders	All	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Loss of consciousness	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.

Table 1.2.2.5.2 (Study 201)
Serious Adverse Events of Special Interest (AESI) by System Organ Class, Preferred Term and Maximum Grade
Tumour lysis syndrome
Safety Population - BP-CML Patients

		BP-CML Patients (N=62)			
System Organ Class	*Preferred term*	*Grade 3 & 4*	*Grade 5*	*Grade >=3*	*All grades*
Any AE		1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
Metabolism and nutrition disorders	All	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)
	Tumour lysis syndrome	1 (1.6%)	0 (0.0%)	1 (1.6%)	1 (1.6%)

Safety Population: All treated patients
Percentages are based on the safety population.